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Abstract 
 
Venous valve failure and associated venous hypertension is common in man, 
yet very little is known about the development and maintenance of venous 
valves. Existing therapies for valve failure most commonly involve removal or 
ablation of the vein in the superficial venous system. Little can be done to 
correct reflux in the deep veins.   
Immunofluorescence and electron microscopy were used to visualise and 
quantify venous valves at different stages of development in an experimental 
mouse model. Several proteins previously thought to be specific markers for 
arterial or lymphatic endothelium were found in venous endothelia and venous 
valves. Constitutive and conditional loss of function genetic approaches 
revealed how an initially homogenous population of endothelial cells acquire 
distinct expression patterns and behaviours, but act co-ordinately to 
orchestrate valve formation. The expression of several factors, previously 
found to be required for cardiac and/or lymphatic valve formation, was also 
found to be important for venous valve formation, including connexins 37, 43 
and 47, integrin-α9, ephrinB2, Foxc2, and NFAT-calcineurin. Mutations in 
VEGFR3, FOXC2, GJC2 and GJA1 were found to be associated with 
structural venous valve defects in man. 
It has been postulated that fluid flows regulate lymphatic and venous valve 
development in vivo. A novel model of altered blood flow was developed, and 
used to show that normal blood flow is required for postnatal valve 
development.  
These data enhance our understanding of the cellular mechanisms underlying 
human venous valve disease caused by mutations in VEGFR3, FOXC2, GJC2 
and GJA1, and suggest novel candidate genes, such as Itga9 and GJA4 for 
human venous valve disease. Improved knowledge of the factors regulating 
venous valves could lead to new treatments for valve failure, or regenerative 
medicine approaches to venous reflux.   
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1 GENERAL INTRODUCTION 
1.1 The venous system 
The primary function of the venous system is to return blood to the heart. It 
also plays a capacitance role and can accommodate large volumes of blood.1 
An effective venous return from the extremities requires the interaction of the 
heart, peripheral muscle pump in the leg, and competent venous valves 




Figure 1 Deep and superficial veins of the lower limb2 
The fascia covers the muscle and separates the deep and superficial compartments of 
the limb. Superficial veins (a) drain the skin via the subpapillary and reticular venous 
plexuses (in the dermis and subcutis) which drain into the deep veins via valved 
perforating veins (b). The great saphenous vein is invested by its own layer of fascia 
within the superficial compartment. Blood flow is from distal to proximal. 
 
Compression of valved muscular veins forms a muscle pump (found in the 
foot, calf and thigh in the lower limb) and with the onset of walking the venous 
pressure at the ankle rapidly drops from around 100mmHg to a mean of 
22mmHg within 7-12 steps. Whilst valves in the named veins are most 
in pressure over the normal range of 5 to 25 mm Hg,
reflecting the large capacitance of the venous system. How-
ever, as the veins fill, distention is accompanied by an
escalating increase in pressure per unit volume (Fig 6).
Substantial, acute volume shifts can be ccommodated
by expansion or contraction of the large, variably sized
venous reservoir. In the healthy individual, an acute 10%
decrease in blood volume can be accommodated without
significant physiological consequence.20 Large increases in
total body fluid volume are also rapidly accommodated by a
healthy venous system.
Regulation of venous physiology
Regulation of venous tone is an important aspect of
volume accommodation and works in concert with arterial
tone to control the distribution of cardiac output. Sympa-
thetic mediated adjustments of smooth muscle tone are
most pronounced in the splanchnic and cutaneous distri-
butions.
Circulatory homeostasis upon assumption of upright
posture is largely achieved by immediate changes in heart
rate  followed  by  adjustments  in  arterial  resistance.18,20
Reflex mediated control of the resistance (precapillary)
vessels is thus a major determinant of the distribution of the
circulation. Depending upon activity and posture, 60% to
80% of the resting blood volume (70 ml/kg in men; 65
ml/kg in women) resides in the venous system. Twenty-
five to fifty percent of this volume resides in the smaller
postcapillary venules and their collecting systems. Approx-
imately 25% (18 ml/kg) resides in the splanchnic network.
A diurnal increase in late day capacitance is normal after
standing and sitting.21
Cutaneous blood flow is approximately 3 ml/min/100
gm of tissue in cool weather. Skin blood flow increases with
reduced adrenergic i pulses leading to both arterial and
venous dilation; maximal flow may increase by over 10-fold
to 30 ml/100g/min or 2 to 3 L/minute. Venous pressure
measurements are unreliable at the extremes of ambient
temperature  (0°  to  55°  C).22  A  cold  extremity  never
achieves a full hydrostatic pressure head and requires pro-
longed filling to reach even a reduced hydrostatic pressure.
A warm extremity achieves full hydrostatic pressure almost
immediately, making assessment of post exercise pressures
difficult.22  Thus,  physiologic  venous  testing  should  be
conducted in the morning and examinations performed in
rooms maintained at a comfortable temperature range.
Determinants of venous pressure
Blood moves through both arteries and veins because
of dynamic pressure derived from the pumping action of
the heart. In a closed circulatory system, venous return
must equal cardiac output. The majority of dynamic pres-
sure is dissipated in the arterial circulation. The remaining
energy is released in the venous system. Under normal
circumstances, the pressure is 12 to 18 mm Hg at the
venous end of the capillary and falls steadily toward atrial
pressures of 4 to 7 mm Hg. When supine, gravitational
pressures are neutralized and blood flows along this dy-
namic pressure gradient. Respiratory motion also strongly
Fig 2. Relationship between the fascia and veins of the lower extremity. The fascia covers the muscle and separates the deep
from the superficial compartment. Superficial veins (a) drain the subpapillary and reticular venous plexuses and they are
connected to deep veins through perforati g veins (b). The saphenous fascia invests the saphenous vei . The saphenous
compartment is a s bcomp rtm nt of the superficial compartment. From Mozes G, Gloviczki P. New discoverie in anatomy
and new terminology of leg veins: clinical implications. Vasc En ovasc Surg 2004;38:367-374.121
JOURNAL OF VASCULAR SURGERY
Volume 46, Number S Meissner et al 7S
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commonly discussed, the majority of valves are in fact found in veins less than 
100µm in diameter.1-3  
 
1.2 Ambulatory venous hypertension 
 
Unlike the collecting lymphatics, veins themselves do not contract to produce 
a pumping action.1, 4 In the lower limb the most important muscle pump is 
formed by the gastrocnemius and soleus muscles and their valved draining 
veins; muscular contraction generates pressures of around 200mmHg, driving 
blood in the high capacitance popliteal and femoral veins.1 Repeated pumping 
lowers the distal venous pressure (Figure 2). The normal calf venous blood 
volume is approximately 100-150ml, of which a single contraction will eject 40-
60%.1 Without deep venous valves, blood oscillates between the calf and 
more proximal veins, and there is failure of the normal reduction in ankle 




Figure 2 Foot-vein pressure changes on walking5 
On standing, venous pressure in veins of the foot is approximately  90-100mm Hg. In a 
normal limb, activation of the calf muscle pump during walking results in a rapid fall in 
distal venous pressure and stopping walking is followed by a gradual return to the 
resting state. In a limb with incompetent VV, the calf pump fails to lower distal pressure 
(ambulatory venous hypertension) and recovery to the resting state is faster.5 
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alone in 12 percent, and both forms in 43 per-
cent.25 An analysis of cases of chronic venous 
disease indicated that primary valvular incompe-
tence was present in 70 to 80 percent and a con-
genital anomaly in 1 to 3 percent; valvular in-
competence was due to trauma or deep-vein 
thrombosis in 18 to 25 percent.6,24
Pressure in the veins of the leg is determined 
by two components: a hydrostatic component re-
lated to the weight of the column of blood from 
the right atrium to the foot and a hydrodynamic 
component related to pressures generated by con-
tractions of the skeletal muscles of the leg and 
the pressure in the capillary network. Both com-
ponents are profoundly influenced by the action 
of the venous valves. During standing without 
skeletal-muscle activity, venous pressures in the 
legs are determined by the hydrostatic compo-
nent and capillary flow, and they may reach 80 to 
90 mm Hg. Skeletal-muscle contractions, as dur-
ing ambulation, transiently increase pressure with-
in the deep leg veins. Competent venous valves 
ensure that venous blood flows toward the heart, 
thereby emptying the deep and superficial ve-
nous systems and reducing venous pressure, usu-
ally to less than 30 mm Hg (Fig. 2). Even very 
small leg movements can provide important 
pumping action. In the absence of competent 
valves, however, the decrease in venous pressure 
with leg movements is attenuated. If valves in 
the perforator veins are incompetent, the high 
pressures generated in the deep veins by calf-
muscle contraction can be transmitted to the 
superficial system and to the microcirculation in 
skin. It seems likely, therefore, that the clinical 
signs of chronic venous disease stem from venous 
pressures in the leg that reach higher-than-normal 
levels and remain elevated for prolonged periods.
VA LV E A ND V EIN-WA L L CH A NGES 
IN CHRONIC V ENOUS DISE A SE
Changes in Venous Valves
Venous valve incompetence is central to the ve-
nous hypertension that appears to underlie most 
or all signs of chronic venous disease. Alterations 
in and damage to valves have been noted on ex-
amination with an angioscope, a fiberoptic cath-
eter that allows clinicians to view the interior of 
a blood vessel. These changes include stretching, 
splitting, tearing, thinning, and adhesion of valve 
leaflets.27 A reduction in the number of valves 
per unit length has been observed in segments of 
saphenous veins from patients with chronic ve-
nous insufficiency.28 An important step forward 
came when Ono et al.29 found infiltration of valve 
leaflets and the venous wall by monocytes and 
macrophages in all vein specimens from patients 
with chronic venous disease and in no specimens 
from controls. Infiltration was associated with 
areas of endothelium that expressed intercellular 
adhesion molecule 1 (ICAM-1).30
Structural Changes in the Vein Wall
Histologic and ultrastructural studies of varicose 
saphenous veins have found hypertrophy of the 
vein wall with increased collagen content,31 to-
gether with disruption of the orderly arrangements 
of smooth-muscle cells and elastin fibers.32,33 Cul-
tures of smooth-muscle cells from varicose sa-
phenous veins have disturbed collagen synthesis, 
resulting in overproduction of collagen type I and 
reduced synthesis of collagen type III.34 Because 
collagen type I is thought to confer rigidity and 
collagen type III to confer distensibility to tissues, 
such changes could contribute to the weakness 
and reduced elasticity of varicose veins.
A complicating factor is the heterogeneity of 
the varicose-vein wall; hypertrophic segments can 
alternate with thinner atrophic segments with 
fewer smooth-muscle cells and reduced extracel-
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Figure 2. Action of the Musculovenous Pump in Lowering Venous Pressure 
in the Leg.
After prolonged standing, venous pressure in the foot is approximately 
90 mm Hg in both a patient with incompetent venous valves and a person 
with a normal leg. During walking, the musculovenous pump rapidly lowers 
the venous pressure in the normal leg but is ineffective in the leg with valvu-
lar incompetence. (Reproduced from Coleridge Smith26 with the permission 
of the publisher.)
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org by OLIVER T. LYONS MD on September 25, 2009 . 
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This failure of the venous system to function normally results in persistently 
raised venous blood pressure in the lower limbs, termed ambulatory venous 
hypertension (Figure 2).6 This leads to the associated skin and subcutaneous 
tissue changes of chronic venous insufficiency (CVI), but the mechanisms 
underlying this clinico-pathological relationship remain poorly understood.1, 6 
The features of CVI include pain, oedema, pigmentation, fibrosis, and 
ulceration.1 The end stage, ulceration (Figure 3), is very difficult to treat; 
approximately 50% of ulcers require a year or more to heal, and they may 
recur after treatment.6, 7 Long term management places a significant burden 
on western healthcare systems and is estimated to consume approximately 




Figure 3 Chronic venous insufficiency with ulceration5 
The photograph shows a chronic venous ulcer near the medial malleolus, with 
surrounding evidence of skin changes including pigmentation.5 
mechanisms of disease
n engl j med 355;5 www.nejm.org august 3, 2006 489
A C
DB
Figure 1. Clinical Manifestations of Chronic Venous Disease.
Telangiectases (clinical, etiologic, anatomical, and pathophysiological [CEAP] class C1) are shown in Panel A, varicose 
veins (CEAP class C2) in Panel B, pigme tation (CEAP clas  C4) in Panel C, and active ulceration (CEAP class C6) in 
Panel D.
Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org by OLIVER T. LYONS MD on September 25, 2009 . 
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1.2.1 Primary venous disease 
CVI may be primary (genetic) or secondary. Primary CVI involves only venous 
reflux.1 Duplex ultrasound studies have suggested that primary valvular 
incompetence (sometimes partially compensated for by an effective calf pump) 
is more common than previously thought, and it may underlie 20% of CVI.1 
Primary valvular agenesis is rare.7 Venous reflux in association with rare 
cases of primary lymphoedema will be discussed in detail later in this chapter. 
 
‘Varicose’ veins are abnormally dilated and tortuous superficial veins and are 
estimated to affect 5-30% of the Western population.7, 8 It is not known 
whether varicose veins are caused by a primary failure of the venous valves, 
dilatation of the vein wall, or a combination of the two.8, 9  
 
 
1.3 Secondary venous disease 
Secondary disease typically involves a combination of reflux and obstruction.1 
The most common cause of secondary CVI is deep venous thrombosis (DVT). 
Other causes include trauma, surgical complications, and tumours.10  
 
Recanalisation of the vein lumen after DVT is rarely complete, and residual 
thrombus is replaced by cribiform synechiae of endothelialised fibrous tissue 
that may cause obstruction to blood flow. In addition, valves may be damaged 
with resulting structural defects including leaflet adhesions, widening of the 
valve commissure, and shrinkage of the leaflets.10, 11  
 
1.4 Treatment of chronic venous insufficiency 
1.4.1 Non-operative therapy 
The mainstay of therapy for CVI is graduated elastic compression stockings.6, 7 
This aims to counteract the venous hypertension, but is poorly tolerated by 
patients. Some studies have suggested a role for pharmacotherapy, 
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particularly micronized purified flavonoid fraction (Daflon), which can reduce 
symptoms of pain, heaviness and oedema in patients with venous reflux.12 
 
1.4.2 Operative and interventional procedures 
The most commonly performed procedures for superficial venous disease 
involve ablation of the great or short saphenous veins, using methods such as 
radiofrequency or laser ablation.6, 7 These less invasive techniques have 
rapidly replaced open surgical disconnection of the sapheno-femoral junction 
and stripping of the vein.  
 
Relief of deep venous CVI, which is most commonly secondary, may involve 
treatment directed at relief or obstruction, reflux, or both. Approximately 10%-
30% of patients with severe CVI show significant abnormalities in venous 
outflow involving the iliac segments; in the past this has been treated 
surgically (for example by Palma bypass), but with the success of venous 
stenting this is now less commonly done.7 Duplex studies show that reflux of 
deep veins is seen in around 40% of patients with chronic venous insufficiency 
and may be significant in 10-15%.6, 7, 13 
 
Various procedures have been performed in an attempt to achieve long lasting 
resolution of valve failure in highly selected patient groups, but have been 
troubled by early thrombosis, poor patency and competency, and high patient 
morbidity.6, 7, 14-18 Venous valvuloplasty provides only 59% competency and 
63% ulcer-free recurrence at 30months.7 Other procedures include 
transposition of vein containing functional valves (eg from the axillary or great 
saphenous vein) into the popliteal or femoral vein segments.  Cryopreserved 
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1.5 The development and valves of the venous and 
lymphatic systems 
 
1.5.1 Venous system 
 
In man, primitive vascular channels first appear in the limb in the third week of 
gestation. Prior to this, only a capillary network is present, followed by the 
appearance of large plexiform structures. By the by the third week of gestation 
large channels develop including arteries and veins1 Between 9 and 11 weeks 
the great saphenous vein wall is reported to consist only of endothelium, and 
is joined by irregular cells of tunica media from 12 to 16 weeks. From weeks 
18 to 37, three distinct layers are seen.20 The superficial veins of the lower 
limbs develop earlier than the deep veins.21  
 
Intraluminal valves appear after the organisation of the veins. The first studies 
of the development of the venous valves were made in the 1920’s by 
Kampmeier and La Fleur Birch in the United States.22 They cut 20µm paraffin 
sections of decalcified human cadavers from 2.5months gestation onwards, 
and focused their search on the saphenous veins where the first venous 
valves begin to develop near the sapheno-femoral junction at 3.5 months, with 
a tendency for development to progress from proximal towards distal veins. 
Valves in the upper limb were found to develop earlier than those in the lower, 
where valve formation was found to be complete by the fifth month of 
gestation. An increase in the number of valves between 13 and 19weeks 
gestation is seen in the human foetal short saphenous veins with no further 
increase (on average) after 19weeks.23  Similarly, the first valves appear at 
13weeks in human foetal great saphenous veins.20 Others have found the first 
venous valves appearing between 18 and 25weeks.24 
 
Although there have been significant advances in our understanding of 
lymphatic valve (LV) development, there is little information describing the 
morphological processes responsible for VV development.22, 25, 26 Kampmeier 
arbitrarily divided the development of the venous valves into five stages 
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(Figure 4).22 Development began as two ‘ridge-like’ endothelial thickenings 
placed opposite to one another and ‘more or less transversely to the long axis 
of the vessel’ just distal the ostium of a tributary (stage 1). These ridges were 
thought to join to form a complete ring-shaped or circular ledge within the 
lumen of the vein. Almost synchronously with stage 1, the ‘endothelial anlage’ 
(valve leaflets) was seen to lengthen in the direction of flow by ‘invasion of the 
subjacent mesenchyme’, and the valve sinus became perceptible (stage 2). 
The key conformational changes to produce two near-parabolic lines of 
attachment of the leaflets (stage 3) were not clearly elucidated. Enlargement 
of the sinus and thickening of the free edges of the leaflets completed 
development by 5months gestation (stage 4). By term, the vein wall at the 
sinus was thinned by a reduction in the tunica media (stage 5). They found a 
large variability in the developmental stage of valves, even within segments of 
the same vein. 
 
 
Figure 4 Stages in human venous valve development 22 
 I. Ridge-like endothelial thickenings placed opposite to one another 
II. Endothelial anlage (valve leaflets) lengthen in the direction of flow 
III. Two near-parabolic lines of attachment of the leaflets 
IV. Enlargement of the sinus and thickening of the free edges of the leaflets 
V. Thinning of vein wall by reduction in the tunica media. 
Arrows indicate the direction of flow 
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!
These developmental findings were confirmed by Otto Jager in 1926, who 
similarly reported ‘progressive deepening of outgrowths from the inner layers 
of the vein wall, beginning near the tributary entries’ in pig embryos25 as 
reviewed in 15,18. This process was thought to be influenced by the mechanical 
stimulus of blood flow.11, 25, 26 There are some data describing the anatomical 
features of the formed venous valves in the rat (lower limb) and duckling (head 
veins), mouse (coronary veins), giraffe, ostrich and other animals.27-33 
However, there are no data describing the development of VV in an animal 
model and the precise morphological events resulting in this complex three 
dimensional VV structure are not clearly understood.20 
 
1.5.2 Lymphatic system 
Work in this thesis is based in the hypothesis that some molecular regulators 
are shared between the arterial, venous and lymphatic systems, and it is 
therefore necessary to examine the development of the lymphatic system. The 
lymphatic system originates by the sprouting of endothelial cells dorsally from 
the cardinal veins and superficial venous plexus as loosely adherent strings of 
cells.34,35 In a restricted subset of venous endothelial cells, proteins including 
Sox18, Prox1, VEGFR3 are expressed, leading to differentiation of lymphatic 
endothelial cells that migrate away from the parent veins.35-37 (Reviewed in 38) 
These initial lymphatic endothelial cells (iLECS) subsequently coalesce to form 
lumenised paired dorsal peripheral longitudinal lymphatic vessels (PLLV) and 
ventral primordial thoracic ducts (pTD). The pTD’s maintain strongly positive 
Prox1-expressing connections to the Cardinal Veins, and these sites are likely 
to form the first lymphovenous valves.37 The lymphatic system develops from 
these initial condensates by further sprouting and migration to give a plexus of 
lymphatic vessels, followed by remodelling into a hierarchical system of 
capillaries and valved collecting vessels. These converge on the subclavian 
veins, where the thoracic duct and right thoracic duct empty into the venous 
system.37,39,40 
 
There are similarities in the way that human venous and lymphatic valves 
develop. Human lymphatic valves (LV) develop earlier than venous (VV) 
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valves, with 3 processes of LV development described (the 3rd – describing 
valve formation in large lymphatic trunks – closely resembles the description of 
venous valve formation, Figure 5).41 
 
 
Figure 5 Lymphatic valve formation - Kampmeier 1928  
Endothelial cell proliferation and ‘invasion of the subjacent mesenchyme’ causes the 
leaflets to elongate into the vessel, and paired sinuses are separated by the buttresses 
(commissures). Lymphatic valves are described as almost always being bicuspid.  
 
More recently, lymphatic valve development has been analysed by confocal 
microscopy, primarily in the murine mesenteric lymphatics.42-44 Four stages 
have now been defined in LV development (Figure 6).42,45  At Stage 1, Prox1 
expression is increased in a clustered subset of LEC’s on one side of the 
vessel, typically near a branch point. Prox1hi LECs are subsequently termed 
lymphatic valve-forming cells (LVC’s). This is followed by circularisation of 
Prox1hi LECs to form a ring-like domain of cells at Stage 2. Constriction alters 
the vessel morphology, and invagination of LVC’s into the lumen with 
increased deposition of lamininα5 in the leaflet core produces the appearance 
of valve leaflets at Stage 3. Further undefined ‘maturation’ events occurs to 
produce a bicuspid valve at Stage 4 (Figure 6).42 Similar findings have been 
reported by Levet et al.45 Bazigou et al reported similar stages to 2-4, but did 
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Figure 6 Lymphatic valve development - Sabine 201242 
Immunolocalisation of the nuclear transcription factor Prox1 is shown in red, and the 
extracellular matrix protein lamininα5 (expressed in the leaflet core) in green. Scale bar 
20µm.  
Stage 1 - Prox1 expression increased in clustered subset of LEC’s, near a branch point.  
Stage 2 - Circularisation of Prox1hi LECs to form a ring-like domain of cells   
Stage 3 - Constriction alters the vessel morphology, and invagination of LVC’s into the 
lumen with increased deposition of lamininα5 in the leaflet core.  
Stage 4 - Undefined ‘maturation’ events produce a bicuspid valve  
 
1.6 Primary lymphoedema and links with venous 
reflux 
In man, lymphoedema may be primary (genetic) or secondary.46 In some 
patients with primary lymphoedema, patients have been noted to show venous 
reflux, suggesting some shared molecular pathways controlling venous and 
lymphatic disease. Some clinical aspects of lymphoedema caused by 
mutations in FOXC2, VEGFR3, GJA1 and GJC2 will be discussed here, and 
their known roles in signalling during valve formation will be further discussed 
later in this chapter. 
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1.6.1 Lymphoedema Distichiasis 
Mutations in FOXC2 cause lymphoedema distichiasis (LD) and show 
autosomal dominant inheritance with a high degree of penetrance. A variety of 
FOXC2 mutations have been described in LD, primarily frame shift mutations 
that truncate the protein, but all likely resulting in haploinsufficiency. LD is 
characterised by asymmetric bilateral lower limb swelling of pubertal onset and 
a double row of eyelashes (due to aberrant development of the meibomian 
glands).47, 48,49 Additional features include congenital heart disease, ptosis, 
varicose veins, cleft palate, and spinal extradural cysts.49 Lymphoscintigraphy 
shows a normal or increased number of hyperplastic lymphatics.49 Patients 
with FOXC2 mutations (even those without lymphoedema) have reflux in their 
long saphenous vein, implicating a role for FOXC2 in venous valve 
development. 50  
 
1.6.2  Milroy’s disease 
Mutations in VEGFR3, cause Milroy’s disease and show autosomal dominant 
inheritance with variable penetrance.51,52,53 Mutations in VEGFC (encoding the 
major ligand for VEGFR3) have also been described in patients with a Milroy-
like phenotype.54,55 Patient’s with Milroy’s disease typically show bilateral 
oedema below the knee identified at birth, although oedema can also be 
detected by ultrasound in utero.53 Injections of fluorescent tracer into the feet 
of Milroy’s patients shows greatly reduced or absent filling of dermal initial 
lymphatics in the swollen foot, and is due to initial lymphatic hypoplasia and 
dysfunction.48 Accordingly, lymphoscintigraphy is rarely possible in these 
patients due to a failure of tracer uptake.  
 
 
1.6.3 Lymphoedema associated with GJA1 (encoding Cx43) 
Mutations in GJA1, encoding Cx43, have previously been associated with 
oculodentodigital dysplasia (ODDD), characterised by soft tissue fusion of the 
digits, abnormal craniofacial bone development, small eyes and loss of tooth 
enamel.56 Very recently, mutations the same gene were associated with 
 
  28 
lymphoedema.57 In the proband with lymphoedema, a venous duplex was 
normal other than showing ‘mild incompetence’ in one short saphenous vein. 
Cx43 is the most abundant and widely expressed connexin in the family, but it 
remains unclear how GJA1 mutations cause such a diverse range of 
pathologies.56   
 
1.6.4  Lymphoedema associated with GJC2 (encoding 
Cx47) 
Mutations in GJC2 (also known as GJA12), encoding Cx47, were recently 
described as a cause of primary 4-limb lymphoedema.4,58 The first report of 
GJC2 lymphoedema noted sporadic venous insufficiency4 and although a 
venous phenotype had not been systematically assessed, several patients  
who had venous duplex ultrasound assessments demonstrated reflux in their 
long saphenous veins, or had varicose veins.58 This is surprising as the first 
study to show a role for GJC2 in lymphoedema was based in part on the 
finding that Cx47 is expressed in lymphatic and not blood endothelial cells.4 It 
has been suggested that the predominance of lower limb lymphoedema may 
be as a result of excessive filtration secondary to venous hypertension.58  
 
Mutations in GJC2 also cause Pelizaeus-Merzbacher-like disease (PMLD), a 
rare central nervous system hypomyelinating disorder.59 These patients have 
not been described as affected by venous reflux or lymphoedema, nor have 
patients with GJC2 lymphoedema been noted to have neurological defects. It 
remains unclear how mutations in the same gene may produce two possibly 
distinct syndromes, especially since lymphoedema-associated mutations are 
distributed throughout the gene, and in one example the same mutation has 
been independently reported as being causative of both disorders.4, 59, 60 
 
Notably, two mutations predicted to result in a null allele have been identified 
and produced no discernable clinical phenotype. This is analogous to the 
Cx47 heterozygous or homozygous deficient mouse, which has been reported 
to show no gross phenotype, and will be discussed further in this chapter.4,61 
These findings have led to the conclusion that the lymphatic phenotype in 
patients with GJC2 mutations is caused by a functional rather than structural 
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defect; likely improper coordination of lymphatic pumping as a result of altered 
gap junction intercellular communication.4 
 
1.7 Molecular regulation and signalling in lymphatic 
and venous valve development 
 
1.7.1 Integrinα9 
The integrins are a family of heterodimeric transmembrane glycoproteins that 
associate with both extracellular and intracellular proteins to facilitate ‘inside-
out’ and ‘outside-in’ signalling, and regulate cell-cell and cell-extracellular 
matrix (ECM) adhesion.62 They are known to play essential roles in 
developmental and other processes where cells are required to interact with 
each other and their surrounding ECM. 18 alpha subunits and 8 beta subunits 
comprise the 24 known heterodimers in man.63 Integrinα9, encoded by Itga9, 
was first discovered in 1993, with a widespread expression pattern that 
included veins.63, 64 Itga9-/- pups were subsequently found to fail to survive 
beyond postnatal day 6-12, and die with lymphatic defects including severe 
bilateral chylothorax, but no obvious structural defects were observed in the 
analysed thoracic ducts.65 Mutations in Itga9 have subsequently been 
identified in human foetal chylothorax.66,67 Integrinα9 is only known to dimerise 
with β1 (other than in gametes) and has several known ligands, including ECM 
components such tenascin C, VCAM-1, the EIIIA splice variant of fibronectin, 
EMILIN1, and soluble growth factors VEGFA/C/D.64,63, 65 
 
In lymphatics, integrins α5 and α6 are present at low levels throughout the 
vessels, whilst α9 is localised at high levels to the valves43 Subsequent 
analysis of Itga9-/- mesenteric LV at P0 revealed a failure to develop beyond 
the ring stage (analogous to stage 1 in VV formation) associated with a failure 
to remodel the fibronectin-EIIIA expressed around the valve, and failure to 
form the matrix core of the valve leaflet.43 Accordingly, Fn-EIIIA null mice also 
showed LV defects, but these were overcome by P21, suggesting possible 
redundancy in signalling through integrinα9. EMILIN-/- mice show a more 
complex lymphatic defect, involving the capillaries, valves, and accumulation 
of mural cells.68 At P0 and P6 EMILIN1-/- mice show similar defects to double 
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EMILIN1-/-;FnEIIIA-/- knockout mice, suggesting that EMILIN1 may be the more 
important α9 ligand. Whilst Fn-EIIIA is progressively downregulated 
postnatally, EMILIN1 persists and P21 EMILIN1-/- mice show persistent 
lymphatic defects. It remains possible that other parts of the lymphatic 
phenotype seen in Itga9-/- mice (e.g. chylothorax, which is not seen in  
FnEIIIA-/- or EMILIN1-/- mice) is due to further undescribed signalling roles. 
Interestingly Prox1 and integrinα9 are also expressed in cardiac valves, but a 
cardiac phenotype has not been identified to date.69 Recently we showed that 
integrinα9 is expressed in developing VV, and is required for VV development 
and maintenance.44 (Appendix 13)  
 
1.7.2 Eph-ephrin signalling 
The Eph receptors are the largest family of receptor tyrosine kinases found in 
man, and are bound by two subclasses of ligand – ephrinAs and ephrinBs. 
Whilst the A-subclass proteins are tethered to the membrane by a 
glycosylphosphatidylinositol anchor, the ephrinBs are transmembrane proteins 
with a short cytoplasmic region.70 As both ligand and receptor are membrane 
bound, signalling requires cell-cell contact. Several functions have been 
attributed to Eph/ephrin signalling, including in early vascular development, 
formation of tissue borders, axon guidance, cell migration and in synaptic 
plasticity. 70,71,72  
 
Following binding of clustered ligand, Eph receptors oligomerise and 
autophosphorylate leading to the association of adaptor proteins and ongoing 
signalling into the cell (‘forward signalling’) including cytoskeletal effects, which 
may be mediated by actin-binding proteins such as Abl and Arg. In neurons, 
activation of Eph receptors activates Rho, and inhibits Cdc42 and Rac (Rho 
family GTPases), leading to a shift in actin cytoskeletal dynamics towards 
increased contraction and reduced extension. Activation of Eph receptors by 
contacting a cell expressing the appropriate ephrin can therefore lead to 
repulsion away from the ephrin-expressing cell and the establishment of tissue 
boundaries. These mechanisms appear to be cell and context specific, as 
ephrin-Eph interactions may also mediate attractive forces.70,72  
 
 





Figure 7 Structure of Eph receptors and their ephrin ligands70 
PDZ domains are common signalling domains, PDZ being the acronym for the first 
three proteins found to contain the domain. SAM = sterile alpha motif. GPI = 
Glycophosphatidylinositol, a glycolipid attached during posttranslational modification to 
enable membrane anchoring.  
 
Binding of Eph’s to ephrin’s can also result in ‘reverse signalling’ through the 
cytoplasmic domains of the ephrins. Eph binding results in phosphorylation of 
conserved tyrosine resides in the ephrinB cytoplasmic domain. EphrinBs can 
also recruit PDZ-domain proteins to a conserved PDZ-binding motif at the tip 
of their cytoplasmic tail. These PDZ-domain proteins may be adaptor proteins 
or contain functional domains, and mediate further signalling into the cell that 
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is independent of the ephrin tyrosine kinase domains.70 Although ephrinAs 
lack a cytoplasmic tail, they can still mediate reverse signalling.72 Cell-cell 
interaction is terminated (and regulated) by cleavage and trans-endocytosis of 
the entire receptor complex into either the Eph or ephrin-expressing cell, in the 
direction of signalling.72 
 
Notably, in early vasculogenesis, prior to the onset of flow, arteries and veins 
are identifiable by reciprocal expression respectively of ephrinB2 and EphB4. 
EphrinB2 has been reported to be a specific arterial marker and to be absent 
from veins.73,71,70 Experiments in which the cytoplasmic tail of ephrinB2 was 
deleted (and replacement with βgal) demonstrated that reverse signalling is 
not required for events in early angiogenesis, but neonates were found to die 
up to 24hrs after birth with defects in cardiac valve development.71 EphrinB2 is 
expressed on the downstream surface of developing cardiac valves, and the 
aortic and pulmonary valves of ephrinB2lacZ/LacZ hearts were grossly 
thickened.71 Their mitral (but not tricuspid) valves also appeared hyperplastic, 
with the increase in size due to increased numbers of mesenchymal cells. It is 
possible that ephrinB2 reverse signalling regulates the endothelial-
mesenchymal transition of endocardial cells that occurs during cardiac valve 
formation.71 
 
A critical requirement for ephrinB2 reverse signalling has been identified in in-
vivo lymphatic development by generating two knock-in alleles in its c-
terminus.73 The first, termed ephrinB2ΔV, lacked a functional c-terminal PDZ 
domain. In the second, ΔY (previously ΔF), the tyrosine residues were 
replaced with phenylalanine or leucine to block tyrosine phosphorylation (but 
possibly also interfere with signalling through the PDZ domain).73 
EphrinB2ΔVΔV mice survived the requirement for ephrinB2 in early 
vasculogenesis, but showed severe lymphatic defects including chylothorax, 
lymphatic hyperplasia, lack of lymphatic remodelling and a failure to form 
lymphatic valves. These defects were almost entirely rescued (with normally 
valved collecting vessels) in ephrinB2ΔYΔY mice, indicating that reverse 
signalling through the ephrinB2 PDZ domain (rather than the tyrosine kinase 
domains) is critically required for lymphatic development and LV formation.73 It 
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has been suggested that ephrinB2 could be required for guiding cell 
elongation and migration during valve formation.73 Recently we showed that 
ephrinB2 is expressed in developing VV, and is required for their development 
and maintenance.44 (Appendix 13) 
 
1.7.3 Fox family of transcription factors  
The forkhead box (Fox) proteins constitute a large family of transcription 
factors that share an evolutionarily conserved 100 amino-acid DNA binding 
domain – the forkhead motif (first identified in the Drosophila gene forkhead) 
with wide ranging roles including development, cell cycle control, metabolism, 
acquisition of speech and immune function.74,75 The ‘c’ subfamily of FOX 
genes consists of Foxc1 (formerly Mf1) and Foxc2 (formerly Mfh1) which 
encode proteins with virtually identical DNA-binding domains and generally 
similar embryonic expression patterns.74,76  
 
In man, mutations in FOXC2 cause Lymphoedema Distichiasis in which 
typically asymmetrical bilateral lower limb lymphoedema of variable age of 
onset is associated with a double row of eyelashes.77,78 Mutations in FOXC2 
have previously been associated with venous reflux and it has been suggested 
that the venous valves in these patients are defective.50 It is interesting to note 
that these patients are not reported to develop typical venous hypertensive 
skin changes with ulceration. The mechanism for VV failure in these patients 
has not been identified.  
 
Mutations in a closely related gene, FOXC1, can cause the Axenfeld-Rieger 
syndrome, with primarily ocular and craniofacial phenotypes.79 Although 
lymphoedema and venous reflux have not been described as part of this 
syndrome, these phenotypes are often subtle and it is possible that it has been 
missed (as has recently been described for GJA1 mutations and suggested for 
GJC2 mutations58). 
 
Both Foxc1 and Foxc2 are implicated in cardiovascular development and are 
expressed in multiple cell types contributing to cardiac outflow tract 
development, including the secondary heart field, neural crest cells, and 
 
  34 
endocardial cells.76,80, 81  Most compound Foxc1;Foxc2 heterozygotes, as well 
as all single homozygotes, die pre- or perinatally with a variety of problems 
including hypoplasia of semilunar valves.80 Compound Foxc1;Foxc2 null 
embryos die much earlier and with more severe cardiovascular defects 
(including hypoplastic semilunar valves) than single Foxc null mutants.82 Mice 
that are homozygous for Foxc1 null alleles die pre- or perinatally with 
phenotypes including the interruption/coarctation of the aortic arch, ventricular 
septal defects, and aortic and pulmonary valve dysplasia.83,84 Together these 
data suggest that Foxc1 and Foxc2 play partially redundant and dose-
dependent roles in cardiac development. 
 
In the lymphatic system, Foxc2 is required for maturation of collecting vessels, 
and deficiency results in abnormal mural cell recruitment around lymphatic 
valves.39,40  Foxc2 has been proposed to function downstream of signalling 
from Vegfr3, consistent with the widespread expression of Vegfr3 and Foxc2 
in mesenteric lymphatics. Whilst Vegfr3, Foxc2 and Prox1 expression falls in 
the lymphangion, expression remains high in the valves.39,40,85 Signalling 
through Vegfr2/3 will be discussed further below.  
 
Over 1600 sites where a Foxc2 binding site is very close to a NFATc1 binding 
site have been identified39, suggesting that nearby genes are targets of 
combined activation by Foxc2 and NFATc1. Notable targets include:  Gja1 
(encoding Cx43), foxp1, SEMA3A, NRP1, EfnB2 (encoding ephrinB2), HEY2, 
TEK (encoding Tie2), NR2F2 (encoding Coup-TFII). In the lymphatic system, 
constitutive deletion of Foxc2 (or inhibition of NFAT signalling with ciclosporin) 
produces a failure to remodel the initial lymphatic plexus into collecting 
vessels, and an associated failure to form intra-luminal valves.39,40 SMCs are 
normally absent around LV’s, whereas in Foxc2 null mice, there is abnormal 
recruitment of SMC’s to these sites.40 This has been hypothesised to be the 
result of loss of NRP1/semaphorin signalling between lymphatic endothelial 
cells and pericytes.86 The role of Foxc2 in the maintenance of the lymphatic 
system has not previously been studied because of the failure of constitutive 
knockouts to survive and the lack of tools for conditional Foxc2 deletion.40 
 
 
  35 
1.7.4 Notch signalling 
In Foxc1 and Foxc2 null murine embryos compound, endothelial cells appear 
to fail to adopt an arterial identity, and Foxc1/2 are thought to act upstream of 
Notch in arterial specification.87,76,88 In vitro, over-expression of Foxc2 
produces upregulation of the arterial markers Notch1 and delta-like ligand 4 
(Dll4).76 In pulmonary microvascular endothelial cells Foxc1 and Foxc2 directly 
activate the Hey2 promotor via upstream forkhead binding elements. In 
addition, Foxc2 binds the mediator of Notch signalling, Su(H), and so directly 
contributes to activation of the Hey2 promoter by Notch.87 Mutations in 
NOTCH1 have been found to segregate with a spectrum of aortic valve 
developmental disorders (and subsequent valve calcification).89 Recently, after 
completion of the work in this thesis, signalling through Notch1 was found to 
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1.7.5 Calcineurin-NFAT signalling 
Nuclear Factor of Activated T cells (NFAT) was originally identified in the 
response of T cells following T-cell receptor binding to antigen-MHC complex. 
(Figure 8) The NFAT family comprises 5 members with generally non-
redundant functions.91 NFAT1-4 are found in vertebrates. NFAT2, which is a 




Figure 8 Regulation of NFAT signalling by calcineurin and calcium92 
In the resting state NFATc is phosphorylated (PO3) and resides in the cytoplasm. A rise 
in intra-cellular Ca2+ leads to activation of calcineurin, which dephosphorylates NFAT’s, 
revealing a nuclear localization sequence. In the nucleus NFATs act as signal 
integrators with other proteins. In T lymphocytes (from where most information on NFAT 
signalling derives), stimulation of a cell surface receptor (TCR) results in activation of 
phospholipase C (PLC), release of Inositol-triphosphate (IP3) and release of intracellular 
Ca2+ from intra-cellular stores via the IP3 receptor. Influx of extra-cellular Ca2+ via 
Calcium Release Activated Ca2+ (CRAC) channels is required for full NFAT activation. 
In cardiac valve formation, it has been suggested that IP3 may pass between 
endocardial cells via gap junctions, leading to NFAT activation in neighbouring cells.92-94 
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In the resting state NFATs reside in the cytoplasm but upon an increase in 
intracellular Ca2+ (released from intracellular stores) calcineurin is activated 
(via calmodulin) and dephosphorylates serine residues on a conserved 300-
amino-acid NFAT regulatory domain, resulting in the exposure of a nuclear 
localization sequence. Once dephosphorylated, NFAT proteins translocate to 
the nucleus and form complexes with other factors to bind transcriptional 
targets. NFATs are weak transactivators, and binding with other proteins is 
typically required for their full downstream effects. The interaction of Foxc2 
and NFATc1 in the nucleus to form regulatory complexes on DNA targets has 
been discussed previously.39 NFATc1 and NFATc4 bind their own promoters, 
establishing a positive feedback loop. NFATs are rapidly dephosphorylated by 
a GSK3 dependent mechanism and exported from the nucleus, allowing 
discrimination between brief and prolonged Ca2+ stimuli. The activity of 
calcineurin is inhibited by the drug ciclosporin A (CsA), derived from the 
fungus Tolypocladium inflatum. CsA crosses the placenta and has been 
shown to block all detectable calcineurin phosphatase activity in embryos. In 
the cytoplasm it forms a complex with cyclophilin, and the drugprotein 
composite surface then binds to the interface of the calcineurin A/B complex, 
which blocks its phosphatase activity by preventing access of the 
substrate.95,96 When Ca2+ entry is prevented or calcineurin activity is inhibited 
the half-life of nuclear NFAT is ~15mins. Additional modulation of this pathway 
is provided, for example, by DSCR1 inhibition of calcineurin, and DYRK1a-
mediated acceleration of phosphorylation. These mechanisms may have 
important roles in clinical disease, having been suggested to be responsible 
for the phenotype of Down’s syndrome.97  
 
NFAT signalling has important roles in cardiac valve morphogenesis. In man, 
a mutation in NFATc1 has been identified in a patient affected by tricuspid 
atresia.98 In murine models it has been demonstrated that in response to local 
myocardial cues, endocardial cells in the cardiac outflow tract (OFT) and 
atrioventricular canal (AVC) undergo an endocardial-to-mesenchymal 
transformation (EMT) to form endocardial cushion cells.99 NFATc1 is 
expressed in endocardium and constitutive homozygous deficiency of NFATc1 
is fatal at mid gestation due to a failure to form cardiac valves.100,101 
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Conditional deletion of the calcineurin regulatory subunit CnB1 in endocardial 
cells (mediated by Tie2Cre) results in an almost identical phenotype to 
constitutive NFATc1 deletion. Aortic, pulmonary, mitral and tricuspid valves all 
failed to remodel and elongate, with associated lethality at E13.5-E14.5.96, 102 
EMT occurred normally, indicating a specificity for endocardial NFATc1 
signalling in valve remodeling. Experiments with CsA indicated a critical time 
window between E11-E12 in which calcineurin-NFAT signalling is required for 
valve development.96 
 
NFATc1 is required for lymphangiogenesis and maturation of lymphatic 
collecting vessels, including valve formation.39, 42, 103 Deletion of CnB1 in 
endothelial cells inhibited early events in lymphatic valve formation, leading to 
a broad area of high Prox1 signal, instead of a narrow ring of rotated nuclei.42 
CnB1 was also required for the maintenance of formed lymphatic valves – 
conditional deletion resulted in a reduction in the length of the leaflet matrix 




Gap junctions form conduits between adjacent cells, and are found joining 
virtually all cells in solid tissues, mediating the passive diffusion of metabolites, 
ions and signalling molecules.104, 105,106 (Figure 9) In vertebrates gap junctions 
are composed of connexins, integral membrane proteins composed of 4 
transmembrane domains with 2 extracellular loops, and a cytoplasmic loop. 
Both the N- and C- termini are cytoplasmic, with the C-terminal tail of variable 
length involved in the regulation of channel gating and other functions.107 Six 
connexins aggregate to form a hexameric connexon, which may either form a 
hemi-channel linking the cytoplasm and extra-cellular space, or dock with a 
connexon from a neighbouring cell to form a gap junction channel. Individual 
gap junction channels coalesce to form ‘plaques’. 22 connexin genes have 
been identified in man, with their protein products being named according to 
approximate molecular weight.108  
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Some connexins have been shown to oligomerise into hexamers with the 
same (homomeric) or another (heteromeric) connexin, and additionally a gap 
junction channel may be formed from connexons formed of more than one 
type (heterotypic junctions). This allows for an increase in the potential 
combinations of connexins that can contribute to a channel, and variability in 
the regulation of communication through the channel. Importantly, it is possible 
for mutated connexins to exert dominant-negative effects, for example in the 
case of a heterozygous carrier of a mutated protein.108 At the cell membrane 
connexins associate with a range of proteins – the ‘connexome’, and it is 
possibly through these associated proteins that they exert their non-gap 
junction-mediated effects, such as on cytoskeletal rearrangements, cell 
migration and proliferation.108  
 
 
Figure 9 Gap junction channels are composed of connexins105 
Each connexin protein has four membrane spanning regions, with cytoplasmic N- and 
C-termini. Six connexins are assembled to form a transmembrane connexon, which 
may form a hemi-channel or dock with a connexon on a neighbouring cell to form a gap 
junctional channel, characterized by a narrow core axial channel joining the cytoplasm 
of the cells.  
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Connexins have variable permeability to ions and small signalling molecules, 
(such as cAMP) and variable voltage-gating properties, allowing for a variety 
of signalling functions even before mixed channels are considered. The 
identification of the precise signalling molecules responsible for specific 
defects has remained challenging.105  
 
1.7.7 Connexins 43, 47 and 37 
The GJC2-eGFP knock-in mouse is not reported to show any lymphatic or 
venous phenotype, and expression of eGFP was not noted in either system.61 
However, expression of Cx47, Cx43 and Cx37 was recently reported in 
lymphatic structures using immunohistology.42, 109 Whilst Cx37 and Cx43 
immunostaining was reported in the lymphatic endothelium, Cx47 
immunostaining was more restricted and appeared to localise to a subset of 
valve cells in some mesenteric lymphatic valves, but was more clearly 
identified in thoracic duct valves.110 Whilst mesenteric lymphatic valves are 
composed of 2 layers of endothelial cells, thoracic duct valves are reported to 
include interstitial cells within their matrix core in a structure more consistent 
with that which will be described in murine VV in this thesis.109 
 
The lack of lymphatic phenotype in the Cx47-eGFP knock-in mouse has been 
suggested to be as a result of complete loss of the protein, rather than the 
presence of a mutated form that could exert dominant-negative effects on 
other connexins.4, 61 Accordingly, carriers of early nonsense mutations leading 
to a grossly shorted polypeptide do not show a lymphoedema phenotype.4    
 
Mutations in Cx37 have not been associated with human venous or lymphatic 
disease, but it is required for lymphatic valve development.109, 111 Recently, it 
was demonstrated that adult Cx37 knockout mice do not have VV, but the 
authors were unable to comment on whether Cx37 is required for valve 
development or subsequent maintenance, or identify the cellular phenotype 
caused by loss of Cx37.111 These authors analysed valves after development 
was complete, and did not examine the localisation of Cx37 during valve 
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development, or elucidate the cellular processes that go awry with loss of 
Cx37. 
 
Cx37 also has important roles in the arterial system. In man, a common 
polymorphism is associated with cardiovascular mortality risk. Cx37 appears 
to be important in revascularisation as the Cx37-/- mouse recovers limb 
perfusion more rapidly following induction of hind limb ischaemia.112-114  
 
Connexins have important additional functions unrelated to channel activity. 
For example, knockdown of Cx43 in cortical neurons produces defects in 
migration that are rescued by channel-dead mutants, suggesting adhesivity 
between connexins or an effect on migration machinery independent of 
channel activity.105 Cx43 is thought to regulate cell polarity and directional 
migration in vivo and in-vitro, and loss of Cx43 function is associated with 
abnormal actin stress fiber organization and a loss of polarized cell 
morphology.115,116 
 
Whilst the regulation of connexins has not been examined in the venous 
system, the intricate pathways linking nuclear transcription factors, lymph flow, 
and connexins 37 and 43 have been examined in the lymphatic system.  
Increased Cx37 immunostaining was identified in two regions on opposite 
sides of lymphatic vessels in their valve-forming region. In the Cx37-/- mouse, 
Prox1hi/Foxc2hi cells coalesce, but fail to organise into the ring-like 
constrictions (corresponding to stages 1-2 of VV development) seen in wild-
type littermates.42 Cx37 may be regulated by Foxc2 in lymphatics as this 
connexin was absent in the jugular lymph sac of Foxc2-/- mice, and its mRNA 
reduced in LECs from Foxc2-/- mice.42,109  
 
In vitro, oscillatory flow produced upregulation of Foxc2, nuclear localisation of 
Nfatc1 and downregulation of Cx43, mimicking the appearance of valve-
forming cells in vivo. Interestingly, upregulation of Prox1 occurred more in 
response to laminar flow, whilst that of Foxc2 in response to oscillatory flow. 
In-vitro knockdown of Prox1 and Foxc2 prevent the response of Cx37 and 
NFatc1 to flow. In addition, Cx37 was required for the NFATc1 response to 
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fluid flow but remarkably loss of Cx37 did not simply result in uniform failure of 
nuclear accumulation of NFATc1, but rather in activation in isolated cells. This 
implies that in-vivo Cx37 (and GJIC) can contribute to the organisation of the 
region of valve forming cells (VFC’s). The identity of the molecule that may 
pass through gap junctions is unknown; two possible candidates for this role 
are Ca2+ and IP3 (Figure 8).92, 106 
 
Taken together, these in-vitro and in-vivo findings by Sabine et al point to an 
accumulation of mechanisms by which a valve-forming region of vein can 
gradually acquire its phenotype, and VFC’s can subsequently organise to form 
the ring of endothelial cells with upregulated transcription factors that identifies 
early LV formation. It is expected that those processes demonstrated in 
lymphatic endothelial cells in-vitro also occur in vivo, and that similar 
processes may regulate venous valve development.  
 
The larger size of venous valves and the consistent site of development of the 
proximal femoral valve in mice provides the opportunity to further examine 
these processes in-vivo, and to develop a model of altered flow in-vivo. The 
role of Cx47 in VV (or LV) development has not been described, nor has the 
contribution of Cx43 to early developmental events been shown. Furthermore, 
whilst Kanady et al recently showed failure of lymphatic-valve formation and 
lymphatic drainage in Cx37/;Cx43+/ mice109, it is not known whether Cx43 
deletion alone produces a lymphatic phenotype. Homozygous constitutive loss 
of Cx43 is lethal within a few hrs after birth due to cardiac right ventricular 
outflow tract malformation, precluding detailed analysis of lymphatic or venous 
valve development.117 
 
1.7.8 VEGFR2 / VEGFR3 signalling 
The vascular endothelial growth factors (VEGF’s) are secreted dimeric 
glycoproteins that include VEGFs A-D and placental growth factor (PLGF).118 
The VEGF receptors (VEGFR’s) are members of the receptor tyrosine kinase 
superfamily, and belong to the same subclass as receptors for the PDGF’s 
and FGF’s (Figure 10).118  VEGF-VEGFR signalling is critically required for 
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early events in the development of the blood vascular system, and genetic 
constitutive deletion of VEGFR2 or VEGFR3 results in embryonic lethality.118  
 
 
Figure 10 VEGFR ligand binding118 
VEGFR’s consist of 7 extracellular IgG-like domains (6 for VEGFR3, represented by 
spheres), a single transmembrane domain, and a split intracellular tyrosine kinase 
domain (represented by red cylinders and affected by mutations causing Milroy’s 
disease). Proteolytic processing is required for VEGFC/D to bind VEGFR2, and these 
factors bind VEGFR2 with less affinity that VEGFR3. Several protein (not shown) act as 
co-receptors to VEGFRs, including heparan sulphate proteoglycans and neuropilins 
(NRP1/NRP2). Binding of ligand guides and stabilises receptor dimerization and is 
accompanied by activation of the receptor-kinase activity, leading to receptor 
autophosphorylation. Phosphorylated receptors subsequently recruit interacting proteins 
and induce activation of signalling pathways. Receptor complexes are subsequently 
internalized and downgraded. VEGFR3 interacts with (and is regulated by the presence 
of) EphrinB2 via intermediate proteins. The cell surface glycoproteins neuropilin1 
(NRP1) and NRP2 act as non-kinase coreceptors; NRP1 enhances binding of VEGF to 
VEGFR1/2, and NRP2 enhances binding of VEGFC to VEGFR3. VEGFR’s may also 
form mechanosensory complexes with of platelet-endothelial-cell adhesion molecule-1 
(PECAM1), vascular endothelial (VE)–cadherin and integrins. PLGF = placental growth 
factor. 118,119,120,  
 
VEGFR3 transduces signals following binding by VEGFC or VEGFD          
(Figure 10).121 VEGFR3 inactivation causes significant defects in arterial–
venous remodelling of the primary vascular plexus, resulting in lethality by 
E10.5.122 At later stages, expression of VEGFR3 was thought to be restricted 
to the lymphatic endothelial system, but more recently it has been shown to 


























that have been characterized 
as receptors for semaphorins in 
neuronal guidance and as 
co-receptors for VEGFs in 
angiogenesis.
Oedema
Abnormal and excessive 
accumulation of fluid in the 
tissue, which might be localized 
or generalised.
Structure and expression of VEGFs. Structurally, the 
VEGFs are related to the PDGF family of growth factors, 
with intrachain and interchain disulfide bonds between 
eight cysteine residues in conserved positions. The cry s-
tal structure of VEGFA revealed two monomers that are 
organized in an anti-parallel fashion to form a dimer, 
with the receptor-binding sites located at each pole of 
the dimer3. The VEGFs preferentially form homodimers, 
although VEGFA and PLGF heterodimers have been 
identified4 (FIG.1a).
Alternative splicing of several of the VEGF family 
members gives rise to isoforms with different biological 
activities. The human isoforms are denoted VEGFA121, 
VEGFA145, VEGFA165, VEGFA189 and VEGFA206 
(see Supplementary information S1 (figure)). The 
mouse isoforms are one amino-acid residue shorter 
than the corresponding human isoform, and they are 
denoted VEGFA120 and so forth. The activities of the 
VEGFA isoforms are dictated by their different abilities 
to interact with VEGFR co-receptors, such as neuropi-
lins and HSPGs (FIG. 1b,c). Another splice variant of 
VEGFA, known as VEGF165b, has been proposed to 
negatively regulate VEGFR activity5.
The bioactivity of VEGF family members is also 
regulated by proteolytic processing. This mechanism 
might enable specific interactions with different 
types of receptor. For example, in humans, processed 
VEGFC and D bind to VEGFR2, as well as to VEGFR3. 
Furthermore, proteolytic processing of VEGFA splice 
variants affects their ability to interact with the VEGF 
co-receptors HSPGs and neuropilins6.
Structure of VEGFRs. The VEGFRs are members 
of the RTK superfamily and they belong to the same 
subclass as receptors for PDGFs and fibroblast growth 
factors (FGFs). The VEGFRs are equipped with an 
approximately 750-amino-acid-residue extracellular 
domain, which is organized into seven immunoglobulin 
(Ig)-like folds. In VEGFR3, the fifth Ig domain is 
replaced by a disulfide bridge. The extracellular domain 
is followed by a single transmembrane region, a juxta-
membrane domain, a split tyrosine-kinase domain that 
is interrupted by a 70-amino-acid kinase insert, and a 
C-terminal tail (FIG. 2). Structural and functional studies 
have yielded insights into how the distinct domains 
contribute to VEGFR activity. The crystal structure of 
part of the extracellular domain of VEGFR1, alone and 
in complex with ligand, shows that the Ig domain-2 
constitutes the ligand-binding site on the receptor7. 
In addition, biochemical analyses showed that the 
Ig domain-3 in VEGFR2 is important for the determin-
ation of ligand-binding specificity8. Alternative splicing 
or proteolytic processing of VEGFRs give rise to secreted 
variants of VEGFR1 (REF. 9) and VEGFR2 (REF. 10), and in 
humans, to a C-terminal truncated VEGFR3 (REF. 11).
Although the VEGFRs are primarily expressed in the 
vascular system, more sensitive methodologies com-
bined with improved reagent quality have allowed the 
detection of VEGFR expression in non-endothelial cells 
(see Supplementary information S2 (table)). However, 
genetic models (TABLE 1) imply that the most important 
function of VEGF/VEGFRs is in the vascular system.
Regulation of VEGFR activity
The activity of RTKs is regulated by the availability of 
ligands. A particular feature of the VEGFA ligand is the 
dramatic upregulation of its expression levels under 
hypoxic conditions. Hypoxia allows the stabilization 
of hypoxia-inducible factors (HIFs) that bind to specific 
promoter elements that are present in the promoter 
region of VEGFA12. Similarly, expression of VEGFR1 
is directly regulated by HIFs13. VEGFR2 is also upregu-
lated during hypoxia, but the role of different HIFs 
in this regulation remains to be clarified. VEGFR3 
expression is upregulated in differentiating embryonic 
stem cells that are cultured in a hypoxic atmosphere14. 
However, the contribution of hypoxia to regulation of 
VEGFR3 expression in vivo is still unclear.
Figure 1 | VEGF receptor-binding properties and signalling complexes. 
a | Mammalian vascular endothelial growth factors (VEGFs) bind to the three VEGF 
receptor (VEGFR) tyrosine kinase , leading to the formation of FR homodimers and 
heterodimers. Proteolytic processing of VEGFC and D allows for binding to VEGFR2. 
b | VEGFR signalling is modulated by different co-receptors. VEGFs as well as VEGFRs 
bind t  co-r ceptors such as heparan sulphate proteoglycans (HSPGs) and neuropilins. 
These interactions can influence VEGFR-mediated responses, for example, affecting 
the half-life of the receptor complex. c | Mechanosensory complex formation. Blood 
flow might activate VEGFRs in a ligand-independent manner, by the formation of 
mechanosensory complexes that consist of platelet-endothelial-cell adhesion 
molecule-1 (PECAM1), vascular endothelial (VE)–cadherin, VEGFRs and integrins. 
PLGF, placenta growth factor.
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postnatal transgenic over-expression of soluble VEGFR3 results in regression 
of lymphatic vessels, but not major blood vessels, with an associated onset of 
lymphoedema.125 Homozygous gene-targeting of VEGFC leads to embryonic 
lethality at E16.5 as a result of a complete failure in lymphatic vessel 
formation, whereas VEGFC heterozygous mice survive with lymphatic vessel 
hypoplasia and lymphedema, but do not appear to exhibit blood vascular 
defects as found in adults.15 Notably, homozygous loss of VEGF-C and    
VEGF-D does not phenocopy loss of VEGFR3 (i.e. embryos survive longer), 
indicating that other critical signalling processes occur through VEGFR3.126 
These may involve other (unknown) ligands or ligand independent signalling, 
described as active and passive pathways.123 Inhibition of these pathways 
produces different phenotypes in retinal angiogenesis. Whilst inhibition of 
ligand-dependent signalling with anti-VEGFR3 antibodies suppressed 
angiogenesis (with reduced sprouting), conditional endothelial cell-specific 
VEGFR3 deletion resulted in excessive angiogenesis (increased sprouting). 
123, 127 These contrasting results emphasise that inhibition of ligand binding or 
inhibition of intrinsic tyrosine kinase activity block only some (active pathway) 
VEGFR3 activities, whilst conditional VEGFR3 deletion will block all.123 
 




Figure 11 Proposed model of active and passive signalling through 
VEGFR3123 
VEGFR3 can be phosphorylated by the tyrosine kinase Src following cell-matrix 
adhesion, even in the absence of VEGFR3 intrinsic kinase activity. Only the active 
signalling pathway is targetable by inhibitor molecules, including the small molecule 
inhibitor MAZ51. Dll4, Hey1 and Hey2 are canonical Notch targets also known to be 
upregulated by the transcription factor Foxc2. It has become clear that in lymphatics 
Foxc2 is upregulated downstream of VEGFR3; Foxc2 mRNA was not detected in the 
endocardium of homozygous VEGFR3lacZ embryos.40 Subsequently, in retinal 
angiogenesis, Foxc2 was found to be upregulated by signalling through VEGFR3.123 
ECM=extra cellular matrix, NICD = Notch intracellular domain. PLGF = placental growth 
factor.  
 
It remains unclear precisely how known human mutations in VEGFR3 result in 
lymphoedema. Most mutations are missense, although a few deletions and a 
single splicing variant have been reported.128 These mutations result in 
tyrosine kinase–negative receptor proteins with extended cellular half-lives, 
with the mutant protein residing for longer periods of time at the cell 
membrane.128,129 Mutant protein may exert dominant-negative effects.130 The 
Chy mouse exhibits constitutive heterozygous loss of VEGFR3 protein 
tyrosine kinase function, and displays cutaneous lymphoedema.130 The same 
mutation carried in the Chy strain was recently reported in a patient with 
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Figure 7 VEGFR-3 interacts with the transcription factor FoxC2 to control
angiogenesis. (a) Fold change in the level of FOXC2 mRNA expression
following stimulation of hBECs with 200ngml 1 VEGF-C (n =3 plates
per group). (b) Immunostaining for FoxC2 (red) and isolectin B4 (iB4;
green) in Vegfr3i EC and wild-type littermate pups at P5. Arrowheads
indicate FoxC2-negative tip cells. (c) Quantification of FoxC2-positive
nuclei from the retinas shown in b. Nuclei in the area of iB4-positive
endothelial cells were quantified at the angiogenic front (n = 3 pups
per group). (d,e) Fold change in the level of Foxc2 mRNA expression
in Vegfr3i EC and wild-type littermate retinas (d), and in Vegfc+/ 
or wild-type littermate retinas (e) at P5 (n =3 pups per group). (f) iB4
staining (white) in Foxc2+/ ;Vegfr3+/ , Foxc2+/ , Vegfr3+/  or wild-type
littermate retinas at P5. Yellow dots in the lower panels indicate filopodia.
(g–i) Quantitative analysis of the retinas shown in f. (g) iB4-positive
surface area normalized to total area. (h) Number of vessel branching
points. (i) Filopodia per length of vascular front. Data pooled from 2 litters;
n = 3 Foxc2+/ ;Vegfr3+/ , 4 Foxc2+/ , 4 Vegfr3+/  and 4 wild-type
pups. Scale bars, 50 µm. ⇤P < 0.05, ⇤⇤P < 0.01, ⇤⇤⇤P < 0.001. Error
bars, s.e.m. (j) Schematic of VEGF-C-expressing macrophages in vessel
anastomosis and branch maintenance during developmental angiogenesis.
Initially, 2 tip cells that lead vascular sprouts are chaperoned to fuse
by a macrophage (green). VEGF-C expression (purple) ensues in the
macrophage, activating VEGFR-3 in the tip cells, which leads to the
expression of Notch target genes and decreased sensitivity to the VEGF
gradient in the cells. Vegfr3 loss-of-function (LOF) leads to decreased
Notch signalling. A simplified summary of the ‘active’ (green) and
‘passive’ (red) signalling pathways originating from VEGFR-3 is shown in
the upper left corner. Only the ‘active’ pathway is targetable by inhibitors.
Our analysis of mice harbouring various allelic combinations of
endothelial-cell-deleted (i1EC), kinase-dead mutant and wild-type
Vegfr3 allowed for a titration of both kinase activity and genetic
dose of VEGFR-3. The combination of a 50% decrease in genetic
dose and loss of kinase activity in the remaining allele (i1EC/KD)
represented a threshold for the degree of VEGFR-3 phosphorylation
NATURE CELL BIOLOGY ADVANCE ONLINE PUBLICATION 9
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1.7.9 A role for flow in valve development 
Since the first descriptions of lymphatic and venous valve development in the 
late 1920’s it has been suggested that intraluminal flow has an important role 
stimulating their development.22,41 Abnormal blood flow and shear stress 
adversely affect heart valve formation in the chick and zebrafish,131-133 and in 
the mouse flow directs formation of a left-sided aortic arch, indicating the 
importance of blood-flow in directing morphogenesis.134 In the lymphatic 
system, flow has been suggested to have a role in valve formation.42 To the 
best of my knowledge a critical requirement for normal flow has not been 
demonstrated for lymphatic or venous valves in vivo. 
 
Several mechanisms by which flow might modulate valve formation have been 
proposed. Intravital microscopy has demonstrated oscillatory fluid flow in 
lymphatics prior to the onset of valve development, and a similar pattern of 
oscillatory flow might be expected prior to valve development in veins.42 In 
vitro, oscillatory blood flow upregulates Foxc2 and Cx37, and acts in concert 
with Prox1 to regulate LEC morphology.42 In bEnd3 murine capillary 
endothelial cells there is an earlier and greater increase in the expression of 
Cx43 in response to oscillatory flow compared with unidirectional shear 
stress.135  
Shear stress induces phosphorylation of the receptor tyrosine kinase Tie2 in 
endothelial cells and the effect is proportional to flow velocity, leading us to 
speculate that shear stress induced phosphorylation of Tie2 may be one 
mechanism in VV development.136 Blood flow might activate VEGFRs in a 
ligand-independent manner, by the formation of mechanosensory complexes 
consisting of PECAM1, (VE)–cadherin, VEGFRs and integrins.118 
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1.8 Background summary 
A recent review85 suggests the following interaction between the previously 
described pathways (Figure 12), suggesting activation of VEGFR2/3 (possibly 
interacting with EphrinB2119) leading to PLC-IP3-Ca2+-calmodulin-calcineurin 
activation of NFATc1, which binds to and signals with Foxc2 in concert with 
Prox1 to stimulate valve development by upregulating integrinα9 and 
Fibronectin-EIIIA, and downregulating PDGF-B and Collagen IV.85 (Data for 
Figure 12 in this review85 quotes a personal communication from Prof. T. 
Petrova, and Appendix 13 44 to this work.) Both Foxc2 and Prox1 upregulate 
Cx37, and Foxc2 may downregulate Cx43.42, 111. It is possible that signals 
(possibly IP3 or Ca2+) pass between endothelial cells via gap junctions to 





Figure 12 Proposed signalling events in LV formation 85 
A schematic of a valve-forming lymphatic EC is shown (green). The white circle 
represents the nucleus. It has been proposed85 that signalling via VEGFR2/3 (arrow 
above VEGFR2/3), possibly interacting with ephrinB2, acts upstream of Calcineurin-
NFAT signalling. Prox1, Foxc2 and NFATc1 are nuclear transcription factors that have 
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Several of these proteins have been described as being specifically expressed 
in arterial or lymphatic (and not venous) EC’s, and Prox1 is widely thought to 
act as the master regulator of lymphatic EC fate in their differentiation away 
from venous EC’s.35, 37, 103, 137, 138  However, given the phenotype of venous 
reflux shown in patients with mutations in FOXC249, 50 and VEGFR351-53, and 
some known similarities in the phenotypes of VV endothelial cells40, this thesis 
will explore the hypothesis that these factors (and others) regulate VV 
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1.9 Rationale for this study  
 
Venous valve failure, associated with venous reflux and hypertension, is 
commonly found in human venous disease and leads to significant morbidity. 
A better understanding of the processes involved in the development and 
maintenance of VV may lead to new therapies that replace absent or 
dysfunctional valves, and could help alleviate the chronic complications 
associated with hypertension. This thesis will explore the factors affecting 
venous valve formation and maintenance in murine models and in man. 
 
Current knowledge of venous valve development relies on histological studies 
performed in human embryos several decades ago and no methods exist for 
the study of valve development in rodent models. The use of murine models 
combined with study of human venous valves could explain the mechanisms 
of venous valve failure in known single-gene disorders and identify further 
candidate genes for human venous disease. The ability to understand the 
processes that regulate venous valve development and maintenance could 
lead to new treatments to prevent venous valve failure and allow a novel 
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1.10 Hypotheses   
 
1) Venous valve development and maintenance are regulated by processes 
similar to those identified for cardiac and lymphatic valves. 
 
 
2) Several human primary lymphoedema syndromes, some previously 









1) Develop and characterise venous valve development in the mouse and to 
use this model (in conjunction with genetic loss of function models involving 
genes associated with cardiac and lymphatic valve development or disease), 








3) Develop methods to locate and measure human venous valves in vivo in 
order to investigate the effects of known genetic mutations in genes that give 
rise to primary lymphoedema (VEGFR3, Foxc2, GJC2, and GJA1), on the 
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2 GENERAL METHODS 
 
2.1 In vivo conditional genetic deletion 
A constitutive loss of function (“knockout”) approach has several limitations 
including: the potential for increased morbidity and mortality that may limit the 
utility of the line, difficulty in determining which cell type in a tissue contributes 
to an observed phenotype, and an inability to study the role of a gene in adult 
mice after normal development. For example, Foxc2-/- mice on a bl/6 
background do not survive beyond the requirement for Foxc2 in cardiac 
development around E15 and before initiation of venous valve development. 
Itga9-/- mice die between P6 and P12. Conditional deletion overcomes these 
limitations by allowing for deletion of an allele in a particular cell type 
(expressing a particular promoter) and/or at a particular time point after an 
experimental stimulus.  
 
Several experiments in this study rely on the Prox1CreERT2 line developed by 
Drs Taija Makinen and Eleni Bazigou using bacterial artificial chromosomes44 
(Appendix 13). In this line Cre recombinase is fused to a mutated ligand-
binding domain of the oestrogen receptor (CreERT2) and is expressed under 
control of the Prox1 promotor.139,140 Under normal conditions the fusion protein 
resides inactive in the cytoplasm, bound to heat shock protein 90 (HSP90), 
which inhibits nuclear translocation. 4OH-Tamoxifen (4OHT, administered i.p. 
or in feed) displaces HSP90 and results in translocation of CreERT2 to the 
nucleus and subsequent Cre-mediated deletion of a section of LoxP-flanked 
DNA - the ‘floxed’ allele (Figure 13).141 Use of various floxed alleles allows for 
spatially and temporally controlled genetic loss of function experiments of each 
allele during valve development. Deletion of an allele after valve development 
is complete produces a loss of function experiment to study the role of a 
particular allele in maintenance of the formed valve. 140 
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Figure 13 Mechanism of CreERT2 in response to 4OH-Tamoxifen140 
In the absence of 4OH-Tamoxifen (represented by violet circles) CreERT2 resides in 
the cytoplasm, bound to HSP90. 4OHT binds the estrogen receptor (1) displacing 
HSP90 (2), resulting in translocation of the fusion protein to the nucleus (3) and Cre 
recombinase activity (4). Cre excises DNA between LoxP sites (represented by black 
triangles). CreERT2 is not activated by endogenous oestrogens.  
 
Various crosses were used to produce the animals described, which resulted 
in a mixture of CreERT2+ or CreERT2-, heterozygous or homozygous floxed 
or wildtype alleles. No homozygous CreERT2+ animals were analysed. 
Littermates were grouped as appropriate into ‘effective genotypes’ of wildtype, 
heterozygous deletion and homozygous deletion and are referred to as such in 
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2.2 Animal genotyping 
 
2.2.1 DNA extraction 
DNA extraction for animal genotyping was carried out using tail or ear snips 
and the HotSHOT extraction method. 142 
 
1. Tissue samples were placed in 100µl PCR tube strips containing 75µl 
of lysis reagent (pH12.6).  
2. Samples were incubated in a thermocycler (Biorad MJ Mini) at 94oC for 
30mins, with 1min of vortexing after 15 and 30mins.  
3. 75µl of neutraliser reagent (pH5.0) was added to each sample, and the 
labelled tube strips stored at -20oC. 
 
2.2.2 PCR 
Genotyping was carried out by end-product PCR using the HotstarTaq PCR kit 
(Qiagen) according to the manufacturer’s instructions. Primer sequences and 
PCR conditions are given in Appendix 4. 
 
 
2.3 Immunofluorescence of venous valves 
 
1. Pups were culled by decapitation, and dissected to allow injection of the 
infra-renal aorta with heparinised phosphate buffered saline, pH7.4 
(PBS)  
2. When required, wholemount photographs where taken with a Leica MZ 
16F microscope fitted with a Leica DFC 420C camera.  
3. Tissues around the femoral vein were removed to allow rapid 
penetration of fixative, and facilitate subsequent dissection steps.  
4. Samples were placed in freshly thawed 4%w/v paraformaldehyde (PFA) 
for 2hrs on ice. 
5. Samples were rinsed in PBS before the vascular bundle from above the 
bifurcation to the distal femoral vessels was dissected out and stored in 
blocking solution at 4oC.  
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6. Samples were incubated with primary antibodies in PBS 24-hrs to 
5days on a shaker at 60 rpm at 4oC. 
7. Samples were washed for 2hrs at room temperature (RT) on a shaker 
in copious 0.3% v/v Triton-x100 in PBS (PBST), with changes at 0, 60 
and 120mins. 
8. Samples were incubated with secondary antibodies (and conjugated 
primaries) for 2hrs at RT on shaker. 
9. Samples were washed for 3hrs at RT on a shaker in PBST, with 
changes at 0, 60, 120 and 180mins. 
10. Samples were further dissected and mounted in Mowiol (Appendix 1) or 
Prolong Gold (Life Technologies) with a spacer (colour modelling clay, 
Scolaquip UK) between slide & cover slip. 
11. Samples were examined by widefield (Leitz DMRB) or confocal 
microscopy (Leica SP5). For confocal microscopy, optical sections were 
obtained at 1024x1024 resolution, 200Hz, 2 frame averages, z-step of 
1.5-2µm, pinhole 1Airy Unit. To minimise cross talk, fluorophores were 
excited sequentially and narrow emission filters were used around the 
predicted peak for each fluorophore. Offset was set at ~-2.4%, and 
photomultiplier tube gain adjusted to generate signal within the full 
range of the detector over the z-depth of the imaged part of the 
specimen (the vein and few microns either side), whilst avoiding >few% 
saturated pixels within the VV. 
12. Confocal z-stacks were typically 3D median filtered using a kernel size 
of 3 to reduce background noise. In NIH ImageJ, the stack was 
cropped, and a 2D maximum z projection was created. Stacks were 
retained and used to assist in identification of lymphatic vessels and 
other tissues passing near the vein, and analysis of 3D structure during 







  55 
2.4 Immunofluorescence of murine mesenteric 
lymphatics 
 
1. The small bowel was excised and pinned flat on custom made silastic-
lined (Dow Corning) 6-well plates for fixation in freshly thawed 4% PFA 
at room temperature for 2hrs.  
2. Mesenteries were washed and dissected free of the bowel and 
mesenteric lymph nodes prior to permeabilising in PBST for 2hrs, then 
blocking in 3% FCS at +4oc in 1.5ml Eppendorf polypropylene tubes 
overnight. 
3. Mesenteries were incubated with primary antibodies in eppendorfs at 
+4oc for 1-5 days, prior to washing in PBST for 2hrs and incubation with 
secondary antibodies for 2hrs.  
4. Mesenteries were washed for 2hrs and mounted (without spacers) in 
Prolong Gold, and allowed to cure for 24hrs at room temperature.  
5. Imaging was performed with a Leitz DMRB widefield microscope and/or 
Leica SP5 confocal microscope.  
 
 
2.5 Drug preparation and administration 
 
2.5.1 4-Hydroxy Tamoxifen (4OHT) 
To stimulate nuclear translocation and activity of the CreERT2 construct, 
dam’s received 2mg 4OHT i.p, whilst pups received 50µg i.p. 4OHT, 
administered in sunflower oil (Sigma) at the times indicated in individual 




Following 4OHT injection dams are unable to successfully litter to produce 
viable offspring. Progesterone (Sigma P3972, 37.5µg/g of body weight) was 
therefore administered (10mg/ml sunflower oil, Sigma S5007, i.p) to prevent 
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labour and allow explantation of embryos at a time point equivalent to P0 
(‘E19’).  
 
2.6 Obtaining human venous valves for comparison 
with murine valves (structure and protein 
expression) 
 
The aim of this study was to collect clinically normal venous valves and 
surrounding vein for use in subsequent experiments. The ethics committee 
approval number for this study was 10/H0701/68. 
 
1. Patients referred for coronary artery bypass grafting (CABG) were 
identified by the routine cardiac surgical care team at St Thomas’ 
Hospital (STH).  
2. Patients were consented for participation in the study on admission to 
hospital. Consent was obtained in accordance with the GMC guideline 
“Good practice in research and consent to research”. Participants were 
allocated a unique study code.  
3. During routine CABG surgery, any ‘spare’ or unused vein was placed in 
in a solution of normal saline (as prepared by the scrub nurse). 
4. Samples were placed in appropriate containers labelled with the 
participants unique study code and transferred to the Academic 
Department of Surgery (ADS) at STH.  
5. All samples were allocated an anonymous ‘ADS’ number on entering 
the laboratory. This was used for labelling of all samples, and 
subsequent subsamples (eg blocks, slides). All storage, use, processes 
applied to, and disposal of Relevant Material was recorded in the 
laboratory Human Tissue Act database. When no longer useful, 
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2.7 Preparation of human venous valves for scanning 
electron microscopy(
 
Veins were collected directly from theatre and opened under a dissecting 
microscope with blunt-tipped scissors in a distal to proximal direction to avoid 
causing damage to the valves. Frequently no valves were present in short 
samples. Any sections of vein containing a valve were pinned onto a cork 
board and placed upside-down in 2.5%v/v glutaraldehyde fixative and 
subsequently processed as described in section 3.5 except that samples were 
visualised in a Hitachi S-3500N scanning electron microscope. 
 
!
2.8  Preparation of human venous valves for 
transmission electron microscopy  
 
1. Vein was collected directly from theatre and opened with large blunt-
tipped scissors under a dissecting microscope in a distal to proximal 
(antegrade) direction to avoid causing damage to the valves.  
2. A section of vein containing a valve was pinned onto a cork-board and 
placed upside-down in 2.5%v/v glutaraldehyde fix overnight at +4 oC. 
3. Valves were post-fixed in 1%w/v osmium tetroxide in 0.13M Millonig’s 
phosphate buffer with 0.3M glucose pH7.3 at 4oc for 1.5hrs.  
4. Valves were dehydrated for 10mins in 10% ethanol, 30mins in 70% 
ethanol, and 3x20mins in 100% ethanol at room temperature. 
5. Valves were placed in propylene oxide for 2x10min at RT. 
6. Under a dissecting microscope a single valve leaflet was dissected from 
the vein using a razor blade on dental wax. 
7. The leaflets was pre-infiltrated in 50:50 100% ethanol:resin (TAAB 
embedding resin, medium) 
8. The leaflet was then infiltrated in 100% resin overnight at 4oC 
9. The leaflet was embedded in resin at the correct orientation for cutting 
sections and polymerised at 70oC for 24hrs. Until the resin hardened, 
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the orientation of the specimen was checked every 10mins (as 
convection currents disturbed it) 
10. Semi-thin (0.5µm) and ultra-thin (70-90nm) sections were cut using a 
Reichart OMU4 Ultracut microtome. 
11. Semi-thin sections were stained with toluidine blue and examined  
 under a microscope to determine orientation within the specimen. 
12. Ultra-thin sections were examined and recorded using a Hitachi H7600 
transmission electron microscope fitted with an AMT digital camera 
system. 
Steps 4-8 and 10-11 were carried out by Dr Gema Vizcay-Barrena at the 
centre for ultrastructural imaging (CUI) 
!
2.9 Preparation of human venous valves for paraffin 
embedding and sectioning  
 
1. Veins were opened longitudinally using blunt-ended scissors under a 
dissecting microscope. Alternatively, the vein was probed in a 
retrograde manner to identify the sites of valves. Maintaining a closed 
vein was preferable in order to obtain transverse sections of valves that 
were attached at either end to the vein wall. This prevented them from 
floating off during processing and avoided ‘edge effects’.  
2. Samples were fixed in 10% formal saline (4% formaldehyde in 0.9% 
NaCl) for 24-48hrs.  
3. Samples were dehydrated through sequential alcohol washes to xylene 
and infiltrated with paraffin wax overnight in a TissueTek VIP 5E-F2 
automated tissue processor (Sakura Finetek, Netherlands).  
4. Samples were embedded in a suitably sized mould and place on a cold 
plate for at least 1hr before removing the wax block from the mould. For 
long samples a custom-made deep silastic (Dow Corning) mould was 
used. 
5. 5µm sections were cut for histological analysis. 
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2.10 Preparation of human venous valves for frozen 
sectioning 
 
1. Veins were opened longitudinally using blunt-ended scissors under a 
dissecting microscope. Alternatively, the vein was probed in a 
retrograde manner to identify the sites of valves and maintained closed. 
2. Pieces of vein were placed on a labelled cork disc and snap-frozen in 
OCT (TissueTek) in isopentane precooled in liquid nitrogen. 
3. Samples were wrapped in foil and stored at -80oC until sectioned. 
Sections were cut at 7-10µm in a cryostat microtome (Bright Instrument 
Co) set at -26oC. 
 
 
2.11 General strategies for optimising and detecting 
antibody binding for immunohistology 
 
Many antibodies used in this project had not previously been optimised for 
their utility in locating their respective antigens by immunohistochemistry or 
tissue immunofluorescence and a strategy was developed to expedite the 
choice of different methods of staining. 
 
Formalin fixed paraffin embedded (FFPE) sections were used initially because 
they give better preservation of tissue architecture than frozen sections (FS). 
Initial testing in FFPE sections was with and without heat induced epitope 
retrieval (HIER), and with retrieval in pH6 and pH9 buffer. Primary antibody 
concentrations in the range 1-10µg/ml were tested and final concentrations are 
given in Appendix 3. Initial testing was typically with amplification, for example, 
using an HRP-polymer-conjugated secondary antibody (Menarini). The 
proprietary HRP-polymer-conjugate was used with primary antibodies raised in 
either rabbit or mouse. Alternatively, a biotinylated secondary antibody was 
used in conjunction either an Extravidin-peroxidase or Extravidin-alkaline 
phosphatase complex. Microwave heat retrieval was also assessed, as was 
the use of a tyramide-based amplification system (Perkin Elmer). In general, if 
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the above strategy failed to localise staining, then staining was attempted in 
frozen sections, without fixation and using fixation with either 4% PFA at room 
temperature or acetone at -20oC. 
 
2.12 Immunohistochemistry on paraffin sections 
 
The following is a typical method used during optimising staining. Controls 
were incubated with IgG to match the species, isotype and concentration of 
the test antibody. 
 
1. Slides were heated for 30mins in a dry oven at approximately 60oc to 
melt the paraffin wax. Slides were then washed twice in xylene at room 
temperature (10mins per wash).  
2. Sections were hydrated through graded ethanol 100%, 75% and 50% 
for 1min each. Care was taken to avoid carry-over of solutions from one 
bath to the next. Samples were rinsed briefly in running tap water. 
3. Heat induced epitope retrieval was performed in an Access Retrieval 
Unit (Menarini) using Access Antigen Revelation solution (pH 6.0) and 
Access Super solution (pH 9.0, Menarini) at 124oC for 30secs then 
allowed to cool to 90oC. Ice was then added to cool the slides to a 
comfortable handling temp and avoid rapid evaporation and drying-out 
of sections. 
4. Sections were washed in PBS (2x1min) on the ‘belly dancer’ (Sovall 
Life Sci)  (always at speed setting 5½). 
5. Endogenous tissue peroxidase was quenched by incubating the slides 
in 1% H2O2 in industrial methylated spirit (IMS, 3ml of 30% hydrogen 
peroxide solution in 97ml IMS) for 30mins.  
6. Slides were washed in PBS for 2min on the belly dancer.  
7. Slides were wiped dry (making sure that the section remained moist) 
and the tissue section ringed with a hydrophobic pen (DAKO). Specific 
binding of the primary antibody was facilitated by blocking with neat 
DAKO super block at RT in a humidity chamber for 7min 30sec. All 
subsequent incubations were carried out in a humidity chamber. 
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8. Blocking agent was gently tipped off and sections were incubated at RT 
for 1hr with primary antibody (in PBS) in humidity chamber.  
9. Sections were washed in PBS (5x2min) on the belly dancer. 
10. If a primary antibody raised in mouse was used, then sections were 
incubated for 7.5min with Menarini Universal Probe (rabbit anti-Ms 
antibody) at RT. Unbound antibody was then washed off in PBS 
(5x2min) on the belly dancer.  
11. Sections were incubated for 15min at RT with Menarini HRP-polymer 
(proprietary anti-rabbit antibody). 
12. Slides were washed in PBS  (5x2min) on the belly dancer. 
13. HRP activity was localised by incubating with Vector SG substrate (as 
per the manufacturer’s instructions, Vector Labs) for 2-10min whilst 
monitoring signal development under the microscope. 
14. The reaction was stopped by washing in PBS (2x2min) on the belly 
dancer.  
15. Sections were counterstained using Nuclear Fast Red for 11mins. 
16. Sections were rinsed for 1min in tap water, dehydrated through graded 
alcohols (50%, 75%, 100%, 100% and further 100% alcohol) for 1min 
each and cleared by 2x2min immersions in xylene (BDH, UK).  
17. Slides were carefully mounted using DPX (BDH, UK) under cleaned 
glass coverslips and allowed to dry at room temperature overnight. 
 
2.13 Immunohistochemistry on paraffin-embedded 
sections using tyramide-based amplification 
!
This method was carried out using the Perkin Elmer Tyramide Amplification 
kit. Buffer compositions are given in Appendix 1. 
 
1. Slides were warmed for 30mins in dry oven to melt paraffin wax 
2. Slides were immersed in xylene (2x10min) at RT.  
3. Sections were hydrated though graded ethanol’s 100, 75 and 50% 
(2mins each) and briefly rinsed in running tap water. Heat induced 
epitope retrieval was carried out using Access antigen revelation 
solution (pH6.0) and Access super solution (pH9.0) by heating the 
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slides at 124oC for 30sec and then cooling to 90oC in a digital pressure 
cooker (Menarini) 
4. Slides were washed in TNT buffer for 2x2mins on belly dancer (always 
set at 5½). 
5. Endogenous tissue peroxidase as quenched by incubating the slides in 
1% hydrogen peroxide (H2O2) in industrial methylated spirit (IMS) for 
30mins (3ml of 30% H2O2  solution in 97ml  IMS).  
6. Slides were washed in TNT buffer for 5mins x2 on the belly dancer.  
7. Sections were incubated in TNB blocking buffer for 30mins at RT. 
8. Remaining block was gently removed and the slide dried around the 
wax rings. Sections were placed in the humidity chamber and 
incubation with primary antibody was performed overnight at 4oC. All 
antibodies were diluted in 1x TNB blocking buffer.   
9. Unbound primary antibody was washed off for 5mins x3 in TNT wash 
buffer on the belly dancer. 
10. Sections were then incubated with secondary antibody (biotinylated 
polyclonal goat anti rabbit IgG) for one hour at RT. 
11. Unbound secondary antibody was wash off in TNT wash buffer for 
3x5mins on the belly dancer 
12. Slides were incubated for 30mins at RT with Streptavidin-HRP 
conjugate diluted 1:100 in TNB blocking buffer. 
13. Slides were washed in TNT wash buffer (3x5mins).   
14. TSA biotin signal amplification step: 
15. Dilute biotinyl tyramide amplification reagent 1:50 using 1x amplification 
diluents provided with the kit and incubate for 10mins at RT. 
16. Slides were washed three times with TNT wash buffer (3x5mins) on the 
belly dancer.   
17. Slides were incubated with Streptavidin-HRP conjugate diluted 1:100 in 
TNB blocking buffer for 30mins at RT. 
18. Slides were washed with TNT wash buffer (5mins x 4) on belly dancer.   
19. Peroxidase activity was localised using the Vector SG substrate kit 
(Vector Laboratories) and ~200µl of chromagen substrate was applied 
to each slide. Chromagen substrate was prepared just before use. To 
5ml of Dulbecco’s PBS pH7.4 (DPBS) was added 3drops (~150µl) of 
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chromagen, and then 3drops of hydrogen peroxide solution, with mixing 
after each addition. 
20. Slides were washed in TNT wash buffer (3x5mins) on the belly dancer.   
21. Tissue sections were counterstained with Nuclear Fast Red (Vector 
Laboratories) for 10mins at RT 
22. Slides were rinsed in running tap water for 30sec. 
23. Sections were dehydrated through graded alcohols (50%, 75%, 
2x100%) for 1min each and cleared by 2x2min immersions in xylene. 
 
 
2.14 Immunohistochemistry on frozen sections 
 
The following is a typical method used for optimisation of antibody staining in 
frozen sections. For uncharacterised antibodies, optimisation was performed 
by testing at a range of primary concentrations between 1-10µg/ml. All 
incubations were carried out in a humidity chamber. 
 
1. Slides, stored at -80oC, were allowed to warm to room temperature for 
30mins.  
2. Sections were fixed in acetone pre-cooled to -20oC for 10mins in a 
fume hood, then rinsed in PBS for 1min. 
3. Slides were wiped dry (making sure that the section remained moist) 
and the section of tissue ringed with a hydrophobic pen,. 
4. Blocking of non-specific binding sites was carried out by treating 
sections with 3% w/v bovine serum albumin (BSA) in PBS for 3hrs.  
5. Block was gently tipped off and sections incubated with primary 
antibody (diluted in 3% BSA) overnight at +4oC.  
6. Sections were washed in PBS (5x2min) on belly dancer (setting 5.5). 
7. Slides were incubated for 1hr at RT with a 1/200 dilution of stock 
Extravidin-alkaline phosphatase complex (Sigma)  
8. Slides were washed in PBS (5x2mins) 
9. Alkaline phosphatase activity was located using the Vector BCIP/NBT 
substrate kit (Vector Laboratories), prepared according to the 
manufacturer’s instructions. 
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10. Staining was stopped by washing for PBS (5x2min)  
11. Sections were counterstained with Nuclear Fast Red for 11mins. 
12. Slides were washed in PBS for 2min. 
13. Sections were dehydrated through graded alcohols (50%, 75%, 100%, 
2x100%) for 1min each and cleared by 2x2min immersions in xylene. 
 
 
2.15 Imaging of stained frozen and paraffin embedded 
sections of human valves 
Sections were photographed using a Micropublisher 3.3RTV camera mounted 
on a Leitz DMRB microscope with PL Fluotar x5, x10, x20 and x40 lenses 
(Leica).   Micrographs of a 1mm graticule were obtained with each lens to 
enable the addition of scale bars. 
 
2.16 Animal Husbandry 
All UK experiments were performed in accordance with UK Home Office 
regulations. Animals were maintained at SGUL, CRUK’s London Research 
Institute, UNIL and KCL. Transgenic lines were maintained in house on a bl/6 
background. Pregnant and adult Balb/c mice were obtained from Charles 
River UK.  
 
Animals were maintained on a 12hr light cycle and fed food and water ad 
libitum. Matings were formed overnight; the morning of plug identification was 
termed E0. Dams littered overnight and were identified in the early morning; 
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3 NORMAL MURINE VENOUS VALVE 
STRUCTURE AND DEVELOPMENT 
 
3.1 Introduction 
At the onset of my study, research into the development of valves in the 
vasculature in animal models was limited to those in the heart 71, 92, 96, 143 and 
lymphatics 40, 42, 43, 109, 138. There were no animal models available in which a 
defined location for VV was described. 
  
3.2 Aims 
The aims of the work in this chapter were to carry out the following. 
1) Identify a consistent site where a venous valve is present and develop 
methods for the study of valve development at that site using an endothelial 
reporter, resin casting, and SEM. 
2) Compare the structure of murine and human venous valves. 
3) Describe stages in venous valve development to enable the quantification 
of phenotypes in subsequent experiments. 
 
3.3 Study design and methods 
 
Resin casts of the lower limb venous system and a Tie2LacZ reporter strain 
were used to identify a consistent site of valve development. Subsequently 
143 proximal femoral venous valves were visualised in 84 Tie2LacZ reporter 
mice (1-2 valves per mouse) at ages from E18 to adult (Table 1).  
 
Wholemount confocal microscopy of the murine femoral vein (as described in 
the General Methods chapter) was utilised to examine the expression of Prox1 
and Foxc2 was at E17, P0 and P6 (≥6 valves per age).  
 
TEM analysis of developing VV was carried out in 3 valves from 3 balb/c mice 
at P0.  
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All experiments were carried out as described below or in the general methods 
chapter. Solutions and antibodies are given in Appendix 1 and Appendix 3.   
 
3.3.1 Visualisation of VV in Tie2LacZ mice 
Mice expressing β-galactosidase (βGal) driven by the Tie2 promoter 
(Tie2LacZ) were maintained on a mixed background (MF1 and FVB). Tie2 is a 
thought to be ubiquitously expressed in endothelial cells, and LacZ expression 
driven by the Tie2 promoter allows localisation of endothelium, including the 
endothelium lining valves.144 Valves were assigned a developmental stage by 
an observer blinded to their age. The composition of all solutions used in these 
studies is given in Appendix 1. 
 
1. Explanted embryo’s or pups/adults were culled and rinsed in PBS at 
37oc 
2. Samples were fixed at 4oc for 90mins and then rinsed in 3x5mins 
washes (Washing Solution).  
3. Samples were placed in Working Staining Solution in the dark at 37oc, 
and inspected at intervals for an appropriate level of stain. Staining time 
varied with sample age from a few hours to 1-2days, and was 
monitored under the microscope.  
4. Samples were rinsed in 3x5mins PBS washes prior to fixation in 4% 
PFA for 2hrs. Samples were then stored in a solution of 70% glycerol, 
30% PBS to clear.  
5. For imaging, the samples were rinsed with PBS and photographed 
using a Nikon Coolpix 995 camera mounted on a dissecting microscope 
(Leica M3C). Veins were opened with either a scalpel over a tungsten 
needle, or with microscissors (Fine Science Tools).  
6. For combined localisation of βGal and SEM of venous valves, samples 
were processed to visualise βGal activity and photographed with the 
vein closed and then opened (with scissors or a knife over an intra-
luminal tungsten needle). Samples were then pinned to silastic (Dow 
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3.4 SEM of opened murine veins 
All buffers and solutions are provided in Appendix 1 
1. Pups or adult mice were culled using CO2 confirmed by cervical 
dislocation. To reduce hair contamination of samples, the fur was wet 
with 70%v/v ethanol in H20. The abdomen and lower limbs were 
prepared under a dissecting microscope (Leica M3C). 
2. Samples were attached to slides using elastic bands and fixed in 5%v/v 
formaldehyde and 0.8%v/v glutaraldehyde for 90mins at 4°C 
3. Under a dissecting microscope, the femoral vein was opened 
longitudinally using a curved scalpel blade over an intraluminal tungsten 
wire. 
4. Samples were further fixed in 2%v/v glutaraldehyde and 1%v/v 
formaldehyde in sodium cacodylate buffer for 24hrs at RT. 
5. Samples were trimmed to a small block, osmified (1%v/v osmium) for 
24 hours on a rotator, dehydrated through graded alcohols (30mins at 
each step), critical point dried via CO2, and sputter coated (Polaron 
SC7640) with gold. 
6. Samples were viewed in a Cambridge Stereoscan 360 scanning 
electron microscope. 
 
3.5  SEM of resin casts of the murine venous system 
1. Pups or adult mice were killed using terminal anaesthesia (isofluorane) 
or CO2 confirmed by cervical dislocation. 
2. The abdomen was opened under a dissecting microscope. 
3. Batson’s No. 17 (Polysciences) promoter, catalyst, methyl methacrylate 
monomer and red pigment were mixed as per the manufacturer’s 
instructions.  
4. Resin was injected into the IVC using a 30-gauge needle. The IVC was 
clamped around the needle to prevent leakage. Samples were allowed 
to cure for 2-3hrs. 
5. Samples were placed in several changes of potassium hydroxide at 
37oC for several days (to weeks) until all tissues had dissolved. 
6. Casts were carefully washed and dried in ethanol and mounted on a 
15mm SEM stub using araldite. Casts were sputter coated with gold 
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(Polaron SC7640) and imaged using a Cambridge Stereoscan 360 
scanning electron microscope. 
 
3.5.1 Statistical analysis 
Change in developmental stage with increasing murine age was analysed by 
Kruskall Wallis test, with Man Whitney U tests for individual comparisons. All 
analyses were carried out in SPSS 21 (IBM corporation). 
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3.6 Results  
  
A valve was consistently identified in the murine proximal femoral vein, and 
was visualised by localisation of βGal activity in wholemount samples from 
Tie2LacZ reporter mice (Figure 14). Opening the vein allowed SEM analysis of 
overall valve structure (Figure 14), and cellular arrangements (Figure 15). 
Endothelial cells lining the leaflets had a rounded morphology, whilst those of 
the free edges were always spindle shaped. The free edges of each leaflet 
fused prior to a common junction with the vein wall at the commissures (Figure 
15). Analysis of human VV showed similar macroscopic structural features to 
murine valves (Figure 16).   
  
 




Figure 14 SEM and wholemount images of murine adult left femoral VV  
A) SEM of adult venous valve (arrowheads) in the proximal femoral vein. An ostial valve 
(*) guards the orifice of a tributary vein. 
 
B) Wholemount micrograph in Tie2LacZ reporter strain showing venous valve 
(arrowheads). The edge of the femoral artery is visible running vertically to the right (*). 
Both femoral valves are stage 4 (it is not typically possible to stage valves within 
opened veins). The Tie2 promoter is not active in LECs.145 Scale bar=100µm. Flow 
direction is upwards. 
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A 
 
Figure 15 SEM of adult murine venous valve 
A) Fusiform free-edge cells (arrowheads).  
B) Rounded leaflet cells (arrowhead indicates bulge of nucleus, lumen surface shown) 
(flow upwards)  
C) Commissure (large arrowhead). Note that free edge cells do not insert into the 
vessel wall but form a complete ring (small arrowhead). Scale bars 10µm. The valve 
shown is the same as the previous figure. 
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Figure 16 Representative SEM of normal adult human long saphenous vein 
valve showing similar structure to murine valves 
A) Fusiform free edge cells (arrowhead).  
B) Rounded cells lining the lumen surface of the leaflet.  
C) Commissures are similar to those seen in murine valves, but may branch (arrowhead 
on right). Multiple small downstream tributaries are seen.  
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3.6.1 Valve developmental stages using Tie2LacZ and SEM 
VV development was assigned stages according to the observed changes in 
valve structure (Figure 17). Using the Tie2LacZ reporter, at stage 0 no valve 
structure was seen, whilst at stage 1 an organised ring of rotated cells was 
present. Ingrowth of a circular shelf of endothelial cells produced stage 2 of 
development, followed by the development of first one commissure at stage 3 
and a second to form stage 4. The presence of a single commissure stage 
was further identified in a resin cast in an adult mouse (Figure 18). 
Quantification of VV development in 143 valves at ages from E18 to adult 
showed a clear stepwise progression in developmental stages with increasing 
age (Figure 19). The development of valves showed considerable variability 




Figure 17 Developmental stages in venous valve formation. 
These stages were assigned to VV formation to enable quantification of valve 
development. See text for definitions used in assigning stages. n=143 Tie2LacZ. Scale 
200µm. Direction of flow= upwards (SEM at stage 0 and 1 provided by Dr Eleni 
Bazigou). 
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Figure 18 SEM of resin cast of murine Stage 3 valve 
A & B show opposing sides of a stage 3 valve that persisted in an adult, visualised by 
SEM following injection of resin into the venous system. Arrowheads indicate the valve 
leaflets. A single commissure is shown in A. * indicates a single large tributary. The 
existence of a single commissure stage has not previously been demonstrated, and 
was initially identified in valves visualised using the Tie2LacZ reporter. Scale = 250µm 
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Table 1 Evidence for progression through developmental stages using 
Tie2LacZ endothelial reporter 
Venous valves (N=143) were visualised in 84 Tie2LacZ reporter mice. For this analysis 
adults were recorded as age 42 days (ie ≥6 weeks). The table provides the number of 
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Figure 19 Evidence for valve progression through developmental stages  
Analysis of the stage of development in n=143 valves between E18 and adult in n=84 
Tie2LacZ reporter mice showed a significant trend in increased age with each stage of 
development, quantified according to the development of commissures. Box and black 
line represents inter-quartile range and median. Circles represent outliers and the star 
an extreme outlier. § P=0.008, §§ P<0.0001. (Mann Whitney U test for individual 
comparisons, Kruskal Wallis across all four groups) Adults were recorded as age 42 
days (i.e. ≥6 weeks). The raw data including the number of VV analysed at each age 
and stage are provided in Table 1.  
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Figure 20 Venous valve developmental stages at selected ages 
This graph shows selected ages from staging of Tie2LacZ data, to further illustrate the 
general trend. The raw data including the number of VV analysed at each age and 
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3.6.2 Immunofluorescence imaging of murine venous 
valves 
Immunolocalisation of Prox1 and Foxc2 at E17 showing widespread 
heterogeneous signal in femoral vein endothelial cells (Figure 21). Occasional 
nuclei in the valve region showed higher signal, but no organised valve 
structures were identified. At P0 rotated and elongated endothelial cells were 
seen to express higher levels of Prox1 (and other markers including Foxc2) 
and formed a line of cells in a ring around the vein. This corresponds to the 
appearances seen at stage 1 of VV development previously described in the 
Tie2LacZ reporter strain (Figure 17). Elongated nuclei were widely distributed 
across the vein. The most rotated nuclei were identified in the mid-portion of 
the vessel. Further imaging at E17, P0 and P2 is given in Figure 68. Detailed 
analysis of the morphology of Prox1hi valve-forming nuclei (derived from 
wildtype littermates of Connexin-deleted mice) is given in Appendix 9 (Figure 
102, Figure 104, Figure 105). 
 
At P6 stage 3 or stage 4 valves were identified, with well-developed leaflets 
easily identified by expression of markers such as Foxc2. The free edges of 
leaflets showed strong signal for Prox1 and Foxc2. Whilst at E17 and P0 SMA-
expressing pericytes were seen to uniformly surround the vein in the region of 
the developing VV, at P6 a reduction of SMA expression was seen in the 
region of the valve (Figure 21). Quantification of the developmental stages at 
P0 and P6 is given in subsequent chapters in the analysis of wildtype controls.  
Additional examples of confocal micrographs at P0 are shown in subsequent 
chapters in Figure 41, Figure 49, Figure 53 and Figure 56. Further examples 
at P6 are shown in Figure 25, Figure 33, Figure 42, Figure 51 and Figure 55 











Figure 21 Analysis of developing VV by confocal microscopy 
Immunostaining for Prox1, Foxc2 and PECAM1 is overlaid in A-C using the colours 
indicated above each column. For clarity, localisation of SMA in the same valves (given 
in A-C’’’’) is not overlaid. In wildtype mice, immunostaining of Prox1 and Foxc2 was 
widespread and heterogeneous (arrowheads in A) throughout the valve-forming region 
of the femoral vein at E17. By P0 rotated and elongated valve-forming Prox1hi and 
Foxc2hi nuclei are seen (arrowheads in B). Non-VFC Prox1 immunostaining tends to be 
higher upstream, whilst Foxc2 is higher downstream. At P6 rotated free-edge cells 
(nuclei identified by arrowheads in C) form the free edges of the leaflets, whilst cells 
lining the valve leaflets (* in C) have rounded nuclei. Note deficiency in SMA-expressing 
cells that appears by P6 (** in C’’’’). Representative confocal micrographs of n≥6 at 
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3.6.3 TEM imaging of murine VV at P0 
In preliminary analysis of femoral veins at P0, developing VV were clearly 
identified as unique structures protruding into the vein lumen at the previously 
characterised site of VV formation. Even at this early stage numerous 
interstitial cells were seen and the microscopic VV structure illustrates the 
potential complex cellular interactions occurring during development (Figure 
22). Taken with SEM and confocal analysis at the same time point, the cells at 
the edge of this structure (Figure 22) are assumed to be the rotated Prox1hi 
valve-forming cells that have been described to form a ring at stage 1, and 
subsequently line the leaflet free edge at all later stages. Endothelial cells 
lining the primitive leaflet (Figure 22) have a rounded morphology in SEM 
analysis (Figure 15) and also express Prox1 and other markers (Figure 21 and 
subsequent chapters). Because of the lack of strongly expressed markers, 
interstitial cells could not be very clearly identified by confocal microscopy.  
 
 
Figure 22 TEM of developing VV at P0 
A longitudinal section of the region of the femoral vein containing a developing venous 
valve leaflet is shown. At P0 numerous interstitial cells were already present in the early 
venous valve. ** leaflet endothelial cell, $ interstitial cell nucleus, * free-edge (rotated) 
cell. The relatively loose attachment of the free-edge cell to the underlying matrix and 
interstitial cells is reminiscent of that described at similar stages in LV development.146 
Representative of N=3 balb/c valves at P0. Scale bar 10µm. Flow direction left to right.  
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3.7 Discussion 
 
Whilst venous valves have been described in the pig, mouse, rat and duckling 
and other animals using various imaging techniques, a consistently positioned 
valve has not been identified in a small animal model.11, 26,31,33,33  Here I 
describe the localisation of a venous valve in a consistent location in the 
proximal femoral vein. Initial experiments with a Tie2LacZ reporter line 
revealed venous valves distributed throughout the lower limb veins of the 
mouse. The largest valve, and the only one consistently found at the same 
position, was in the proximal femoral vein. The finding of the consistent 
position of this valve has facilitated subsequent studies of early valve 
development, by enabling targeted analysis even at the earliest time points. 
The limit of 2 analysed valves per mouse raises the number of animals 
required in any experiment. Subsequent to this work being carried out, others 
have used immunohistochemical and resin casting techniques to confirm the 
presence of valves throughout the lower limb veins in Bl/6 mice aged 10wks 
and 2yrs.147 Valves were identified most frequently, albeit in only 68% of mice, 
in the region of the ‘sapheno-femoral junction’. This relatively low frequency 
likely relates to the sensitivity of the methods used to identify valves, as I 
identified a valve at this site in near 100% limbs.  
 
Initial analysis of VV in the Tie2LacZ reporter line showed wide variability in 
valve structures, and frequently different structures on either side of the same 
mouse, obscuring any developmental series. To the best of my knowledge a 
unicommissure stage (stage 3) has not previously been described. 
Subsequent analysis of a large number of valves across a wide age range, 
according to the acquisition of commissures, showed a clear progression with 
age. In was not methodologically possible to image valve structure in vivo and 
these data necessarily derive from single time points, but the developmental 
sequence proposed is supported by the progressive development at 
increasing age.  
 
Significant variability was found in analysing valves in the Tie2LacZ line, which 
could relate to difficulty in assigning stages to valves visualised only with the 
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reporter line, or to true increased variability, for example as a result of their 
background (mixed FVB/MF1).  
 
Confocal microscopy of whole (unopened) veins following immunostaining with 
various markers for both the vessel and valve endothelial cells (Prox1, Foxc2, 
PECAM1 and SMA), facilitated localisation of valve forming cells at earlier 
stages than identified using the Tie2LacZ reporter. This also revealed that 
cellular rotation events occurred at an earlier stage than previously identified44, 
148 and are well developed by P0. It has only very recently been possible to 
visualise the valve-forming region at the earliest stages (E15-E18) and this 
remains a methodological obstacle to detailed analysis of events at this early 
stage.  
 
Prior to P0, Prox1 and Foxc2 expression was widespread and heterogeneous, 
which is surprising given their previous characterisation as lymphatic and 
arterial/lymphatic markers, respectively, and the finding that Prox1 is a master 
regulator for the differentiation of LECs from veins44, 149 In lymphatic valves, 
Prox1 and Foxc2 are more highly expressed on one side of the vessel, prior to 
‘circularisation’ and extension of this cellular phenotype around the vessel to 
form a complete ring, or ‘domain’.42,148 These stages were not identified in the 
developing normal venous valve, where the ring of rotated cells seen at P0 
appeared to arise from heterogeneous Prox1hi and Foxc2hi cells scattered 
throughout the valve forming region. It is possible that a highly transient stage 
of development was not identified, or that development proceeds via different 
early stages in the venous and lymphatic systems. Future work should aim to 
examine the polarity of VFCs (indicating any directional migration to form the 
early valve ring) by immunolocalisation of polarised organelles.145  
 
A technique for TEM analysis of developing VV at P0 has only very recently 
been developed, and preliminary TEM data at P0 showed very early leaflet 
formation, consistent with rotated cells at the free-edge. Free-edge cells were 
seen to be loosely attached to underlying cells, with a similar appearance to 
that recently described at a similar stage in LV development,146 suggesting 
that a similar process involving planar cell polarity proteins may have a role in 
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VV development. This supports the idea that leaflet development occurs at the 
site of these rotated cells, which appear to be already forming the free edges 
of the leaflet. Immunostaining of the initiation of VV matrix deposition was 
hindered by the lack of a commercially available laminin-α5 antibody with 
which to clearly label the developing leaflet matrix.  
 
Whilst human VV interstitial cells are identifiable by immunostaining with 
antibodies raised against smooth muscle alpha actin (SMA), similar SMA 
immunostaining was not identified in mice VV leaflets. Analysis by TEM, 
however, confirmed the presence of interstitial cells within murine VV leaflets 
as early as P0. This is consistent with the description of interstitial cells in 
other animals, although their appearance during development has not 
previously been described.11 The identity and roles of these cells remain 
unknown but their presence at such an early stage suggests the possibility of 
a functional role. For example, these cells may produce the matrix that forms 
the core of the leaflet. No strongly-expressed markers for these cells have 
been identified. In future work, identification of a specific marker could allow 
conditional deletion in these cells and analysis of their potential role in VV 
development and/or maintenance.  
 
The conformational changes accompanying development of the valve 
commissures have yet to be clearly described. It has been cautiously assumed 
that the valve commissures develop at the sites of apparent commissures 
seen in the ring of rotated cells at P0, but direct evidence for this is lacking. In 
particular, it is notable that whilst the potential positions of two commissures 
might be indicated by the positions of cells at stage 0, at stage 2 there may be 
little indication of where subsequent commissures will develop. Similarly at 
stage 3 there is little indication of where the second commissure will develop. 
This process requires the appearance of relatively proximal cells to form the 
second commissure, and also a ‘split’ in the rounded shelf of the stage 3 valve 
Mechanisms regulating these processes remain to be explored.  
 
Similar to lymphatic valves, a reduction in SMA-positive pericytes was seen 
around the mature venous valve at P6. In the lymphatic system, this ‘gap’ 
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forms part of the phenotype of the collecting vessels, and abnormal 
recruitment of pericytes to this region is a key part of the phenotype of Foxc2-/- 
mice, which model the human disease lymphoedema distichiasis.40 Contrary 
to events in the lymphatic system, in the veins this gap appears later in 
development, and was not seen at earlier stages.  
 
It is not clear what stimulates the cell-rotation events at P0. Remarkably, cells 
exposed to gradients of wall shear stress in vitro rotate perpendicular to the 
direction of flow.150 This raises the possibility that blood flow could be a 
stimulus to these events. Intra-vital microscopy of murine lymphatics has 
shown that fluid flow is ‘oscillatory’, or ‘reversing’ prior to the onset of valve 
formation.42 A similar requirement for oscillatory blood flow has been 
suggested in developing zebrafish cardiac valves.131,133 Altered flow through 
the chick heart has similarly been demonstrated to produce outflow tract 
malformations.132 Fluid flow through the venous valve-forming region prior to 
valve development has yet to be directly observed or modelled. It remains 
unclear what effect a tributary downstream of the site of endothelial cell 
rotation may have. The effect of flow on leaflet development is studied and 
discussed in a chapter 10.  
 
In these experiments the Tie2LacZ reporter line was used to identify the vessel 
endothelium, but it appears likely that signalling through Tie2 plays a role in 
valve formation, as Tie2 reporter activity appeared to differ on either side of 
the forming valve region in a similar way to Prox1 expression. Foxc2 has been 
shown to upregulate Ang2, a ligand for Tie2, and the Ang-2 knockout mouse 
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3.7.1 Limitations of the study 
• The vein that forms the external iliac has been called the femoral or 
saphenous vein; in this work the term femoral vein has been preferred 
throughout. 
• It has been assumed that Prox1hi cells identified at E17/18 are the rotated 
and elongated Prox1hi cells identified at P0, and that these cells 
subsequently form the free-edges of the leaflets. The latter is reasonable 
given the particular morphology of these cells, which distinguishes them 
from the surrounding endothelium, and the TEM findings at P0.  
• At earlier stages it becomes increasingly challenging to differentiate 
presumptive valve-forming cells from surrounding endothelium.  
• The limit of 2 valves per mouse raises the number of animals needed in 
any experiment. This, together with the requirement for 3 periods of tissue 
dissection in order to process samples for wholemount imaging, increases 
the risk of loss of data through damage and limits the amount of data that 
can be obtained from a single animal, which makes sample variability more 
difficult to assess than in analysis of LV development. 
• The use of other modalities, such as micro-computed tomography (CT) and 
high frequency ultrasound was explored (data not shown) without success 
in imaging murine VV, although the femoral vein was readily identifiable in 
adult mice. Further antibody-labelling techniques with tracers could enable 
this to become a viable modality in future. 
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4 THE ROLE OF INTEGRINΑ9 IN VV 
DEVELOPMENT 
4.1 Introduction 
Integrinα9 is expressed in LV, and is required for normal LV development.43 
Loss of integrinα9 results in a failure to remodel fibronectin-EIIIA and to 
develop the LV matrix core.43  We recently localised integrinα9 on murine 
venous valves and showed that conditional deletion of Itga9 after birth resulted 
in a failure to develop normal valve leaflets, whilst deletion in adult mice 
resulted in a failure to maintain VV.44 These samples were analysed by luminal 
SEM (as described in the General Methods chapter). Because this requires 
the vein to be opened, it was not possible to comment on the intact valve 
structure, or quantitatively assess defects in VV formation following Itga9 
deletion.44   
 
4.2 Aims 
1. To replicate our finding of expression of integrinα9 on VVs using an 
improved imaging technique. 
2. To replicate the finding that integrinα9 is required for leaflet development 
using an improved method of analysis, and quantify the resulting phenotype. 
3. To localise integinα9 in adult human VV leaflets by immunohistochemistry. 
  
4.3 Design and Methods 
4.3.1.1 Localisation of integrinα9 in VV 
Immunolocalisation and confocal microscopy of wholemount unopened veins 
was carried out as described in Chapter 3. 
 
4.3.1.2 Itga9lx;Prox1CreERT2 mice 
A conditional loss of function approach was used to investigate the role of 
integrinα9, using a previously described transgenic line incorporating loxP 
sites around exon 8 of the Itga9 gene.152 Itga9lx;Prox1CreERT2 mice were 
maintained in a colony at CRUK on a bl/6 background.152,43,44 
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4.3.1.3 mTmG reporter mice 
The spatial and temporal activity of the Prox1CreERT2 line in femoral vein 
endothelial (valve-forming) cells was assessed using a previously described 
transgenic double-fluorescent Cre reporter line, termed mTmG.153 In this line 
alleles for the fluorescent proteins tdTomato and eGFP are placed under the 
control of a strong promoter at the ubiquitously expressed Rosa26 locus, and 
are separated by a stop sequence such that under normal conditions only 
tdTomato is expressed. The tdTomato allele and stop sequence are flanked by 
loxP sites, such that after Cre mediated excision of LoxP flanked segments, 
the tdTomato allele and stop site are excised and GFP expression results. 
Ongoing GFP production therefore permanently identifies those cells (and 
their progeny) in which the Prox1 promoter was active at the time of injection 
of 4OHT. Both GFP and tdTomato are tagged with membrane localisation 
sequences, which allows analysis of cellular morphology.153 
Itga9lx;Prox1CreERT2 mice were crossed with the Rosa26mTmG reporter line 
to provide localisation of Cre recombinase activity and endothelial cells.153  
 
4.3.2 Conditional deletion of Itga9 
Crosses were made to obtain double transgenic offspring either homozygous 
of heterozygous for a floxed Itga9 allele, and carrying either 1 or no copies of 
Prox1CreERT2. Prox1CreERT2- offspring were analysed as effective wildtype. 
To enable improved visualisation of the vasculature and confirm 
Prox1CreERT2 in the femoral vein, some crosses were performed on a 
Rosa26mTmG background. For analysis at P6, pups were injected at P0. 22 
effective wildtype mice, 8 mice with heterozygous deletion, and 7 mice with 
homozygous deletion were analysed (up to 2 valves each). Numbers of VV 
visualised in each group are provided in the results table.  
 
4.3.3 Genotyping and immunofluorescence  
Genotyping and immunofluorescence imaging of murine VVs were carried out 
as described in the General Methods chapter. Solutions are given in Appendix 
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4.3.4 Localisation of integrinα9 in adult human VV 
Sections of long saphenous vein were obtained from patients undergoing 
coronary artery bypass grafting (Section 2.6) and integrinα9 was 
immunolocalised using tyramide-based signal amplification as described in the 
General Methods chapter with antibody concentrations given in Appendix 3). 
 
4.3.5 Statistical analysis 
For comparison of stage of valve development Fisher’s exact test was used, 
comparing wildtype with either heterozygous or homozygous knockouts for 
each stage. Data from multiple litters were necessarily pooled. All analyses 
were carried out in SPSS 21 (IBM corporation). 
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4.4 Results 
4.4.1 Expression of integrinα9 in murine & human VV 
Confocal microscopy of immunolabelled murine venous valves confirmed 
expression of integrinα9 in murine VV leaflets (Figure 23). Subsequent 
tyramide-amplified immunohistochemistry localised integrinα9 to normal adult 
human venous valves. Integrinα9 was localised in a membranous pattern and 
expression was widespread in the valve. Integrinα9 was localised to the fluid-






















































































































































































































































































































































































Figure 24 Localisation of integrinα9 in adult human venous valve  
A) Immunolocalisation of integinα9 in transverse sections of adult human long 
saphenous vein VV. Positive signal (* and **) is shown in black, counterstained with 
nuclear fast red. * identifies the leaflet lumen surface, ** marks the sinus surface. 
B) Non-immune IgG negative control.  
The opposing leaflet is shown to the top left of A and B.  
 
  92 
 
 
4.4.2 Conditional loss of function of integrinα9 from P0 
Whilst control valves developed normally, conditional homozygous deletion of 
Itga9 from P0 resulted in a severe phenotype with failure to develop valve 
leaflets, with a significant increase in the proportion of valves at Stage 1 
(P<0.0005) and reductions in those reaching stages 3 (P<0.0005) and 4 
(P=0.026). No valves were seen at stages 2-4 (Figure 25).  Prox1hi rotated 
endothelial cells remained identifiable at P6 (Figure 26B). Heterozygous 
deletion did not produce a statistically significant phenotype. Widespread 
expression of GFP at P6 in Rosa26mTmG;Prox1CreERT2+ mice (Figure 26B) 
confirmed previously demonstrated utility of Prox1CreERT2 in producing Cre 
recombinase activity in these cells at this time point.  
 
Figure 25 Valve development at P6 following conditional deletion of 
integrinα9 from P0 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. P= Fisher’s exact test. ns=P>0.05  (Fisher’s 
exact test); n=number of VV analysed. 
 
B) The proportion of valves at each stage is shown for each genotype. Deletion of 
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integrinα9 from P0 produced a severe phenotype with almost complete failure to 
develop valve leaflets at P6. Heterozygous deletion did not produce a significant 
phenotype. +/+ = wildtype (N=22 mice), +/- = heterozygous deletion (N=8), -/- = 
homozygous deletion (N=7).   
 
 
Figure 26 Valve morphology at P6 following conditional deletion of 
integrinα9 from P0 
In control littermates valves developed normally (A) whilst homozygous conditional 
Itga9 deletion (B) produced a failure of leaflet formation. Free edge cells (arrowheads) 
are marked in A and B, but leaflets (*) are seen only in A. The ring of rotated Prox1hi 
endothelial cells was relatively intact (arrowheads in B). Blood flow is from left to right. 
For clarity membrane-targeted tdTomato (in A) and eGFP (in B) are both displayed as 
green. Scale 50µm 
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4.5 Discussion 
 
Expression of integrinα9 and its role in venous valve development was 
investigated using immunofluorescence/confocal imaging techniques and a 
conditional loss of function approach. These revealed a critical requirement for 
integrinα9 in the development of the valve leaflets. Integrinα9 did not appear to 
be required for the maintenance of the Prox1hi free-edge cell phenotype, as 
these cells tended to remain identifiable (albeit not as a complete ring) at P6. It 
is likely that integrinα9 is required for the interaction between valve leaflet EC’s 
and the matrix core of the VV, as has been suggested in LV.43 The finding that 
integrinα9 is critical to the development of both VV and LV provides clear 
evidence that venous and lymphatic valves may be regulated by similar 
mechanisms.  
 
Expression on human VV, combined with the requirement for integrinα9 in 
murine VV maintenance, suggests a potential role for this protein in human 
disease. One known ligand for integrinα9, tenascinC, has been implicated in 
the pathology of varicose veins and it is possible that disrupted signalling 
through integrinα9 could form part of the disease process in man.154 
 
4.5.1 Limitations of the study 
A potential role for integrinα9 prior to P0 has not been examined. At the time 
this study was carried out the techniques for preparation of immunostained 
venous valves at E16-P0 (and loss of function from E15) used elsewhere in 
this thesis had not been developed. It would be interesting to examine the 
expression pattern of integrinα9 and its ligands during these very early stages 
in development. It is possible that integrinα9 could have a role during these 
earlier stages of valve development, but the persistence of free edge cells at 
P6 after deletion from P0 suggests that integrinα9 does not have a role in 
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EphrinB2 reverse signalling is required for normal cardiac and lymphatic valve 
development.71, 138 In addition, we recently described a requirement for 
ephrinB2 signalling in VV development and subsequent maintenance, a 
surprising finding given previous reports that ephrinB2 expression is restricted 
to arteries and lymphatics (Appendix 13).44, 138 Previously, ephrinB2 promoter 
activity, indicating likely expression, was examined using the EfnB2GFP 
reporter line, using confocal microscopy of opened murine veins, and 




1. Explore the activity of the EfnB2 promoter at P0.  
2. Quantify the phenotype resulting from conditional loss of ephrinB2. 
  
5.3 Design and Methods 
5.3.1 EfnB2GFP 
EphrinB2 promoter activity was visualised at P0 using a previously described 
GFP reporter line in which the start codon of EfnB2 was replaced with 
H2BGFP cDNA (generating a null allele and nucleus-targeted GFP).155 Six 
valves in 3 EfnB2GFP mice were visualised at P0. The EfnB2GFP colony was 
maintained in house on a bl/6 background.  
  
5.3.2  EfnB2lx mice 
To investigate the role of ephrinB2 prior to P6, a conditional loss of function 
approach was selected, using a previously described transgenic line 
incorporating LoxP sites inserted around exon 2 of EfnB2 by homologous 
recombination.156 The Efnb2lx colony was maintained in house, on a bl/6 
background.44 Crosses were made to obtain double transgenic offspring either 
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homozygous of heterozygous for a floxed EfnB2 allele, and either 
heterozygous or wildtype for Prox1CreERT2. Prox1CreERT2- offspring were 
analysed as effective wildtype. To enable improved visualisation of the 
vasculature and confirm Prox1CreERT2 in the femoral vein, some crosses 
were performed on a Rosa26mTmG background as described in the previous 
chapter.153 For analysis at P6, pups were injected at P0. 3 effective wildtype, 3 
mice with heterozygous deletion and 2 mice with homozygous deletion were 
analysed. 2 valves were visualised in each animal.  
 
5.3.3 Genotyping and immunofluorescence  
Immunofluorescence confocal microscopy of murine VVs and genotyping were 
carried out as described in the general methods and Chapter 3. Solutions are 
given in Appendix 1, antibodies in Appendix 3 and primers in Appendix 4. 
 
5.3.4 Statistical analysis  
All analyses were carried out in SPSS 21 (IBM corporation). For comparison of 
stage of valve development Fisher’s exact test was used, comparing wildtype 
with either heterozygous or homozygous knockouts for each stage. Data from 
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5.4 Results 
5.4.1 EfnB2GFP reporter localisation at P0  
Using an improved method of immunostaining, with the vein remaining 
unopened, ephrinB2 reporter activity was detected earlier than we previously 
reported (Figure 27).  At P0 reporter activity was clearly identified in some 
Prox1hi valve forming cells (Figure 27), and downstream of the developing 
valve. Reporter signal was much lower in veins than in neighbouring arteries. 
 
 
Figure 27 EfnB2GFP reporter activity and immunolocalisation at P0 
EfnB2 promoter activity at P0 was examined using the EfnB2GFP reporter (green) with 
immunolocalisation of Prox1 (red) NFATc1 (blue) and Pecam1 (white). GFP is targeted 
to the nucleus. These mice express one copy of wildtype ephrinB2; no clear phenotype 
was seen following heterozygous conditional deletion of EfnB2 at P6, indicating that 
heterozygous deletion at P0 is not expected to produce a phenotype. GFP signal was 
clearly localized to rotated valve-forming cells (arrowheads) and in the downstream 
region (*), but signal was very weak/absent in upstream cells (**). Analysis of ephrinB2 
expression is hampered by a lack of specific antibodies for use in wholemount imaging. 
Further examples are given in Appendix 5. Split channels for this figure are given in 
Figure 28. Representative confocal micrographs of n=6 valves (3 mice) at P0. Flow left 
to right. Scale 50µm 
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5.4.2 Conditional deletion of EfnB2 from P0 
Whilst control valves developed normally, homozygous EfnB2 deletion from 
P0 resulted in a severe phenotype with near complete loss of valve leaflets at 
P6 (Figure 29). No valves reached stages 1-4. Some rotated Prox1hi cells 
remained at P6 (Figure 30). Heterozygous deletion did not produce a 
statistically significant phenotype.  
 
Figure 29 Valve development at P6 following conditional deletion of 
ephrinB2 from P0  
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous deletion of ephrinB2 resulted in a 
severe phenotype, with no leaflet development in these mice.   
ns=P>0.05 (Fisher’s exact test) ; n=number of valves. 
B) The proportion of valves at each stage is shown for each genotype. Deletion of 
EfnB2 from P0 produced a severe phenotype with complete failure to develop valve 
leaflets at P6. Heterozygous deletion did not produce a significant phenotype. +/+ = 













Figure 30    Valve morphology at P6 after conditional deletion of EfnB2 from P0  
 
(A) Valves in wildtype littermates appeared to develop normally.  
 
(B) Homozygous conditional deletion of ephrinB2 resulted in complete loss of leaflets 
with a few remaining Prox1hi valve cells.   
Red = Prox1 immunostain, Green = membrane-targeted tdTomato or eGFP respectively 
for CreERT2- and CreERT2+ valves. (mTmG reporter line).  
Representative of n= 6 wildtype littermates and 4 homozygous knockout VV. 
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5.5 Discussion 
This work aimed to determine the pattern of ephrinB2 reporter activity at P0, 
and quantify using an improved visualisation method the phenotype seen with 
conditional deletion of ephrinB2. Homozygous conditional EfnB2 deletion from 
P0 and analysis at P6 resulted in a severe phenotype with almost complete 
regression of valve development, albeit with some remaining Prox1hi EC’s. 
This is consistent with work carried out on the open vein that showed a 
requirement for ephrinB2 in VV development at P6, and subsequent 
maintenance of the formed valves.44 Contrary to data (obtained by opening the 
vein), with the whole mount method revealed that some rotated Prox1hi cells 
remained at P6, indicating that ephrinB2 is not required for maintenance of the 
free-edge cell phenotype.44 This is consistent with the finding that EfnB2GFP 
reporter activity was not identified in free edge cells at P6, and raises the 
possibility that these free-edge cells express an ephrinB2 receptor (such as 
EphB4) at this time point.44 EphB4 has a widespread expression in murine 
cutaneous veins at P1,73 but expression in the large central veins has not been 
reported.73 EfnB2lx;Prox1CreERT2- are expected to produce normal amounts 
of ephrinB2, but valves did not quite reach the expected normal range of 
developmental stages at P6, since in most groups analysed at P6 
approximately half have reached stage 4, and half stage 3. This may be 
because of the low number of samples available for analysis, but it is also 
possible that the floxed Efnb2 allele is hypofunctional. The latter concern is 
probably excluded by the lack of a significantly worse valve phenotype 
following heterozygous deletion, and it is therefore more likely that an unusual 
random variation affected this sample.  
 
Confocal microscopy on whole mount veins, revealed EfnB2GFP reporter 
activity at earlier ages and developmental stages than identified by the open 
vein technique.44 Previously, studies using opened vessels showed scattered 
EfnB2GFP reporter activity at P2 amongst apparently disorganised Prox1hi 
cells, whilst at P0 almost no GFP expression was seen44, which is inconsistent 
with the valve developmental stages presented in the previous chapters, or the 
localisation of EfnB2GFP in the whole mount studies with the vein remaining 
intact. My whole mount analysis showing elongated and rotated valve-forming 
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cells at P0 is consistent with immunostainings for VFC’s presented in earlier 
chapters. These findings illustrate the benefit of confocal imaging with the vein 
intact (both in allowing more complete imaging of the valve, and also 
facilitating location of the valve site).  
 
The EfnB2GFP reporter allows visualisation of promoter activity; these results 
should be interpreted with some degree of caution given the inability to confirm 
protein expression, and the haploinsufficiency of the reporter. Importantly, the 
expression of Prox1 and NFATc1 appeared relatively normal in the reporter 
line. Organisation of VFC’s did not appear entirely normal in all reporter valves 
analysed. It was not possible to quantify this EfnB2 constitutive heterozygous 
knockout phenotype in the low number of samples available for analysis; 
although the striking pattern of EfnB2GFP activity at P0 strongly suggests 
ephrinB2-based cell sorting could be involved in patterning the early VFC’s. In 
endothelial cells the cognate receptor for ephrinB2 is EphB470 and so it is 
therefore likely that EphB4 is expressed in the VV forming region and has a 
role in early VV formation.  
 
Whilst EfnB2GFP reporter activity has been identified in some Prox1hi cells at 
P0, is absent from Prox1hi free-edge cells at P6, suggesting that it is 
differentially regulated at the two time points.44 It is possible that signalling 
through ephrinB2 is involved in the selection of free-edge cells at P0, and in 
maintenance of their phenotype. In experiments involving ectopic expression 
of full length and truncated Eph’s and ephrins in excised zenopus caps, 
bidirectional signalling was required for cell-cell repulsion and the maintenance 
of a tissue boundary; repulsion of each cell type was required to prevent 
invasion into the territory of the other.157 It remains to be seen whether uni- or 
bi-directional signalling is required to establish the ephrinB2 expression 
pattern observed at P0 in VV development. In the same xenopus ex-vivo 
experimental system, unidirectional signalling was sufficient for suppression of 
gap junction communication between tissue compartments.157 It is therefore 
possible that one role of ephrinB2 expression seen in early VV development is 
to prevent gap junction inter-cellular communication between the upstream 
region and valve forming cells. The roles of gap junction proteins in VV 
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development is discussed further in Chapter 8. Further work could examine 
gap-junctional communication between compartments.  
 
It remains to be determined whether an Eph-ephrin interaction is required for 
normal organisation up to P0 and it is unclear how the marked boundary in 
ephrinB2 reporter activity at P0 arises. Limited availability of the ephrinB2GFP 
line, prevented examination of the activity of the ephrinB2 promoter at earlier 
stages. Further work at these stages could elucidate the pattern by which this 
clear boundary in ephrinB2 expression arises. It is possible that ephrinB2 is 
upregulated in endothelial cells in a heterogeneous pattern, and that 
subsequent ephrin-dependent cell sorting and migration results in the 
organised ring of valve-forming endothelial cells identified at P0 (and clearly 
associated ephrinB2 expression boundary now identified at P1).   Reporter 
activity was also identified downstream of the valve-forming cells, consistent 
with the previous report of expression in this region at P6.43 One possibility is 
that ephrinB2 is upregulated in this region by Foxc2 and NFATc1, both of 
which are expressed in valve forming cells, and in the region downstream of 
the rotated cells at P0.39 
 
A phenotype in Prox1hi valve-forming cells at P0, which exhibit ephrinB2 
reporter activity (and assumed Eph expression on upstream cells), would 
suggest that reverse signalling is likely to occur into these cells. This would be 
consistent with the known requirement for reverse signalling in cardiac and 
lymphatic valve formation.73 It is reasonable to speculate that reverse 
signalling (and likely through the PDZ motif) is required for VV development. 
This could be investigated further using ephrinB2ΔV/ΔV mice. In this discussion 
it has been assumed that these ephrinB signalling events are confined to the 
endothelium. It is possible that signalling with pericytes and/or interstitial cells 
is involved.158 
 
EphrinB protein interactions have been implicated in other critical signalling 
pathways at the cell membrane, involving numerous membrane proteins 
including the VEGF receptors, integrins, and connexins. Notably, ephrinB2 
and its PDZ domain are required in-vivo for normal sprouting angiogenesis, 
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and in this context ephrins are required for endocytosis and full signalling 
through both VEGFR2 and VEGFR3.72 In the absence of ephrinB2, VEGFR2/3 
were not endocytosed even in the presence of VEGFA, resulting in reduced 
downstream signalling into the cell.72,119 It is possible that ephrinB2 functions 
to regulate VEGFR2 and/or VEGFR3 in venous valve development in a similar 
manner.119 
 
EphrinB’s have not been directly implicated in human venous reflux, but 
insufficiency of the receptor, EphB4, has recently been implicated in human 
capillary malformation-arteriovenous malformation (CA-AVM) in a pathway 
with ephrinB2 and RASA1 (in a zebrafish model).159 It is striking to note the 
finding of ephrinB2 reporter activity in veins as well as arteries (the present 
study and44 as it has been suggested that defective ephrinB2-EphB4 signalling 
may account for the recurrence of CA-AVM in adults following treatment. It has 
been suggested that rapamycin (used to inhibit mTOR) in this pathway, may 
avoid recurrence of CA-AVM in man. Previous data suggest a requirement for 
ephrinB2 in VV maintenance, suggesting that one side effect of this therapy 
could be VV failure.44, 159,160 It is likely that Eph-ephrin signalling plays different 
roles in the vasculature at different time points during development and in 
adult life. Signalling through these proteins is required for normal 
arteriovenous separation in vasculogenesis, but expression of ephrinB2 in 
veins at the site of VV formation would suggest a different role in more mature 
vessels. This is not consistent with an ongoing requirement for Eph-ephrin 
signalling to avoid CM-AVM. A likely explanation is differential regulation in 
new sprouting vessels in adults. Alternatively an effect of the different levels of 
ephrinB2 promoter activity (expression) seen in murine arteries and veins, and 
regulation at a different step in the pathway may be involved. EphrinB2 has 
previously been thought to be a specific and critical marker for arterial or 
lymphatic endothelial cells, and the finding of its expression in venous 
endothelial cells and valves is surprising.73 Reported activity was found at 
much lower levels in the femoral vein than femoral artery and it was therefore 
difficult to visualise both together as a result of saturation of the arterial signal.  
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The expression and critical requirements for ephrinB2 in cardiac valve and 
lymphatic valve development71, 138, together with the finding that ephrinB2 is 
required for venous valve development, reinforces the concept that similar 
pathways are required for cardiac, lymphatic and venous valve development. 
 
5.5.1 Limitations of the study 
• All tested commercially available ephrinB2 antibodies are not specific 
for ephrinB2, as demonstrated by continued binding in ephrinB2 knockout 
mice (Dr Taija Makinen, personal communication 2013). It has therefore not 
been possible to confirm whether ephrinB2 promoter activity results in protein 
expression in the valve-forming cells and downstream regions. The finding of a 
clear phenotype at P6 following ephrinB2 deletion is strongly suggestive of 
ephrinB2 expression at this time.  
• It was not possible to quantify the phenotype in the EfnB2GFP 
(heterozygous for wildtype EfnB2) reporter at P0, because of the mild 
phenotype seen and low number of samples available for study.  
• Similarly, limited availability of the floxed EfnB2 line did not allow 
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6 ROLE OF FOXC2 IN VV DEVELOPMENT 
 
6.1 Introduction 
The nuclear transcription factor Foxc2 has been strongly implicated in cardiac 
and lymphatic valve development.39, 40, 47, 80, 82, 161. In lymphatics, loss of Foxc2 
is associated with a failure of maturation of the collecting vessels, and 
absence of the gap in SMA-expressing pericytes that is found around normal 
LV.40 Constitutive deletion of Foxc2 in mice is fatal from E13.5 up to shortly 
after birth due to cardiac abnormalities.80, 161, 162. A recently described Foxc2lx 
line163 now allows conditional Foxc2 deletion, enabling investigation of the role 
of Foxc2 in VV development (and in lymphatic vessel maintenance). In man, 
mutations in FOXC2 cause lymphoedema distichiasis and in addition to their 
abnormal lymphatics, these patients have been shown to suffer reflux in their 
veins, implying an additional venous phenotype.47, 50 Foxc2 has been 
suggested to act upstream of Notch1 pathway signalling.88 Mutations in 
Notch1 are associated with abnormal cardiac valve in man.89 Recently, and 
after completion of this work, a role for Notch1 was described in LV 





1) Validate the use of the Prox1CreERT2 line in deleting floxed alleles prior to 
P0.  
2) Confirm the presence of a phenotype resulting from use of a newly 
described Foxc2lx line, by identifying a requirement for Foxc2 in LV 
maintenance. 
3) Investigate whether there is a requirement for Foxc2 in early or late VV 
development.  
4) Investigate whether there is a requirement for Notch1 signalling during early 
or late valve formation.  
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6.3 Design and Methods 
 
6.3.1 Mice 
A conditional loss of function approach was used to investigate the role of 
Foxc2 in VV development and circumvent the lethality of constitutive deletion. 
This was done using a recently described transgenic line incorporating a 
floxed Foxc2 allele.163 This line was imported for this work from the laboratory 
of Professor Tsutomo Kume, (Northwestern University, USA) rederivatised 
and crossed with the Prox1CreERT2 line to allow conditional deletion of Foxc2 
in Prox1-expressing cells as previously described.44 The mTmG line is 
described in Chapter 4.  
 
6.3.1.1 Validation of Prox1CreERT2 recombinase activity 
Rosa26mTmG;Prox1CreERT2 dams were injected  at E15 and VV in embryos 
analysed at late E18. 3 VV in 3 mice were analysed by confocal microscopy as 
described in Chapter 3. 
 
6.3.1.2 Conditional deletion of Foxc2   
Crosses were made to obtain double transgenic offspring either homozygous 
of heterozygous for a floxed Foxc2 allele, and either heterozygous or wildtype 
for Prox1CreERT2. Prox1CreERT2- offspring were analysed as effective 
wildtype. For analysis at P0, dams received i.p. 4OHT at E15, whilst for 
analysis at P6, pups were injected at P0+P1.  
At P0, 12 effective wildtype mice, 7 mice with heterozygous deletion and 8 
mice with homozygous deletion were analysed. At P6, 12 effective wildtype 
mice, 6 mice with heterozygous deletion and 7 mice with homozygous deletion 
were analysed. Numbers of VV visualised in each group are provided in the 
results tables. 
P6 mesenteric lymphatics (following administration of 4OHT at P0) were 
immunostained as described in the general methods. Mesenteries were 
examined using a fluorescence microscope (Leitz DMRB) and the number of 
mesenteric lymphatic valves per ray counted and recorded in Excel (Microsoft, 
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Redmond). For quantitative analysis of the requirement of Foxc2 for lymphatic 
valve maintenance, the number of LV in radial lymphatics was quantified in 
wildtypes (n=9 mesenteries, 56 vessels), in littermates with heterozygous 
deletion (n=4 mesenteries, 26 vessels) and homozygous deletion (n=3 
mesenteries, 24 vessels). Data were exported into SPSS (IBM) for analysis. 
  
6.3.1.3 Conditional deletion of Notch1 
In vitro, Foxc2 upregulates Notch1 and the downstream Notch pathway 
components Hes and Hey.123, 164 It was therefore decided to analyse a 
potential role for Notch signalling in venous valve formation using mice with 
conditional deletion of Notch1 from E15 and P0. AT P0, 8 effective wildtype 
and 7 homozygous conditional deletion mice were analysed. At P6, 4 effective 
wildtype and 4 homozygous conditional deletion mice were analysed. 
Numbers of VV visualised in each group are provided in the results tables. 
 
6.3.2 Genotyping and immunofluorescence  
Immunofluorescence imaging of murine VV and mesenteric LV, and 
genotyping were carried out as described in the general methods chapter and 
Chapter 3. Solutions are given in Appendix 1, antibody concentrations in 
Appendix 3 and primers in Appendix 4.  
 
6.3.3 Statistics 
Fisher’s exact test was used to compare the stage of VV development, in 
wildtype mice with either heterozygous or homozygous knockouts for each 
stage. Data from multiple litters were pooled.  
For analysis of the number of mesenteric LV per vessel, P values represent 
Bonferroni post hoc after ANOVA for heterozygous/homozygous deletion Vs 
wildtype. 
All analyses were carried out in SPSS 21 (IBM corporation). 
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6.4 Results 
Widespread expression of Prox1 in the murine femoral vein was confirmed at 
late E18. Analysis of VV in mTmG;Prox1CreERT2 mice showed widespread 
GFP expression, confirming cre-mediated deletion in endothelial cells 
following 4OHT injection at E15-16 (Figure 31). 
 
Figure 31 Prox1CreERT2 produces recombination in developing VV  
A) R26mTmG;Prox1CreERT2, 4OHT at E15-16, analysed very late E18. GFP (green), 
Prox1 (red), tdTomato (white), Foxc2 (blue). Separated channels are shown in B-E. 
GFP expression, indicating cre-mediated recombination, is seen in almost all cells in the 
femoral vein, and almost all valve forming cells (arrowheads in D). Note elongated 
upstream cells (single arrowhead in B) and rounded downstream cells (double 
arrowhead in B). Some cells immediately downstream of the valve (arrowheads in C) 
express tdTomato and not GFP, indicating lack of recombination. Flow from left to right. 
Representative of n=3 VV. 2D maximum projection of confocal z-stack. 
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6.4.1 Conditional deletion of Foxc2 from E15 
Conditional deletion of Foxc2 from E15 did not produce a significant 




Figure 32 Valve development at P0 following conditional deletion of Foxc2 
from E15 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Analysis of VV at P0 following conditional 
deletion of Foxc2 from E15 did not show any significant phenotype in valve 
developmental stage. ns=P>0.05 (Fisher’s exact test); n=number of VV analysed. 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(n=12 mice), +/- = heterozygous deletion (n=7), -/- = homozygous deletion (n=8). 
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6.4.2  Conditional deletion of Foxc2 from P0 
Homozygous conditional deletion of Foxc2 from P0 resulted in inhibition of 
valve development with a significant (P=0.017) increase in the proportion of 




Figure 33   Valve development at P6 following conditional loss of Foxc2 from P0  
 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Analysis of VV at P0 following conditional 
deletion of Foxc2 from P0 showed an increase in the proportion of valves at stage 0.  
ns=P>0.05 (Fisher’s exact test); n=number of VV analysed. 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(n=12 mice), +/- = heterozygous deletion (n=6), -/- = homozygous deletion (n=7).   
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6.4.3 Effect of conditional Foxc2 deletion on mesenteric LV 
maintenance 
Conditional deletion from P0 produced significant lymphatic phenotypes at P6 
(Figure 34, Figure 35), and some mice developed chylothorax, chylous 
ascites, and reflux of lymph (chyle) into the femoral lymphatics, confirming the 
efficacy of Cre mediated excision of Foxc2 on lymphatic phenotype in these 
animals. Homozygous conditional deletion was noted to result in lethality from 





Figure 34 Conditional deletion of Foxc2 and lymphatic phenotype at P6 
Sporadic lymphatic phenotypes included reflux of chyle into cardiac lymphatics (A and 
A’, arrowhead in A’), chylothorax (B, *), chylous ascites (C, *), and reflux of chyle into 
femoral lymphatics (D, arrows). Photographs taken immediately post-mortem using 
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Conditional homozygous deletion of Foxc2 from P0 resulted in a significant 
reduction in the number of lymphatic valves per vessel, compared with 
wildtype littermates (respectively 1.00 Vs 4.55, P<0.0005, Figure 35). The 
reduction in LV numbers seen with heterozygous conditional deletion did not 





Figure 35 Foxc2 is required for LV maintenance after P0 
A) The table provides the total number of mesenteries (mice) and lymphatic vessels 
analysed for each genotype and the mean number of LV identified at each stage. 
Conditional homozygous deletion of Foxc2 from P0 resulted in loss of LV by P6. 
P=Bonferroni post hoc, Vs WT, after ANOVA (ANOVA P<0.0005). Error bars represent 
1SEM. +/+ = wildtype, +/- = heterozygous deletion, -/- = homozygous deletion. ns= 
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6.4.4 Conditional deletion of Notch1 at E15 
Analysis at P0 following conditional deletion of Notch1 from E15 showed a 
phenotype of reduced organisation of the Prox1hi valve-forming cells, with 





Figure 36 Valve development at P0 following conditional deletion of Notch1 
from E15.5 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Conditional deletion of Notch1 from E15.5 
resulted in failure of normal organisation of the Prox1hi valve forming cells at P0, whilst 
VV developed normally in wildtype littermates. P= Fisher’s exact test. 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
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6.4.5 Conditional deletion of Notch1 from P0 
Notch1 was not required for later events in VV formation, and VV developed 




Figure 38 Valve development at P6 following conditional deletion of Notch1 
from P0 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Analysis at P6 after conditional Notch1 deletion 
from P0 did not show any discernable phenotype. P= Fisher’s exact test. 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
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6.5 Discussion and conclusions 
Analysis at late E18 of Prox1CreERT2;Rosa26mTmG valves following 
injection of 4OHT at E15-16 revealed widespread GFP expression in the 
femoral vein. This experiment confirms that the activity of the transgenic Prox1 
promoter is widespread in the femoral vein ECs around E15-16, and supports 
my earlier data using antibody immunolocalisation of Prox1 that suggested 
widespread protein expression at E17. This is surprising given the previous 
characterisation of Prox1 as a master regulator of lymphatic cell fate.149 Some 
endothelial cells did not express GFP; this may be because of a true absence 
of promoter activity, or a degree of mosaicism in the activity of CreERT2. 
Expression of GFP was found in almost all Prox1hi valve-forming cells, 
confirming the utility of the Prox1CreERT2 line in subsequent conditional loss 
of function experiments in these cells. This finding is reinforced by the strong 
phenotype following conditional deletion of Notch1, which will be discussed 
further below. It was noted that some tributaries expressed tdTomato rather 
than GFP, despite staining positively for Prox1 at E18 (not shown). This 
suggests that Prox1 expression may become increasingly widespread after 
E15-16, at least in these vessels. The complete absence of GFP expression in 
Cre- valves (not shown) confirms the failure of endogenous oestrogens to 
activate ERT2 in these mice and the consequent absence of Cre-mediated 
excision in control groups in this thesis. 
 
Given the clear venous phenotypes seen in patients who are heterozygous for 
mutations in FOXC250, it was expected that conditional deletion of Foxc2 in 
VFC’s would produce a clear early defect in VV development.50 Surprisingly no 
significant effect was seen with deletion prior to P0, and only relatively mild 
phenotypes with analysis after deletion prior to P6. It was not possible to 
analyse VV at later stages because this deletion was lethal (likely as a result 
of the identified lymphatic defects) around P8. The observed lack of strong 
phenotype at P0 following earlier Foxc2 deletion is unlikely to be as a result of 
a failure of deletion, because the Prox1CreERT2 line has demonstrated 
activity in a Cre reporter (mTmG) line, has produced strong phenotypes with 
other floxed alleles, and produced strong lymphatic phenotypes in the same 
animals. One plausible explanation for my findings is redundancy in signalling 
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between Foxc2 and NFATc1, which is expressed in VFC’s in a similar pattern 
to Foxc2, or expression of Foxc1. Although Foxc1 and Foxc2 are often co-
expressed in the blood vascular system and demonstrate some redundancy80 
loss of even one copy of Foxc2 is sufficient to produce lymphoedema in mice, 
and both lymphoedema and venous reflux in man.40, 50 Whilst Foxc2 is known 
to be expressed in venous and lymphatic valves, expression of Foxc1 has not 
previously been described in the lymphatic or venous systems in either mouse 
or man, and this transcription factor has not been implicated in their 
development.40 Investigation of the possibility of Foxc1 expression in venous 
but not lymphatic valves was hampered by a lack of anti-murine Foxc1 
antibodies for use in wholemount immunofluorescence. A tested antibody (not 
shown) produced very weak nuclear localisation. Other investigators have 
similarly failed to find a suitable antibody (Petrova.T, personal communication 
2013). Western blot analysis of lysed isolated human VV leaflets (but not non-
valve vein wall) did, however, show a strong band near the expected 
molecular weight with a monoclonal Foxc1 antibody (Figure 95). If we accept 
the generally observed similarity between the expression profile of human and 
murine VV, this finding suggests that Foxc1 is expressed in murine venous 
valves, leading to the speculation that Foxc1 may be able to compensate for 
loss of Foxc2. This hypothesis could be examined in vivo by combined 
conditional deletion of Foxc1 and Foxc2; unfortunately a floxed Foxc1 allele 
was not available for study during this work. Redundancy between 
Foxc1/Foxc2 and NFATc1 also remains unexplored and could be addressed 
by using ciclosporin to inhibit calcineurin-NFAT signalling, and floxed Foxc1/2 
alleles.  
 
Notch1 deletion from P0 produced no phenotype at P6, in contrast to the 
finding that deletion from E15 produced a clear phenotype at P0. It is possible 
to speculate that Notch1 plays a role in the selection and/or maintenance of 
the VFC phenotype at very early stages in VV development, and this will be a 
focus of future work. Because of the need to explant embryos following 
administration of 4OHT, it was not possible to study the later effects of early 
Notch1 deletion. In man, mutations in Notch1 have been associated with 
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bicuspid aortic valve, and mutations in Notch3 with varicose veins, suggesting 
clinically important roles for Notch signalling in man.89,165 
 
6.5.1 Limitations of the study 
• The immunolocalisation pattern of Notch1 was not described at early 
stages, because antibodies for wholemount imaging are not yet well 
characterised. Similarly the localisation of Notch1 ligands remains to be 
explored.  
• Given the possible redundancies between Foxc2, Foxc1 and NFATc1 it 
is not possible to conclude that Foxc2 does not play a role in VV development 
prior to P0 without analysis of concurrent deletion or inhibition of 
Foxc1/NFATc1. Immunolocalisation of Foxc1 in murine and human venous 
valves was attempted to support my western blot analysis of valve lysate, but 
this was not successful.  
• The quantification of valve developmental stages that has been applied 
consistently throughout this work is not well suited to describing the cellular 
events prior to P0; it is possible that new methods of quantification will be 




  120 
7 CALCINEURIN-NFAT SIGNALLING IN VV 
7.1 Introduction 
Calcineurin-NFAT signalling has been clearly implicated in the development or 
cardiac and lymphatic valves.39,42,93,96,100,101  I therefore hypothesised that it 
may also be expressed in VV, and required for their normal development. 
Calcineurin is a heterodimer consisting of a catalytic α subunit and regulatory 
β subunit. The β subunit exists as two isoforms, CnB1 and CnB2. CnB1 is 
expressed in the vasculature and is encoded by PPP3R1.166 Calcineurin is a 
protein phosphatase, and in response to a rise in intracellular Ca2+, 
dephosphorylates NFATs to reveal their nuclear localisation sequence, leading 
to nuclear translocation and transcriptional activity (Figure 8).92 Calcineurin 
activity is rapidly and effectively inhibited by the drug ciclosporin A.39, 96, 103 A 
more refined approach has been enabled by a murine strain with floxed 
PPP3R1 alleles, allowing conditional deletion of CnB1.166  In lymphatics 
conditional PPP3R1/CnB1 deletion has been associated with shorter LV 
leaflets42, and I therefore decided to analyse VV leaflet length in addition to VV 
developmental stage in this conditional knock out. 
 
7.2 Aims 
1) Investigate whether there is a requirement for calcineurin-NFAT signalling in 
venous valve development after P0, using the calcineurin inhibitor ciclosporin.  
3) Investigate whether there is a requirement for Calcineurin signalling during 
early or late valve formation, utilising conditional deletion of PPP3R1, 
encoding CnB1. 
3) Quantify the effect of conditional deletion of PPP3R1 from P0 on leaflet 
length. 
4) Localise NAFTc1 in human VV by immunohistochemistry 
 
7.3 Design and Methods 
7.3.1 PPP3R1lx mice  
Crosses were performed to obtain Prox1CreERT2+ and Prox1CreERT2– 
littermates, all PPP3R1lxlx 42, 166, with 4OHT administered to the dam at E15.5 
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(for analysis at P0) or pups at P0 (for analysis at P6). Mice were maintained at 
University of Lausanne on a bl/6 background.42 AT P0, 5 effective wildtype and 
5 conditional homozygous deletion mice were analysed. At P6, 16 effective 
wildtype and 8 homozygous conditional deletion valves were analysed. The 
numbers of VV visualised at each stage are provided in the results table. 
 
7.3.2 Ciclosporin inhibition of calcineurin-NFAT signalling 
Ciclosporin (Calbiochem 239835) was reconstituted to 100mg/ml in 
Dimethysulfoxide and stored at 4oc and diluted 1:10 in sunflower seed oil 
(Sigma S5007) prior to injection (50µg/g.wt of pup, bid). Balb/c (wildtype) 
littermates in 2 litters were randomly allocated to a ciclosporin or control group. 
The ciclosporin (n=7 pups) or vehicle (n=7 pups) was administered bid from 
P1-P5 with a further dose administered immediately prior to termination of the 
experiment at P6. All mice were culled and analysed at P6 by 
immunofluorescence and confocal microscopy. Six valves were successfully 
analysed following control treatment, and 8 following ciclosporin treatment.   
 
7.3.3 Measurement of VV leaflet length 
Leaflet length was measured in a 2D maximum projection of each confocal z-
stack. In NIH ImageJ, a standard template was referenced to allow 8 
measurements of leaflet length to be obtained at standardised positions 
(Appendix 7). Analysis was performed in 11 effective wildtype valves and 14 
littermates following homozygous conditional deletion.  
 
7.3.4 Immunohistochemistry for NFATc1 
Vein was obtained from patients undergoing CABG, and 5um sections cut 
from paraffin-blocks of embedded valved segments, followed by 
immunohistochemistry for localisation NFATc1, all as described in the General 
Methods chapter. 
 
7.3.5 Genotyping and immunofluorescence  
Immunofluorescence imaging of murine VV and genotyping were carried out 
as described in the General Methods and Chapter 3. All solutions are given in 
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Appendix 1, antibody concentrations/dilutions in Appendix 3 and primers in 
Appendix 4.  
 
7.3.6 Statistics 
For comparison of stage of VV development following administration of 
ciclosporin or conditional deletion of PPP3R1 Fisher’s exact test was used, 
comparing wildtype with either heterozygous or homozygous knockouts for 
each stage. Data from multiple litters were pooled.  
For analysis of the change in VV leaflet length with PPP3R1 deletion, an 
independent samples t test was used. 
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7.4 Results 
7.4.1 Normal expression pattern of NFATc1 
At E18 NFATc1 was heterogeneously expressed in endothelial cells of the 
femoral vein in the region of the developing valve. At P0, NFATc1 was 
expressed by Prox1hi VFC’s, but signal was more widespread than that from 
Prox1. At P6 NFATc1 was heterogeneously expressed in free-edge cells, and 
also in the valve leaflet endothelium (Figure 39). Another example of NFATc1 
localisation at P0 is given in Figure 27. 
 
 
Figure 39  Expression of NFATc1 in wildtype venous valves  
 
Immunolocalisation of NFATc1 (green), Prox1 (red) and PECAM1 (blue) are shown at: 
A-A’’’) E18, B-B’’’) P0, C-C’’’) P6. At E18 NFATc1 and Prox1 were heterogeneously 
expressed by endothelial cells (arrowheads in A’ and A’’). At P0 Prox1hi VFC’s were 
organized into a ring of rotated and elongated cells (arrowheads in B’) whilst NFATc1 
retained a more widespread expression pattern (arrowheads in B’’).  At P6 Prox1 signal 
was strongest in free edge cells (arrowhead in C’), but NFATc1 was expressed 
throughout the valve leaflets (outlined by arrowheads in C’’). A valve guards the orifice 
of a downstream tributary in C (* in C’). Representative confocal micrographs from n≥6 
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7.4.2 Effect of inhibiting NFAT signalling with ciclosporin 
Three ciclosporin-treated pups did not survive to P6 (leaving 4 for analysis), 
compared with complete survival of the solvent treated pups. Ciclosporin 
treated pups failed to gain weight normally compared with littermate controls, 
(P=0.015, ANOVA, Figure 96). Vein samples in this experiment were 
surrounded by an unusual amount of fat, which interferes with the laser, and 
prevents complete staging of valves. Because a strong phenotype was clear, 
(Figure 40B) valves were classified as having a normal appearance or thin 
valve leaflets. Inhibition of calcineurin-NFAT signalling by administration of 
ciclosporin resulted in a failure of valve leaflet development (n=6 VV, Figure 
40A, compared with valves in pups receiving vehicle control (n=8 VV), which 
developed normally (P<0.05, Fisher’s exact test). 
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Figure 40  Morphology of valves at P6 after inhibition of NFAT signalling at P0-6 
A) The table provides the total number of VV analysed for each treatment and the 
number of VV identified at each stage. P= Fisher’s exact test. 
B-C) Valves in pups receiving solvent control developed normally (B) whilst ciclosporin 
treated valves (C) had thin leaflets. In B+C, arrowheads indicate free edge cells, * 
indicates leaflets. Note predominantly cytoplasmic staining pattern of NFATc1 signal 
(green) following treatment with ciclosporin (C) compared to nuclear pattern in control 
valves (B) consistent with loss of calcineurin phosphatase activity on NFATc1. The 
nuclear localization in control valves indicates active NFATc1 signalling at this stage. 
Scale bars 50µm 
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7.4.3 Inhibition of NFAT signalling at P0 following 
conditional deletion of PPP3R1 (CnB1) from E15  
Conditional homozygous deletion of PPP3R1 (encoding CnB1) from E15 did 




Figure 41  Valve development at P0 following conditional deletion of 
PPP3R1 (CnB1) from E15 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous deletion of PPP3R1 (encoding 
CnB1) from E15 had little effect on valve phenotype and the majority of VV developed 
to stage 1 at P0. P= Fisher’s exact test. ns= >0.05.n=number VV analysed. 
B) The proportion of VV at each stage is shown for each genotype. +/+ = wildtype (n=5 
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7.4.4 Valve development at P6 after inhibition of NFAT 
signalling by conditional deletion of PPP3R1    
(Calcineurin B1) from P0 
Whilst control valves developed normally to stages 3-4, conditional 
homozygous loss of CnB1 from P0 inhibited the development of VV leaflets, 
with a failure to progress beyond stage 1 of VV development (Figure 42). The 
initial ring of rotated endothelial cells remained entirely intact (Figure 43).  
 
 
Figure 42 Valve development at P6 following conditional deletion of 
PPP3R1 (CnB1) from P0 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous conditional deletion of CnB1 from 
P0 resulted in failure to develop valve leaflets, compared to wildtype littermates that 
developed normally. P= Fisher’s exact test. ns= >0.05 
B) The proportion of valves at each stage are shown for each genotype. +/+ = wildtype 
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Figure 43 Morphology of valves at P6 following conditional deletion of 
PPP3R1 (CnB1) from P0 
A) Prox1CreERT2- (effective wildtype) valves developed normally. B) Conditional 
deletion of PPP3R1 (encoding Calcineurin B1) resulted in a failure of leaflet 
development at P6 (arrowheads in B). Scale bars 20µm. Green = Foxc2, Red = Prox1, 
Blue = PECAM1. 
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7.4.5 Effect of PPP3R1 deletion on venous valve leaflet 
length at P6 
Conditional homozygous deletion of PPP3R1 from P0 resulted in significantly 





Figure 44 Conditional deletion of PPP3R1 (CnB1) from P0 analysed at P6. 
A) The table provides the total number of VV analysed and the mean normalized leaflet 
length for each genotype. Homozygous conditional deletion of CnB1 from P0 resulted in 
significantly shorter valve leaflets, compared to wildtype littermates that developed 
normally. P= independent sample t test.  
B) The mean normalized leaflet length for each genotype is shown. Error bars represent 
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7.4.6 Localisation of NFATc1 in human VV 
 
NFATc1 was localised to nuclei of endothelial cells lining the lumen surface of 
the VV leaflets, suggesting active calcineurin-NFATc1 signalling in these cells.  
 
 
Figure 45 Immunohistochemical localisation of NFATc1 in human VV 
A) NFATc1 was localised to nuclei of endothelial cells lining the luminal surface of two 
opposing VV leaflets in FFPE transverse sections of human VV. (arrowheads).  
B) No signal was detected with concurrent use of non-immune IgG on a section on the 
same slide.  
Scale bar 50µm   
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7.5 Discussion  
 
Endothelial deletion of the regulatory subunit of calcineurin, CnB1 (encoded by 
PPP3R1) from P0 restricted subcellular localisation of NFATc1 to the nucleus 
and effectively blocked VV development beyond stage 1, with approximately 
40% shorter valve leaflets at P6. This suggests a cell-autonomous function for 
calcineurin-NFAT signalling in VV development. A similar defect was found 
with inhibition of calcineurin phosphatase activity by administration of CsA, 
although this caused other, systemic effects including failure to gain weight.  
 
NFATc1 is thought to be critically required for valve elongation in cardiac and 
lymphatic valves42, 96 and our results appear to confirm the underlying 
hypothesis that some similar mechanisms regulate cardiac, venous and 
lymphatic valve development. The mechanism by which leaflet elongation fails 
is unknown. It is possible that endothelial cells fail to proliferate, since NFATc1 
has been shown to promote proliferation of human pulmonary valve 
endothelial cells in vitro.167  
 
NFATc1 and Foxc2 show similar patterns of immunolocalisation in the 
developing valve (and downstream region) and it is likely that these proteins 
interact in VV development, as has previously been demonstrated in lymphatic 
collecting vessel maturation.39, 40. Conditional deletion of either CnB1 or Foxc2 
in endothelial cells from E15 did not result in a significant valve phenotype at 
P0. It was not possible within the time and geographical constraints of this 
work to analyse the phenotype of double transgenics, or following Foxc2 
deletion with CsA. NFATc1 binds to GATA5, and it is notable that loss of 
GATA5 function produces an abnormally bicuspid aortic valve, demonstrating 
a role for GATA-binding proteins in valve formation. Whilst GATA5 has not 
been identified in VV, the related protein GATA2 has been immunolocalised to 
human VV and could also interact with NFATc1 in valve development. 
NAFTc1 associates with GATA2 in skeletal muscle.168 Whilst mutations in 
GATA2 can lead to lymphoedema, it is not known whether these patients are 
affected by VV failure. 169,98,165 This will be the focus of future work. 
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In the pro-valve endocardium an enhancer within the first intron of NFATc1 
functions as an autonomous cell-specific enhancer leading to high expression 
of NFATc1 in valve endocardium.170 It is an intriguing possibility that the same 
enhancer directs expression in venous and lymphatic valve development.  
 
Endothelial-mesenchymal transition has never been suggested to occur in LV 
or VV development, although the origin of VV interstitial cells remains 
unknown. Analysis of venous valves in Prox1CreERT2;Rosa26mTmG mice at 
P6 following administration of 4OHT at P1+P2 did not reveal GFP-expressing 
interstitial cells (Appendix 11), indicating that Prox1-expressing EC’s at P1 had 
not become interstitial cells by P6. This preliminary result does not exclude 
EMT at earlier stages (prior to P1). Whilst murine LV do not have interstitial 
cells (except in the thoracic duct), pericytes are consistently identified near the 
valve agger. 146 
 
7.5.1 Limitations 
Activity of other NFAT’s has not been examined in the context of venous 
valves. NFATs other than NFATc1, if present in VV endothelium, would 
similarly be inhibited by CsA or CnB1 deletion. It is an intriguing possibility that 
NFATc3 or NFATc4 in pericytes may play a role in VV and LV development, 
analogous to their role in myocardium. The VV phenotype (prevention of valve 
elongation) observed in the limited number of valves imaged after postnatal 
CsA administration was similar to that seen with endothelial CnB1 loss of 
function in  Prox1CreERT2;PPP3R1lxlx mice and is consistent with the findings 
of Chang et al 96 regarding the endocardial requirement for CnB1 in cardiac 
valve elongation. Experiments were carried out to examine the hypothesis that 
earlier administration of CsA prevents valve development, but were 
complicated by early littering (data not shown). It remains possible that other 
NFATs are expressed and may play a role in VV (and LV development).  
 
Calcineurin activity is calcium dependent, but the upstream stimulus to 
calcineurin-NFAT signalling in VV development has not been studied. Ca2+ 
has been suggested as a candidate carrier for valve-regulatory signals 
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passing between endothelial cells via gap junctions, and will be discussed 
further in Chapter 8.106 
 
The requirement for calcineurin-NFAT signalling in maintenance of the formed 
VV has not been examined. The nuclear localisation of NFATc1 in adult 
human VV demonstrates on-going active signalling via this pathway, and a 
requirement for VV maintenance could lead to a detrimental VV phenotype in 
patients treated with ciclosporin (or other calcineurin inhibitors such as the 
clinically-used drug FK506).  
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Connexins are transmembrane proteins that have important roles including the 
formation of gap junctions between adjacent cells.105 In man, mutations in 
GJA4 (encoding Cx43) and GJC2 (encoding Cx47) have recently been shown 
to cause lymphoedema.4, 57 In mice, Cx37 and Cx43 have been found to be 
required for normal lymphatic valve development.42, 109 Uniquely for primary 
lymphoedema, the lymphoedema caused by GJC2 mutations in man has been 
attributed to a functional rather than structural lymphatic defect, possibly 
related to abnormal lymphatic pumping.4 Whilst Cx47 expression has been 
identified in adult VV and LV, no lymphatic or venous phenotype with loss of 
Cx47 in mice has been described.61, 111 
Recently, and after this work on Cx37 was completed, it was found that adult 
Cx37 homozygous knockout mice have absent VV; the mechanisms 
underlying this finding have not been described.111 
 
8.2 Aims 
1) Characterise the expression pattern of Cx37, Cx43, and Cx47 at P0. 
2) Analyse the VV developmental phenotypes produced by genetic loss of 
function of Cx37, Cx43 and Cx47. 
3) Develop and apply novel techniques for analysis of the cellular phenotypes 
seen in these experiments. 
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8.3 Design and Methods  
8.3.1 Mice 
Transgenic mice were maintained at the University of Lausanne on a Bl/6 
background. For immunolocalisation of connexins 37 and 43, balb/c mice from 
Charles River UK were used and ≥VV analysed per connexin. 
 
8.3.1.1 Constitutive deletion of GJA1 (Cx37) 
In this line the majority of the single coding exon of GJA1 has been deleted. 171 
Cx37-/- females are infertile and therefore Cx37+/- females were interbred with 
Cx37-/- or Cx37+/- males. At P0, 3 wildtype, 11 heterozygous knockout and 14 
homozygous knockout littermates were analysed. At P6 2 wildtype, 18 
heterozygous knockout and 16 homozygous knockout littermates were 
analysed. Numbers of VV visualised at each age and stage for each genotype 
are provided in the results. 
 
8.3.1.2 Conditional deletion of GJA4 (Cx43) 
Prox1CreERT2+ and Prox1CreERT2– littermates, all GJA1lxlx were analysed, 
with 4OHT administered to the dam at E15.5 (for analysis at P0) or pups at P0 
(for analysis at P6). At P0, 6 effective wildtype and 6 homozygous conditional 
deleted littermate mice were analysed. At P6 2 wildtype and 4 homozygous 
conditional deleted littermates were analysed. Numbers of VV visualised at 
each age and stage for each genotype are provided in the results. 
 
8.3.1.3 Constitutive deletion of Cx47 in Cx47GFP reporter 
In this line the coding region of GJC2 is replaced by eGFP.61 eGFP in these 
mice is not specifically targeted to the nucleus, and has been identified in the 
nucleus and cytoplasm.61 At P0 4 wildtype, 5 heterozygous knockout and 8 
homozygous knockout littermate mice were analysed. At P2 2 wildtype, 2 
heterozygous knockout and 6 homozygous knockout mice were analysed. 
Numbers of VV visualised at each age and stage for each genotype are 
provided in the results. GFP signal was amplified with a biotinylated anti-GFP 
antibody and streptavidin-conjugated Dylight-488 secondary antibody.  
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8.3.2 Correlation between nuclear and cellular morphology 
measurements in mTmG reporter 
The correlation between valve-forming cell nuclear and cellular morphology in 
wildtype mice at late E18 was assessed using membrane targeted GFP in the 
mTmG Cre reporter line, crossed with Prox1CreERT2, in 2 VV (Figure 
31).44,153  
 
1. Rosa26mTmG;Prox1CreERT2 mice were injected at E15-16 to produce 
recombination and therefore membrane-targeted eGFP expression in the 
valve-forming cells at late E18. Valves were immunostained for Prox1 and 
Foxc2 and confocal z-stacks were obtained as described in the General 
Methods Chapter and Chapter 3. 
 
2. Measurements were made of the nuclear and cellular maximum length and 
width of Prox1hi cells in NIH ImageJ software, using single optical sections 
within Z stacks. For cell measurements, the centre of the line of membrane-
tagged GFP fluorescence was taken as the boundary of the cell. Only cells 
where the nuclear and cell boundaries could be clearly identified were 
measured. Cells throughout the valve were included.  
 
3. Data were exported into Excel and SPSS 21 (IBM) for analysis. 
 
8.3.3 Quantification of effect of connexin deletion on 
nuclear elongation and rotation at P0  
A total of 3382 nuclei were measured. The numbers of nuclei contributing to 
the analysis in each group are provided in the results section in Table 2 and 
Table 3. For Cx37, 6 wildtype, 4 heterozygous knockout and 8 homozygous 
knockout littermate VV were analysed. For Cx43, 6 wildtype and 11 
homozygous conditional deleted littermate VV were analysed. For Cx47, 5 
wildtype, 6 heterozygous knockout and 6 homozygous knockout littermate VV 
were analysed.  
 
1. Confocal z-stacks of VV were created as described in Chapter 3.   
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2. The Prox1 channel was isolated and a XY maximum projection produced 
and reflected/rotated so that the centreline of the vessel was horizontal in the 
image with blood flow from left to right.  
 
3. Following the method of Tatin et al,146 length and width were measured in 
NIH ImageJ software for all nuclei with Prox1hi immunosignal above the 
background of adjacent vessel endothelium in the valve-forming region. The 
composite (four channel) z-stack was used to identify the boundaries of the 
vein and avoid measurement of non-venous nuclei. 
 
4. The centre and angle of the length measurement line were extracted and 
used for nuclear position and rotation, respectively.  
 
5. Data were exported to Microsoft Excel. The length:width ratio was 
calculated for each nucleus.  
 
6. To appropriately convert nuclear rotation (0-360o) into deviation away from 
the midline (0-90o), the angle derived from each length measurement was 
converted to radians, and the following function applied: 
 
Converted angle = asin(sqrt(sin^2) of original angle  
 
The results of this equation are shown in Appendix 9. 
 
7. The position of each nucleus was calculated relative to the most superior 
and inferior nucleus in the valve, generating a ‘centile value’ for the position of 
the measured nucleus across the vessel from superior to inferior. For grouped 
analyses each nucleus was automatically assigned to 1 of three groups 
(tertiles) according to its geometric position in the valve (y axis). The superior, 
middle, and inferior regions were respectively numbered tertiles 1-3 as shown 
in Figure 46. 
 
8. Data for the length:width ratio and position of each nucleus were exported 
to SPSS 21 for analysis.  
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Figure 46 Quantification of nuclear phenotypes in venous valves 
Nuclei were split into three groups according to position within the vein, according to the 
y coordinate of the center of the nuclear length measurement. Rotation was measured 
relative to the midline of the vessel.  
 
 
8.3.4 Genotyping and immunofluorescence  
Immunofluorescence imaging of murine VV and genotyping were carried out 
as described in the General Methods and Chapter 3. Confocal z-stacks of 
Cx37 and Cx43 immunolocalisation were not filtered. All solutions are given in 
Appendix 1, antibodies in Appendix 3 and primers in Appendix 4. 
 
8.3.5 Localisation of Cx43 and Cx47 in human long 
saphenous vein VV 
Segments of vein from patients undergoing coronary artery bypass grafting 
(with clinically normal long saphenous veins) were obtained and 
immunolocalisation for Cx43 and Cx47 was performed on acetone-fixed frozen 
sections using HRP-polymer amplification (Menarini diagnostics) and Vector 
SG substrate (Vector) as described in the General Methods chapter.  
 
8.3.6 8.3.6  Statistical analysis 
For comparison of stage of VV development Fisher’s exact test was used, 
comparing wildtype with either heterozygous or homozygous knockouts for 
each stage. Data from multiple litters were pooled.  
To assess for correlation between nuclear and cellular morphology 
(elongation, rotation) scatter plots were produced, and the Pearson’s r and O 
value calculated.  
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For the analysis of the proportions of nuclei in each region of the vein that 
were elongated (length:width ratio ≥2) a chi square test was used, comparing 
heterozygous or homozygous deletion with wildtype littermates. Similarly, a 
Chi square test was used for the proportion of elongated nuclei in each region 
that were rotated ≥40degrees.  
 
For analysis of the proportion of analysed nuclei that were located in each 
region of the vessel, an independent samples t-test was used for homozygous 
or heterozygous deletion compared with wildtype littermates.  
All analyses were carried out in SPSS 21 (IBM corporation). 
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8.4 Results 
 
8.4.1 Connexin expression at P0 
At P0 Cx37 immunosignal was primarily detected around valve-forming cells, 
particularly in the upper and lower regions of the vein. Cx43 was not detected 
around Foxc2-expressing valve-forming cells, but rather in the upstream 
region in the upper half of the vein (Figure 47). Cx47 promoter activity was 
detected in a Cx47GFP reporter strain (which is heterozygous or homozygous 
knockout for Cx47) using anti-GFP antibodies. As expected, in labelled cells 
signal was detected not in a membranous pattern but distributed throughout 
the cell (Figure 48). GFP+ve cells were identifiable in the femoral vein distal to 
the valve region and in the region of the developing valve (Figure 48, Figure 
57) 
 
Figure 47 Expression of Cx37,43 in the valve-region at P0 
A) At P0, Cx37 was most strongly localized around the Prox1+ VFC’s (between the 
arrowheads in A) 
 
B) Cx43 was localized to the upstream region of the vein in an endothelial pattern (area 
outlined by arrowheads in B). Blue = Pecam1. Representative images from n≥3 per 
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8.4.2 Effect of constitutive deletion of Cx37 (GJA4) 
analysed at P0 
Whilst wildtype and heterozygous constitutive Cx37 knockout valves 
developed normally to stage 1, homozygous deletion almost entirely prevented 
progression to stage 1 of development (Figure 49). Prox1hi cells were still 
identified across the vein at P0, but appeared disorganised with a failure to 
show a normally elongated and rotated morphology (Figure 50). 
 
Figure 49 Valve development at P0 following constitutive deletion of Cx37   
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous knockout of Cx37 resulted in a 
failure of normal organisation to reach stage 1 of VV development, compared to 
heterozygous knockout and wildtype littermates that developed normally. Fisher’s exact 
test. ns= >0.05 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(n=3 mice), +/- = heterozygous knockout (n=11) -/- = homozygous knockout (n=14). 
 
 




Figure 50 Morphological changes in valve development at P0 following 
constitutive deletion of Cx37  
 
Analysis at P0 following constitutive homozygous deletion of Cx37 showed a failure of 
organisation with reduced elongated and rotation of valve-forming cells (arrowheads in 
A’), compared with wildtype littermates in which normally elongated and rotated VFC’s 
are seen (arrowheads in A). Arrowheads indicate line of Prox1hi VFC’s (not individual 
specific nuclei). Scale bar 50µm. Green = Foxc2, red = Prox1, blue=Pecam1 
immunolocalisation. Flow left to right. 
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8.4.3 Effect of constitutive deletion of Cx37 (GJA4) 
analysed at P6 
At P6, whilst wildtype controls and heterozygous constitutive deletion did not 
affect valve development, homozygous deletion of Cx37 resulted in complete 
absence of Prox1hi valve cells (Figure 51). Accordingly, no gap was seen in 
SMA positive pericytes (Figure 52). 
 
Figure 51 Valve development at P6 following constitutive deletion of Cx37 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous knockout of Cx37 resulted 
complete absence of identifiable Prox1+ or Foxc2+ valve cells at P6, compared to 
heterozygous knockout and wildtype littermates that developed normally. Fisher’s exact 
test. ns= >0.05 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
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8.4.4 Effect on valve development at P0 of conditional 
deletion of Cx43 (GJA1) from E15. 
Conditional deletion of GJA1 (encoding Cx43) from E15 resulted in a loss of 
normal valve organisation at P0, albeit the phenotype was not as strong at that 
seen with deletion of Cx37 or Cx47 (Figure 53, Figure 54). Relative to other 
connexin deletions, there was increased variability in the Cx43 homozygous 
deletion VV phenotype when analysed at P0, with some valves appearing 
relatively normal (Figure 53).  
 
 
Figure 53 Valve development at P0 after conditional deletion of Cx43 from E15 
 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous conditional deletion of GJA1 
(Cx43) resulted in significantly fewer valves reaching stage 1 compared to wildtype 
littermates that developed normally. Fisher’s exact test.  
B) The proportion of valves at each stage are shown for each genotype. +/+ = wildtype 
(n=6 mice), -/- = homozygous conditional deletion (n=6 mice). 
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Figure 54 Conditional deletion of Cx43 analysed at P0  
 
A) Wildtype littermates developed relatively normally and showed a line of rotated 
Prox1hi valve-forming cells (line marked by arrowhead in A)  
A’) Conditional homozygous deletion of Cx43 resulted in a phenotype in which Prox1hi 
valve-forming cell nuclei were identifiable but did not appear normally organized, and 
appeared less elongated and rotated (two examples identified by arrowheads in A’). 
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8.4.5 Effect of conditional deletion of Cx43 (GJA1) from P0 
on valve development at P6 
No significant phenotype was detected at P6 following conditional deletion of 
Cx43 at P0 (Figure 55), indicating that the critical requirement for Cx43 activity 
is limited to around P0.  
 
 
Figure 55 Valve development at P6 following conditional deletion of Cx43 
from P0 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Conditional deletion of Cx43 from P0, analysed 
at P6, did not reveal any significant phenotype. Fisher’s exact test. ns=P>0.05 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(n=2 mice), -/- = homozygous conditional deletion (n=4 mice). 
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8.4.6 Constitutive deletion of GJC2 (Cx47) analysed at P0 
Whilst valves in wildtype littermates and those with heterozygous deletion of 
Cx47 from E15 developed normally, homozygous constitutive deletion resulted 
in a failure of organisation of Prox1hi valve-forming cells (Figure 56, Figure 57). 
The lack of any amplified GFP signal in wildtype littermates confirmed the 
specificity of the anti-GFP antibody and imaging of Cx47:GFP signal (Figure 
57). 
 
Figure 56 Constitutive deletion of Cx47 in Cx47GFP reporter at P0. 
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Constitutive homozygous knockout of Cx47 
resulted in failure of organisation to stage 1 of development. Prox1hi cells remained 
identifiable. Heterozygous deletion of Cx47 did not produce a phenotype. Fisher’s exact 
test.  
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(n=4 mice), +/- = heterozygous knockout (n=5), -/- = homozygous knockout (n=8). 
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Figure 57 Constitutive Cx47 deletion analysed at P0 
 
A) In wildtype littermates a line of rotated and elongated Prox1hi valve-forming cell 
nuclei was clearly identified (indicated by arrowheads in A) 
A’) Homozygous knockout of Cx47 (in the Cx47GFP reporter) resulted in a clear 
phenotype in which Prox1hi valve-forming cell nuclei remained identifiable in a band 
across the vein (position indicated by arrowheads in A’), but appeared less elongated 
and rotated, and overall less organized.  
Scale bar 50µm. Green = amplified GFP in Cx47:GFP reporter. Note absence of GFP 
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8.4.7 Constitutive deletion of GJC2 (Cx47) analysed at P2  
Analysis of homozygous Cx47 deleted valves at P2 showed a similar 
phenotype to Cx37 deletion at P6, with a complete absence of Prox1hi valve 
cells (Figure 58, Figure 59). This indicates a critical requirement for Cx47 in 
the maintenance of the abnormal valve structure forming at P0, and a clear 
structural phenotype caused by loss of GJC2. In additional, GFP+ cells were 
greatly reduced and almost undetectable in the vein at P2 (but were 
detectable in other structures, Figure 59). No significant phenotype was seen 
in the limited number of VV analysed following heterozygous deletion (Figure 
58, Figure 59).  
 
Figure 58 Constitutive deletion of GJC2 analysed at P2  
A) The table provides the total number of VV analysed for each genotype and the 
number of VV identified at each stage. Homozygous knockout of Cx47 resulted in 
almost complete absence of valve cells by P2. Heterozygous knockout of Cx47 did not 
produce a phenotype. Wildtype littermates developed relatively normally, although none 
were observed at stage 4. P= Fisher’s exact test. ns=P>0.05 
B) The proportion of valves at each stage is shown for each genotype. +/+ = wildtype 
(N=2 mice), +/- = heterozygous knockout (N=2), -/- = homozygous knockout (N=6). 
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8.4.8 Correlation of nuclear and cellular morphology in 
valve-forming cells at P0 
Analysis of nuclear and cellular morphology in Prox1hi valve-forming cells at 
late E18 showed a strong significant correlation between measurements of 
nuclear and cellular rotation (Pearson’s r=0.99, P<0.0001, Figure 60), and 
nuclear and cellular elongation (Pearson’s r=0.81, P<0.0001, Figure 61). A 2D 
maximum projection of a z stack (from which measurements were obtained in 
individual optical sections) is shown in (Figure 27). The nuclear specificity 
obtained by immunolocalisation of Prox1 is demonstrated in which Prox1 
colocalises with nuclear-targeted GFP. These results indicate that in these 
cells at this time point, measurement of nuclear morphology based on Prox1 
immunostaining could be used as a marker for cellular morphology.  
 
Figure 60 Correlation between cell rotation and nucleus rotation in VFC’s 
 
The angle of the long axis of the nucleus and the cell were measured in 47 cells in 2 
valves. Pearson’s r=0.99, P<0.0001. A line of best fit through the origin is shown. 
Prox1CreERT2;mTmG mice were given tamoxifen at E15 and analysed at late E18 with 
immunostaining for Prox1. Only Prox1hi valve-forming cells, where the cell membrane 
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Figure 61 Correlation of cell and nucleus elongation in VFC’s 
 
The length of the long axis of the nucleus and of the cell, as marked by membrane-
tagged GFP, were measured in 47 cells in single optical sections from confocal z-
stacks. Pearson’s r= 0.81, P<0.0001. A line of best fit through the origin is shown. 
Prox1CreERT2;mTmG mice were given tamoxifen at E15 and analysed at late E18 with 
immunostaining for Prox1, and only Prox1hi valve-forming cells where the membrane 
was clearly defined were measured. Elongation (of cell or nucleus) = length:width ratio. 
Although this correlation is weaker that that for rotation, it remains strong and it can be 
seen that the cutoff of nuclear elongation of 2 used in subsequent analyses will correctly 
identify elongated cells.  
 
8.4.8.1 Morphology of wildtype Prox1hi nuclei at P0 
No correlation was found between elongation and rotation of individual nuclei, 
and these parameters were analysed separately. (Appendix 9, Figure 102). 
Analysis of the variation in WT Prox1hi nuclear rotation across the y-axis (from 
superior to inferior) demonstrated clear variation, with the most rotated nuclei 
present in the central region of the vessel. (Appendix 9, Figure 103, Figure 
104) This is consistent with the qualitative description of VV development 
given in Figure 21. No substantial variation was seen in WT Prox1hi nuclear 
elongation across the vessel (Figure 105). Because the variation in nuclear 
morphology across the vein precluded pooled analysis of all nuclei, 
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subsequent analyses in this chapter were performed within each tertile (1st – 
superior third, 2nd – middle third, 3rd – inferior third, Figure 46).  
 
 
8.4.9 Cellular morphology phenotypes following GJA1, 
GJA4, GJC2 deletion 
The elongation of Prox1hi valve-forming cells was analysed in wildtype 
littermates and following constitutive deletion of Cx37 or Cx47, or conditional 
deletion of Cx43 (Table 2, Figure 62-Figure 64). The upper (1st tertile), middle 
(2nd tertile) and lower (3rd tertile) of the vein was analysed separately, because 
these regions displayed different mean nuclear rotation in a pooled analysis of 
wildtype cells (Figure 46). The proportion of nuclei with length:width ratio ≥2 
was significantly reduced in the 2nd and 3rd tertiles following homozygous loss 
of Cx37. Homozygous deletion of Cx43 produced significant reductions in 
elongation in all regions, whilst homozygous deletion of Cx47 resulted in 
reduced elongation only in the 1st tertile.  
 
Nuclear rotation was analysed for nuclei that were elongated with length:width 
ratio ≥2 (Table 3, Figure 62-Figure 64). The proportions of nuclei rotated ≥400 
was significantly reduced compared with wildtype littermates, in all regions of 
the vein following constitutive homozygous Cx37 deletion.  Conditional 
homozygous deletion of Cx43 or constitutive homozygous deletion of Cx47 
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Table 2 Prox1hi nuclear elongation phenotypes with connexin deletion. 
P values represent Chi square analysis of heterozygous or homozygous deletion versus 
WT for the proportion of nuclei of each genotype elongated ≥2. Tertiles refer to the y-
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Table 3 Prox1hi elongated nuclear rotation phenotypes with connexin 
deletion. 
Rotation was only analysed in nuclei elongated ≥2. P values represent Chi square 
analysis of heterozygous or homozygous deletion versus WT for the proportion of nuclei 
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8.4.10 Proportions of measured VFC’s in each region of the 
vein at P0 
It has been suggested that VFC’s migrate around the lymphatics vessel to 
form the ring in early lymphatic valve formation (equivalent to VV stage 1).42 
Analysis, in each VV, of the proportion of VFC’s in each region of the vein (by 
tertile) showed no difference in the proportions of cells in each region for 
conditional homozygous deletion of Cx43 or constitutive heterozygous 
knockout of Cx47. Homozygous knockout of Cx37 resulted in a lower 
proportion of Prox1hi cells identified in the central region of the vein. The mean 
proportion in wildtype valves was 0.280 Vs 0.195 in homozygous knockout 
valves, P =0.003 (independent samples t test). 
 
 
Figure 65 Proportion of measured VFC’s in each region of vein at P0 
following Cx37 knockout 
 
Knockout of Cx37 resulted in significantly lower proportion of Prox1hi cells identified in 
the 2nd tertile (central region). Mean proportion (wildtype) 0.280 Vs (KO) 0.195,                 
P=0.003 (independent samples t test). Corresponding increases in the proportion in 
tertiles 1 and 3 did not reach statistical significance. Heterozygous deletion resulted in a 
significantly higher proportion of cells in tertile 1 and corresponding reduced proportion 
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8.4.11 Expression of connexins 43 and 47 in human adult 
normal venous valves 
Connexins 43 and 47 were immunolocalised in human long saphenous vein 
valve leaflets. Signal from Cx43 was preferentially detected on the sinus 
surface of the leaflet (Figure 66), whilst Cx47 signal was detected throughout 
the leaflet (Figure 67). Both proteins were localised in a membranous-type 
expression pattern.   
 
 
Figure 66 Localisation of Cx43 in human long saphenous vein valve leaflets 
by immunohistochemistry.  
Cx43 was localised to the sinus side of the valve leaflets, including interstitial cells. 
Nuclear fast red counterstain. Scale 20µm. 
 
 
Figure 67 Localisation of Cx47 in human long saphenous vein valve leaflet 
by immunohistochemistry. 
Nuclear fast red counterstain. Scale 20µm. Cx47 immunostaining was identified 
throughout the leaflet. 
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8.5 Discussion 
 
After these result were obtained, and consistent with these findings, it was 
reported that adult Cx37-/- mice lack venous valves.111 The cellular cause of 
this abnormality has not previously been described, and to the best of my 
knowledge no VV phenotype associated with loss of Cx43 or Cx47 has been 
described. 
 
A genetic loss of function approach to connexins 37, 43, 47 produced a 
grossly similar phenotype for all three proteins. At P0 the Prox1hi VFC’s were 
generally identified in the correct region of the vein, and were distributed 
across the width of the vein, but they displayed abnormal morphology, as 
measured by immunostaining of their nuclei. Importantly, almost all VFC’s 
were unidentifiable at P6 or P2 following loss, respectively, of Cx37 or 47, 
whilst conditional deletion of Cx43 in Prox1-expressing cells after P0 showed 
no phenotype. Taken together with the observation that Prox1hi VFC’s were 
present at P0, these results strongly suggest that the failure of normal events 
around P0 are responsible for failure to develop normal VV in these mice. The 
increasingly severe phenotype from P0 to P2/6, together with the previously 
reported adult Cx37-/- phenotype, excludes developmental delay. It remains 
unclear whether failure of on-going valve formation is caused by loss of 
connexin function, or secondary to the abnormal organisation of Prox1hi cells 
seen at P0, which presumably affects other signalling processes.  
 
Connexins 37, 43 and 47 had very different expression patterns around the 
developing VV at P0. Whilst Cx37 immunosignals were strongest around the 
Prox1hi VFC’s, signal for Cx43 was localised to upstream endothelium and not 
VFC’s. This is consistent with previous work showing that Foxc2 upregulates 
Cx37, and suggesting that Foxc2 may downregulate Cx43, as Foxc2 is highly 
expressed (albeit heterogeneously) in VFC’s.42, 111 It remains unclear why 
immunosignals for Cx43 were consistently increased in he upper half of the 
vessel. Additionally, despite this expression pattern, conditional loss of Cx43 
produced a significant reduction in VFC elongation in the lower third of the 
vessel. 
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In man, mutations in GJC2, encoding Cx47, have been demonstrated to cause 
lymphoedema, but it has been suggested that this phenotype results from a 
functional, rather than structural lymphatic defect.4 Given the observed 
similarities between venous and lymphatic valves it is therefore surprising to 
find a clear structural VV defect resulting from loss of Cx47. It is possible that 
a structural defect in GJC2-mutated lymphatics remains to be discovered. 
Similarly, mutations in GJA1, encoding Cx43, were very recently described as 
causing human lymphoedema.57 Both Cx43 and Cx47 were immunolocalised 
to normal human venous valve leaflets, and the structure of VV in patients 
carrying mutations in GJC2 and a single participant carrying a GJA1 mutation 
will be examined in a subsequent chapter. 
 
It is possible that the conditional deletion approach may not phenocopy known 
human syndromes, since these (human) mutations could result in dominant 
negative effects whilst genetic deletion reproduces protein loss. Further more, 
combination of different proteins in heteromeric connexons or heterotypic gap 
junctions could extend the effects of a mutated protein to signalling events 
predominantly produced by other connexins.105 Induced loss of one connexin 
results in downregulation of other connexin, which could present a particular 
problem with a constitutive rather than conditional knockout approach.172,141 
 
It is notable that with loss of all three connexins, VFC’s were distributed across 
the width of the vein. If the disoriented appearance of VFC’s is accepted as 
indicating disordered directional cell migration, this is inconsistent with a model 
in which differentiation of VFC’s occur in a clump on one side of the vessel 
followed by migration around the vessel to form the ring at Stage 1. Instead, 
these findings would be more consistent with an alternative process - VFC 
differentiation in situ. VFC migration has not been directly observed (in VV or 
LV) and could be an interesting focus for future work. 
 
It remains to be confirmed whether the connexin’s expressed around the 
VFC’s at P0 form functional gap junctions. TEM analysis at P0 did not identify 
clear gap junctions, but this is likely to be because of difficulty in identification 
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of these structures in ex-vivo samples (Figure 22). For Cx43, the phenotype 
observed following endothelial-specific gene deletion confirms the endothelial 
localisation of the protein. Given the known roles for Cx37 and Cx43 in 
endothelial cells, it seems likely that these connexins (and likely Cx47) form 
functional gap junctions during VV development.105 It was not possible in this 
work to determine the messenger that may be communicated between VFC’s. 
Ca2+ has been suggested as a candidate for this role, and could subsequently 
act upstream of calcineurin-NFAT.94 Cx45 has been shown to play a critical 
role in cardiac outflow tract development, and acts upstream of NFATc1 
signalling.92, 93 Expression of Cx45 has not been described in LV or VV, but it 
is an intriguing possibility that Cx45 could also play a role in peripheral valve 
development. In future work it would be informative to attempt to demonstrate 
GJIC compartments via the injection of dye into VFC’s.  
 
Cx43 regulates cell polarity and directional migration via a channel 
independent effect on the cytoskeleton.116 In this work Cx43 was 
immunolocalised to the upstream endothelial cells rather than VFC’s, whilst 
the observed phenotype was in the VFC’s themselves. This suggests that 
signalling between upstream cells and VFC’s was perturbed by loss of Cx43, 
rather than a direct effect of loss of Cx43 in VFC’s themselves.  
 
 
8.5.1 Limitations:  
 
• Cellular phenotypes resulting from connexin loss of function were 
analysed by measuring length and width of Prox1hi nuclei. This was 
performed in blinded fashion, but selection of nuclei could be 
susceptible to bias. Use of automated software to threshold Prox1 
nuclei was attempted but was unsuccessful (data not shown). Signal 
intensity varies with depth in a z-stack, and this is not appreciable in a 
2D maximum projection. In a 2D projection of 3D data, nuclei may 
appear to overlap, and be measured as a single object by automated 
software, particularly given the variation in nuclear intensity between 
and within nuclei. Analysis of z stacks was also attempted using 3D 
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volume rendering software, but nuclear volumes were distorted by 
section thickness and the limited z-resolution of the objective. Analysis 
of a 3D stack would require time-consuming thin section scanning and 
deconvolution, and even within z-stacks, automated thresholding 
remained susceptible to errors.  Nuclear sphericity has previously been 
analysed as indicative of disordered migration.145 
• In future work, loss of cell polarity could be further investigated by co-
staining polarised cellular organelles. 
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9 ROLE OF VEGFR2/3 IN VV FORMATION 
 
9.1 Introduction 
Signalling through the tyrosine kinase VEGFR3 is critically required for early 
blood vascular and lymphatic development.122, 125 In man, mutations in 
VEGFR3 and its ligand, VEGFC, cause Milroy’s disease (lymphoedema).53 
These patients have an increased incidence of venous reflux, suggesting a 
developmental venous defect.50, 53 Our previous work has identified VEGFR3 
promoter activity in developing VV using a VEGFR3LacZ reporter line,44 but 
expression has never been confirmed by immunolocalisation and the timing of 
onset of VEGFR3 expression has not been described. It is not known whether 
signalling through VEGFR3 is required for VV development. 
 
9.2 Aims 
1. To investigate the expression pattern of VEGFR3 is expressed on VVs  
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9.3 Design and Methods 
Inhibition of the various forms of signalling through VEGFR3 can be achieved 
with different and complementary methods. For inhibition of valve induction, 
blocking antibodies would require administration to the dam, and the antibody 
is not widely available. Both the Chy mouse (which exhibits constitutive 
heterozygous loss of VEGFR3 protein tyrosine kinase function) and a mouse 
line with a floxed VEGFR3 allele were not available.123, 130 For these reasons, 
and because patients affected by Milroy’s disease carry mutations inactivating 
the tyrosine kinase domain, I elected to examine the effect of VEGFR tyrosine 
kinase inhibitors in vivo. A recently described small molecule tyrosine kinase 
inhibitor, Maz51, has selectivity for VEGFR3 over other VEGFR’s, and has 
previously been characterised for use in in-vivo murine models.124, 173 In-vivo, 
Maz51 significantly prevents tyrosine phosphorylation of VEGFR3 but has little 
effect on VEGFR2, and its effect has ben verified when administered at 
10mg/kg OD.124, 173. In vitro, Maz-51 inhibited ligand-independent auto-
phosphorylation and also (ligand-dependent) phosphorylation in response to 
VEGF-C.173 Axitinib is a well-characterised small molecule tyrosine kinase 
inhibitor, with selectivity for VEGFR1, VEGFR2 and VEGFR3.174, 175 
 
9.3.1 Axitinib 
Axitinib was administered at 12.5µg/g.mouse weight in acidified water.  
Axitinib was prepared as follows: 
1. 600µl PEG400 (Sigma) and 1ml sterile water (Baxter, UK) and 100µl 
1M HCl were added to 5mg axitinib (LC laboratories) in a 2ml 
polypropylene tube (Eppendorf) and sonnicated (Sonnicator 230HT, 
Crest Laboratories) for 10mins at RT. 
2. The resulting solution was made up to 2ml with 70% v/v PEG400 in 
water, adjusted to pH2 with HCl.  
 
9.3.1.1 Effect of axitinib administration from E16, analysed at 
P0 
Pregnant dams were administered axitinib 12.5µg/g.mouse wt or solvent 
control (70% v/v PEG400 in water, adjusted to pH2) i.p. b.d. from late E16 and 
analysed at P0. Six animals were analysed after treatment with axitinib and 4 
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after solvent control. Eight control and 9 axitinib-treated valves were 
visualised.  
 
9.3.1.2 Effect of axitinib administration from P0, analysed at P2 
Pups in two litters were randomly assigned to receive Axitinib or solvent 
control s/c b.d from P0 to P2, and were culled for analysis at P2. 3 pups 
received Axitinib and 3 solvent control.  
 
9.3.2 Maz51 
Maz51 (Calbiochem 676492) was administered at 10µg/g OD in DMSO from a 
stock solution of 10µg/µl diluted to 1µg/µl. Dose volume was therefore 1µl x 
animal weight in grams (i.p to dams, s/c to pups). Controls received solvent 
alone.  
 
9.3.2.1 Effect of Maz51 administration from E16, analysed at 
P0 
Pregnant dams were administered Maz51 or solvent control i.p o.d. from late 
E16. All dams received a single dose of 37.5µg/g Progesterone (Sigma 
P3972) in sunflower oil (Sigma S5007) to prevent early labour. Embryos were 
explanted at ‘E19’ and analysed as P0. Four animals were analysed after 
receiving Maz51 and 5 after receiving solvent control. 
 
 
9.3.2.2 Effect of Maz51 administration from P0, analysed at P6 
Pups in two litters were randomly assigned to receive Maz51 or solvent control 
from P0 to P5, and were culled for analysis at P6. Twelve pups were analysed 
after receiving Maz51 and 5 after receiving solvent control. Eight control and 
19 Maz51-treated valves were visualised. 
 
9.3.3 Genotyping and immunofluorescence  
Immunofluorescence imaging of murine VV and genotyping were performed 
as described in Chapter 3. Solutions are given in Appendix 1 and antibodies in 
Appendix 3.  
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9.3.4 Statistical analysis 
For comparison of stage of VV development Fisher’s exact test was used, 
comparing wildtype with either Axitinib or Maz51-treated VV compared to each 
solvent control for each stage. All analyses were carried out in SPSS 21 (IBM 
corporation). 
9.4 Results 
9.4.1 Normal expression of VEGFR2/3 
At E17 VEGFR3 immunosignal was readily detected in lymphatics (Figure 68) 
but not in the femoral vein in the region of the developing valve. At P0 and P2 
VEGFR3 signal was detected, particularly around Prox1hi VFC’s.  
 
VEGFR2 is known to be widely expressed in the blood vasculature; 
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Figure 68 Timing of VEGFR3 expression in the valve-forming region 
Immunolocalisation of Prox1, VEGFR3 and Pecam1 is shown at E17 (A-A’’), P0 (B-B’’) 
and P2 (C-C’’). VEGFR3 was not detected at E17 (but was readily detectable in 
lymphatics, arrowhead in A’’). VEGFR3 was detected at P0, primarily around Prox1hi 
valve-forming cells (arrowheads in B’’). Valve leaflets expressed VEGFR3 at P2 
(arrowhead in C’’). Scale bars 50µm. 
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9.4.2 Effect of treatment with axitinib or Maz51 analysed at 
P0 
Treatment with the pan-VEGFR tyrosine kinase inhibitor axitinib, but not the 
more VEGFR3-specific Maz51, resulted in complete failure of induction of 
valve formation (Figure 70). Although expression of VEGFR3 was not detected 
at E17, inhibition with Maz51 was started from late E16 in case low levels of 
receptor expression had not been detected.  
 
Figure 70 Analysis at P0 of pups treated with Axitinib or Maz51. 
A-B) The tables provides the total number of VV analysed for each treatment and the 
number of VV identified at each stage. Whilst treatment with axitinib prevent VV 
development whilst treatment with MAZ51 had no effect. P= Fisher’s exact test.  
C) The proportion of valves at each stage are shown for each treatment group. Because 
inhibitors were given i.p. to pregnant dams, the control and inhibitor groups necessarily 
derive from different litters treated immunostained and imaged at the same time. 
Axitinib & Maz51 experiments were carried out separately. 
 




Figure 71 Representative image of an axitinib-treated femoral vein at P0. 
 Note the abnormal lack of Prox1 signal in femoral vein, but presence of Foxc2 
immunostaining in femoral veins. The femoral vein is identified by * and femoral artery 
by **. The normal site of the developing VV is approximately marked by arrowheads. 
Prox1 signal was identified in lymphatics elsewhere in the sample and in control valves. 
2D maximum projection of confocal z-stack.  (Prox1: Red, Foxc2: Green, SMA: White, 
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9.4.3 Effect on VV of treatment with Axitinib from P0 
 
Axitinib treatment resulted in significant mortality and analysis could not be 
carried out beyond P2. No deaths were seen in littermates treated with solvent 
alone. Survival curves and analysis of pup weight are provided in Figure 99 
and Figure 100, respectively. At P2, no significant VV phenotype was seen 
following treatment with axitinib (Figure 72). 
 
 
Figure 72 Venous valve phenotype after treatment with axitinib to P2 
A) The table provides the total number of VV analysed and the number of VV identified 
at each stage. Treatment with axitinib did not produce a significant phenotype when the 
experiment was terminated early at P2. Data includes two pups that died just prior to 
analysis. P= Fisher’s exact test.  
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9.4.4 Effect of treatment with MAZ51 from P0 
 
All animals survived to P6 and appeared healthy and VV development 
progressed normally (Figure 73). Analysis of mesenteric lymphatics at P0 
revealed almost complete absence of Prox1 immunosignal positive lymphatics 
(and absence of lymphatic valves) in 6/6 samples analysed, compared to a 




Figure 73 Effect of treatment with Maz51 from P0 to P6 
A) The table provides the total number of VV analysed and the number of VV identified 
at each stage. Treatment with Maz51 from P0 to P6 had no discernable effect on valve 
development at P6. P= Fisher’s exact test. ns=P>0.05. n=number VV analysed. 
B) The proportion of valves at each stage is shown for each treatment group.  
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9.5 Discussion 
 
Whilst immunolocalisation of VEGFR2 showed the expected widespread 
distribution, signals for VEGFR3 were more localised to the developing valve. 
This is consistent with the general absence of VEGFR3 from the venous 
system,125 and our finding of VEGFR3 promoter activity in developing but not 
adult venous valves.44 
 
Combined inhibition of the tyrosine kinase activity of both VEGFR2 and 
VEGFR3, but not VEGFR3 alone, resulted in complete failure of valve 
induction at P0. The activity of MAZ51 was confirmed at P6 by analysis of 
mesenteric lymphatics, which showed gross abnormalities in all treated mice. 
Unfortunately postnatal treatment with axitinib resulted in lethality, and no 
clear phenotype was observed at P2. Some pups were noted to be cyanosed, 
suggesting lethality could have resulted from a failure of pulmonary 
angiogenesis. Postnatal inhibition of VEGFR3 with MAZ51 had no discernable 
effect. 
 
Prox1 expression was undetectable in the femoral vein at P0 following Axitinib 
treatment, and Prox1 has previously been reported to be required for VV 
formation; it is possible that loss of Prox1 could be responsible for the VV 
defect observed.176 Taken together these results suggest that signalling 
through VEGFR2, or at least VEGFR2 tyrosine kinase activity, (but not 
VEGFR3 tyrosine kinase activity) may be required for expression of Prox1 in 
these veins at this time point. Foxc2 immunosignal in the femoral vein 
remained easily detectable despite axitinib treatment, which is surprising given 
the suggested role of signalling through VEGFR2/3 in upregulation of Foxc2 
and Notch targets, and suggests that other mechanisms could maintain Foxc2 
in veins despite inhibited VEGFR2/3 signalling (Figure 11).40, 123 
 
Tyrosine kinase inhibitors distribute widely and can be expected to have 
systemic effects, as shown by the post-natal non-viability of axitinib treatment. 
It is difficult to exclude effects caused by a general failure of development. For 
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axitinib the whole vessel appeared abnormal and it is entirely possible that the 
defect observed is due to a general failure of EC growth.  
 
In further work, it may be possible to inhibit ligand binding to VEGFR3 in-vivo 
with a specific rat monoclonal IgG2A antibody, which is expected to cross the 
placenta.177 Blocking antibodies are also available against VEGF-c and 
VEGFR2. These approaches still do not result in cell type-specific loss of 
function and it would also be important to analyse conditional deletion of 
VEGFR3 and VEGFR2 in endothelial cells using floxed alleles, in order to 
block passive signalling.123  
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10 THE ROLE OF FLOW ON VV 
DEVELOPMENT IN VIVO  
 
10.1 Introduction 
Fluid flow has been implicated in the normal development of cardiac and 
lymphatic valves, but has not previously been found to be required for VV 
development.42, 131, 133, 178 A requirement for normal flow has been suggested 
for LV development in vitro, but not in an in-vivo model.42  
 
Understanding the role of flow in valve development requires surgical 
intervention at an early post-natal age. To the best of my knowledge there are 
no published data available demonstrating safe anaesthesia or surgery in mice 
below P6. Methods have been described for performing minor procedures in 
P6 mice and P1 rats.179, 180! Gotoh et al have experience in operating 
successfully in mice at P4 (Gotoh.H, personal communication, 2010). Major 
problems particularly affecting pup anaesthesia include a large surface 
area:volume ratio predicating to hypothermia, practical difficulties in animal 
handling and restraint, skin closure and post-operative rejection by the mother 
- cannibalism rates in the range of 75% have been reported.179, 180 
 
10.2 Aims 
1. Develop techniques for anaesthesia of P0 murine pups 
2. Develop a model of altered flow during venous valve development in vivo, to 
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10.3 Methods 
10.3.1 Development of anaesthetic technique in P0 pups  
Induction was carried out in a custom made small chamber made from a 
pipette-tip box (approximately 12x8x6cm) fitted with a 1ml pipette tip to allow 
connection to the gas supply tubing from the anaesthetic machine. The 
induction chamber was pre-warmed on a heated pad to avoid hypothermia. 
Immediately after induction warmed EMLA cream was placed over the 
operative site. Pups were administered warmed weight-adjusted 
buprenorphine in 5% dextrose saline to provide intra-operative and post-
operative pain relief and fluid replacement. Maintenance of anaesthesia was 
performed via gas inhalation of isofluorane anaesthesia delivered by a 
Univentor 4000 anaesthetic unit. Intra-operative monitoring was carried out by 
manual counting of respiratory rate. Although invasive monitoring has become 
possible in rodent pups, it is doubtful that this is feasible at P0; the equipment 
is expensive and the setup time would add to the duration of anaesthetic.  
 
10.3.2 Development of the surgical model 
Surgery was performed on a heated pad to avoid hypothermia. Minimal 
chlorhexidine skin preparation was used as this removes heat in evaporation. 
The pup was placed on a warmed cotton pad on a heating pad and covered 
with a sterile sheet. Instruments were obtained from Fine Science Tools. A 2-
3mm incision was made using blunt-tipped scissors, which were subsequently 
used for all dissection. Occasionally superglue or compression under a fat pad 
was used for haemostasis, but effective haemostasis was generally achieved 
by avoidance of vessel injury. 
 
The vein distal to the site of the developing valve was identified and dissected 
free of the femoral nerve. The vein could not be dissected free of the artery as 
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10.3.2.1 Occlusive vascular clip 
Placement of a venous clip aimed to reduce or alter blood flow through the 
vein without causing venous or arterial damage. This was technically 
demanding and depended on the optimal mechanical properties and shape of 
the clip, which was sequentially optimised. Titanium wire was selected as it 
does not induce a biological reaction, could be sterilised, and is malleable. 
Initially 250µm Titanium (Ti) wire was used and cut into short lengths with a 
scalpel under a microscope. This was done with the wire attached to autoclave 
tape so that the short segments of wire remained in place. The centre of each 
short length of wire was then depressed into the thickness of the tape with a 
blunt portion of scalpel blade to create a “V” shape. Wires were then placed in 
a 50ml falcon tube (without the lid) and sterilised in an autoclave.  
!
The 250µm Ti wire was found to be too large in diameter, and so 50µm Ti wire 
was tested. Unfortunately Ti wire proved too malleable at 50µm to be able to 
compress the vein – on compression the V shape of the wire tended to bend 
around the vascular bundle. 
 
Following a review of wires available Tungsten (W) wire at 50µm was used. 
This harder metal was far more difficult to cut to length, and to bend, but this 
was subsequently performed prior to surgery. Intra-operatively W wire tended 
to bend at the existing “V” to produce two straight portions of wire that 
compress the vein more successfully. The shape of the wire clip was then 
modified to produce a narrower portion at the base of the “V”. As the 
compression force is applied at the top of the “V”, and the vein is positioned at 
the base, this new shape gave better compression of the vein, and avoided 
compression of the femoral artery. 
 
10.3.2.2 Ligation of the vein 
In order to determine whether a single point of flow interruption could 
sufficiently alter flow through the valve, the vein and artery were ligated 
between the site of the valve and the first distal tributary at P0 and VV 
analysed at P6.  
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10.3.2.3 Ligation and bisection 
The femoral vein and artery were double ligated (10/0 vicryl on a round bodied 
needle) and the vein divided between the ligatures, at a point between the 
valve and first distal tributary. 20 control valves and 16 flow-altered valves 
were successfully analysed. 
 
10.3.2.4 Wound closure 
Skin closure was initially attempted with tissue glue on the recommendation of 
the local veterinary surgeon but the mothers repeatedly removed the glue 
causing wound dehiscence. Use of skin clips has previously been 
recommended, but none could be located of suitable size for P0 pups.179 
Subsequently the skin was closed with running 10/0 monofilament vicryl on a 
curved needle, knotted at either end, using a micro-needle holder. No 




Figure 74 Incision site  
Dotted line marks the incision for ligation upstream of proximal femoral venous valve in 
a P0 pup. Coin=5p, for scale.!
 
10.3.3 Post-operative Care 
Pups were returned to a heated recovery nest made from their mothers 
nesting material and supplied with oxygen until they are clinically judged to 
have returned to a level of responsiveness appropriate for their age. This 
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included movement, attempts at self-righting, and some squeaking. Pup 
surface temperature was assessed using an infra-red thermometer to avoid 
over or under heating during the recovery stage. The majority of pups had 
developed some degree of intra-operative hypothermia. The cage was placed 
in a hot box overnight following surgery. Pups were periodically monitored 
during the recovery phase, bearing in mind that each additional disturbance 
may increase the chances of rejection by the mother, and also that disturbing 
the nest appeared to reduce the density of nesting material and allow pups to 
become more easily dispersed. 
 
10.3.4 Immunofluorescence imaging 
Immunofluorescence imaging of murine VV was performed as described in the 




10.3.5 Statistical analysis 
For comparison of stage of VV development Fisher’s exact test was used, 
comparing wildtype with either heterozygous or homozygous knockouts for 
each stage. For analysis of the effect of flow on vein diameter, VV area, or 
diameter:area ratio, independent samples t tests were used. Data from 
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10.4 Results 
10.4.1 Optimisation of the surgical model 
 Use of a clip was found to be ineffective at altering flow by P6 and valves 
developed entirely normally. Ligation of the vein at a single point had no effect 
on valve development; revascularisation was seen to bridge the point of 
ligation and flow through the normal route appeared restored by P6. Ligation 
of the vein at two points with division of the vein was successful; 
revascularisation was seen to occur from the point of ligation, with blood flow 
diverted via an alternative route (arrow in  Figure 75A). Double ligation and 
dissection of the vein was carried out on 21 pups, and VV successfully 
visualised after processing in 20 control veins and 16 operated veins.  
 
 
 Figure 75 Imaging at P6 following flow alteration by vein ligation and vein 
bisection   at P0.  
A) A micrograph of a P6 pup following left sided surgery at P0. The normal route of 
femoral vein been diverted (arrow indicates the normal route; the diverted bloodflow is 
seen above this).  
B) Confocal images of the operated region identified by the arrow in A are shown. The 
femoral vein is marked by arrowheads and  * = the site of the occlusion at the proximal 
knot. The vein has been divided distal to this point. Flow is diverted through collaterals 
(c) that re-enter the femoral vein just downstream of the valve, which is abnormally 
small (**). In B flow is from right to left. Scale bar 50µm.  
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10.4.2 The effect of altered flow on valve development 
Anaesthetic techniques were successful in allowing surgery at P0 and 
induction of a flow-altering lesion by double ligation and division of the femoral 
vein upstream of the developing valve. Operated pups gained weight normally, 
and no correlation was detected between subsequent pup weight at P6 and 
valve area (Figure 110, Figure 111, Appendix 12).  
 
Flow alteration was associated with qualitatively smaller valves compared with 
control (unoperated) valves on the other side of the same mouse (Figure 77). 
Valve area was reduced by over 4-fold following altered flow (Figure 76). 
Because the change in vein diameter at the site of the valve approached 
statistical significance (Figure 76), valve area:diameter ratio was calculated, 
and confirmed a significantly smaller valve at P6 in association with alteration 
of blood flow from P0 (Figure 79). Flow alteration was also associated with a 
failure of valves to develop normally, with a significant increase in the number 
of valves at stage 2 of development (Figure 80). 
 
 
Figure 76 Valve area is reduced following flow alteration 
Error bars represent sem. P<0.0001 (independent samples t test). Area of Foxc2 
immunostained valve leaflet was measured in a 2D maximum projection of a 3D 













Figure 77 Smaller valves following flow alteration. 
A) A venous valve (arrowheads in A, * in A’) at P6 following induction of a flow altering 
lesion at P0.  
B-B’’’) The corresponding control valve (arrowheads in B, * in B’) for A.  
The valve developing in conditions of reduced flow (A-A’’’) is smaller. It was not possible 
to quantify a reduction in Foxc2 immunosignal (A’). 
2D maximum projections of confocal z-stack. Scale 50µm. Upper panel flow L>R, lower 
panel flow R>L.  
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Figure 78 No significant change in vein diameter at the valve site 
Diameter was measured perpendicular to the vessel axis, at the center of the valve in 
2D projection of confocal z-stack. P=0.096 (independent samples t test with equal 
variance not assumed as Levene’s test P<0.001). Error bars represent 1SEM. (Note 




Figure 79 Flow alteration reduces valve area:vein diameter ratio of valve 
Induction of flow alteration at P0 caused a significant reduction in area:vein diameter 
ratio at P6 (P<0.0001, independent samples t test). Error bars represent 1SEM. 
  
 




Figure 80 Flow alteration delays developmental progression 
A) The table provides the total number of VV analysed and the number of VV identified 
at each stage. N=21 operated pups. Flow alteration at P0 resulted in defective 
development at P6, compared to the contralateral control valve, which developed 
normally. P= Fisher’s exact test. ns=P>0.05. n=number of VV analysed. 
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10.5 Discussion 
The anaesthetic techniques described were successful in avoiding any 
rejection by the mother, despite approximately 1hour of separation. This is 
likely to be because pups were not returned to the mother until they were 
normothermic and appeared to be behaving normally. It was observed that 
mothers did not care for pups that did not respond to them. No olfactory 
conditioning (other than using the mother’s bedding for the anaesthetic 
recovery nest) was required. Perioperative mortality was noted to increase 
with duration of anaesthesia above approximately 12mins.  
 
The surgical model was optimised to produce a flow-altering lesion that was 
resistant to the rapid neovascularisation observed. Double ligation and division 
of the femoral vein resulted in diversion of flow via an alternative route, with 
flow typically regaining the truncal vein via tributaries at the site of the 
developing valve, or just downstream. Flow was therefore maintained at the 
valve site. No thromboses were seen in any veins.  
 
Alteration in the blood flow experienced by the developing valve from P0 
resulted in reduced valve development at P6 when compared with the 
unoperated contralateral control valve in the same pup. Valves exposed to 
altered flow had a significantly smaller 2D area, despite correction for the size 
of the vein. These data suggest that valve endothelial cells are sensitised to 
their local flow, and suggest for the first time that normal flow is required for full 
VV development in-vivo. This finding is consistent with previous data in 
cardiac and lymphatic valve formation.  
 
10.5.1 Limitations 
• I was unable to examine the effect of flow on valve position relative to 
branch points or in early cell rearrangements, as anaesthesia and surgery are 
currently not practicable in embryos. In future work it may be possible to 
characterise a VV that develops at a consistent site postnatally, enabling 
intervention to alter flow during earlier stages of VV development.  
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• As the control contralateral limb was not operated on, I cannot entirely 
exclude the possibility of effect from application of the suture or division of the 
downstream vein. The increase in mortality with increased anaesthetic time 
precluded a sham operation on the contralateral limb.  It is highly unlikely that 
the procedure affected valve development other than by a direct effect on the 
vein, given that repeated experiments with dissection, application of titanium 
or tungsten clips, and ligation of the vein and artery (without double ligation 
and venous division) all failed to affect valve development. 
 
• It was not possible with the existing experimental setup to record the 
effect of the procedure on blood flow, or the anatomy of revascularisation of 
the veins. It is possible that selecting mice in which flow was successfully 
diverted away from the femoral vein would increase the severity of the valve 
developmental phenotype. 
 
• The size of the valves at P6 precluded the acquisition of material for 
analysis of changes in protein expression in response to altered flow. In future 
work it would be interesting to attempt to replicate in-vitro findings of effects of 
flow on critical regulators of valve development such as Foxc2 and Cx37. 42 It 
is entirely possible that the observed phenotype is due to a general effect of 
reduced flow on venous endothelial cells, rather than a specific effect on the 
valve endothelial cells.  
 
• The hypothesis that that normal flow is required for the maintenance of 
venous valves was not examined in this work. Preliminary experiments to alter 
flow in adult mice failed due to rapid revascularisation around the suture used 
to occlude flow (data not shown). Flow patterns around valves at junctions are 
likely to be complex, and be modified by the shape of the valve orifice as well 
as an interacting stream from the tributary. It has been suggested that paired 
venous valves are specifically non-aligned to produce (or in response to) 
helical flow patterns.181 Further work will revisit the role of flow in the 
maintenance of valve structure and function, which may play roles in human 
diseases. For example the progression of venous reflux in varicose veins 
could be exacerbated by a response of the valves to abnormal flow patterns. 
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The reduced flow experienced by endothelium surrounded by thrombosis 
could conceivably contribute to valve failure in Post Thrombotic Syndrome.
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11 IN-VIVO IMAGING ANALYSIS OF 
HUMAN VENOUS VALVES 
 
11.1 Introduction  
 
Venous valve structure has not been systematically assessed in vivo in man. 
Duplex ultrasonography is a common imaging modality used for assessing 
venous disease in man as it is non-invasive, does not involve ionising 
radiation, and no contrast agents are required for the production of high 
resolution images. Dynamic imaging allows assessment of venous reflux and 
any obstruction to flow that may be caused, for example, by thrombus. 
Facilities for ultrasound scanning are widely available, and are relatively cost-
effective compared with other imaging modalities.182 
 
The use of ultrasound for measurement of popliteal venous valve leaflet 
thickness shows that leaflet thickness increases slightly with age.182 
Measurement of leaflet thickness was not validated in other veins, and only 
one valve was measured per individual. Ultrasound has also been employed 
to assess the suitability of venous valves for repair, using a visual assessment 
of flow pattern and measurements of vein diameters in deep and superficial 




1. Develop an ultrasound-based method for in-vivo quantification of the 
presence of venous valves and structural abnormalities in the valves  
2. Analyse venous valve phenotypes in patients with known genetic defects.  
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11.3 Methods 
11.3.1 Study participants 
The National Research Ethics Service provided ethical approval for the study. 
Controls without clinical venous disease were recruited locally. Patients with 
known genetic mutations were recruited from the Lymphoedema Clinic at St 
George’s Hospital, London.  
 
11.3.2 Ultrasound examination of valves 
All valve ultrasound examinations were performed by full-time vascular 
ultrasonographers in the Ultrasonic Angiology department at Guy’s & St 
Thomas’ NHS Foundation Trust.  
 
Veins were scanned using a Phillips IU22 clinical ultrasound machine. An L17-
5MHz transducer was used for most veins. An L9-3MHz transducer was used 











The basilic, brachial, popliteal and short saphenous veins were examined. 
Each vein was scanned along its entire length, switching between longitudinal 
and transverse views to detect valves. The positions of identified valves were 
recorded in a standardised reporting sheet, using the distance from agreed 
surface landmarks. An image of each valve was saved. B-mode cine loops 
were recorded of each valve in B-mode and with colour Doppler. Valve 
maximum leaflet measurements were taken offline using Phillips Xcelera Cath 
Lab software. Due to time constraints in imaging, limited consent for imaging 
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lower limb veins or prior vein ablation, not all veins were imaged in all 
participants.  
 
11.3.3 Statistical analysis 
Age matching was confirmed using an independent samples t test, and sex 
matching using a Fisher’s exact test.  
Reproducibility in counting the number of valves in a vein was assessed using 
a scatter plot and an Intraclass Correlation Coefficient, because Pearson’s r is 
not suitable for low integer variables.  
Reproducibility in measurements of leaflet length (derived from analysis of the 
same scan, or repeated scanning) was assessed using a scatter plot and 
Pearson’s r. 
For analysis of human VV structural phenotypes (number of valves and valve 
length), t tests were used for each genotype compared with the control group. 
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11.4 Results 
11.4.1 Participants recruited 
Table 4 Genotypes of recruited participants 
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11.4.2 Participant age and sex matching 
Study participants were statistically matched for age and sex, although some 
study participants were older than the controls (Table 5, Figure 81). 
 
Table 5 Age and sex matching of participant groups 
Age was compared using independent samples t tests. Sex (proportion female) was 
compared using a fisher’s exact test. 
Group Mean age 
(years) 
p N Females 
(males) 
p  
Control 30.33 - 3 (3) - 
FOXC2 36.00 0.357 3 (5) 1 
VEGFR3 36.67 0.338 2 (1) 1 
GJC2 38.50 0.570 2 (2) 1 




Figure 81 Ages of participants for each genotype studied 
The scatter plot identified some participants who were older than the controls, although 
all groups are statistically matched. 
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11.4.3 Validation of valve quantification by ultrasound 
Analysis of the number of valves identified by two vascular ultrasonographers 
examining the same veins on different days showed a high and significant 
correlation, with intra-class correlation of 0.896 and P<0.0005 (Figure 82). 
Reproducibility in measuring the ultrasound-detected leaflet length was 
assessed by two methods. Analysis of two ultrasonographers analysing the 
same images showed a high and significant correlation of r=0.953 and 
P<0.0005 (Figure 83). The correlation was weaker when based on separate 
scans obtained on different days, but still showed a reasonable correlation 




Figure 82 Reproducibility of counting number of valves 
This graph shows a strong correlation between repeated measures of the number of 
valves in a vein by two different ultrasonographers. Intraclass correlation coefficient 
0.896, P<0.0005. Identical integer values are shown side by side. A graph of the same 
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Figure 83 Reproducibility of length measurements from same scan 
This graph shows the extremely strong correlation between repeated measurements of 
valve length derived from two sonographers analyzing the same images. 
Pearson’s r = 0.953 P<0.0005 A line of best fit through the origin is shown. 
 
 
Figure 84 Reproducibility of length measurements from different scans 
There was a strong correlation between repeated measurements of valve length 
derived from two sonographers performing independent scans.  
Pearson’s r= 0.735 p<0.0005. The line of best fit through the origin demonstrates some 
effect from the outlying data point. 
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11.4.4 Venous valve phenotypes in patients carrying genetic 
mutations and controls  
The number of valves identified by ultrasound in the popliteal vein, short 
saphenous vein (SSV), brachial vein and basilic vein in each group are given 
in Table 6, and shown in Figure 85. The length of each identified valve is also 
provided, and shown in Figure 86. In the control group typically only one valve 
was detected in the popliteal vein whilst a mean of 4.13 valves were detected 
in the SSV. In the upper limbs, 2.10 and 2.40 VV were detected by ultrasound 
respectively in the brachial and basilic veins. 
 
Mutations in VEGFR3 were associated with reduced number of valves in the 
SSV. Mutations in FOXC2 were associated with a more substantial phenotype, 
and were associated with reduced number of valves and shorter valves in all 
veins. Mutations in GJC2, encoding Cx47, were associated with reduced 
number of valves in the SSV, brachial and basilica veins and shorter valves in 
the popliteal, SSV and basilica veins. The sole participant with a mutation in 
GJA1, encoding Cx43, had a significantly reduced number of valves in the 
SSV.   
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Table 6 Quantification of human VV phenotypes in controls and patients  
P valves derive from independent samples t-tests for each genotype Vs control. GJC2 
encodes Cx47 and GJA1 encodes Cx43. SSV = short saphenous vein 
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Figure 85 Number of ultrasound detected VV per vein in patients and 
controls 
Error bars represent SEM. Original data and P values for comparisons are provided in 
Table 6. POPV = popliteal vein, SSV = short saphenous vein 
 
 
Figure 86 Mean VV length in patients and controls 
Error bars represent SEM. Original data and P values for comparisons are provided in 
Table 6. POPV = popliteal vein, SSV = short saphenous vein 
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11.4.5 Analysis of normalised results 
Because of the variable number of valves and length of leaflets found in each 
veins in the control group, it was not possible to combine raw data from 
different veins. The data for each valve/vein were therefore normalised to the 
corresponding values for that vein in the control group. Summary means were 
calculated that reflect the global effects on the observed ultrasound 
parameters in each group. (Figure 87, Figure 88) These data necessarily 
combine deep and superficial veins. In a subsequent analysis no significant 
differences were found between deep and superficial veins when analysed 
sepatately (Figure 89, Figure 90). 
 
Significant reductions in the normalised number of valves were identified in 
participants carrying mutations in FOXC2, GJC2, VEGFR3 and GJA1 
compared with the control group. The phenotype was strongest for FOXC2 
mutations, as participants had approximately 80% fewer valves than the 
control group. Mutations in VEGFR3, FOXC2 and GJC2 but not the mutatiion 
in GJA1 were associated with significantly shorter normalised valve lengths. 
The strongest phenotype was again seen in association with FOXC2, where 
valves were on average 46% shorter. (Table 7, Figure 87, Figure 88) 
 
Table 7 Comparison of the number and length of human venous valves in 
various genotypes.   
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Figure 87 Normalised analysis of number of valves per vein 
This graph shows the differences in mean normalized number of valves per vein for 
each genotype studied. Error bars represent SEM. P values for comparisons are given 




Figure 88 Normalised analysis of valve length 
This graph shows the differences in mean normalized valve length for each genotype 
studied. Error bars represent SEM. P values for comparisons are given in Table 7. 
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Figure 89 Normalised number of valves according to vein type 
This graph shows that there was no difference in normalized number of valves per vein, 
when comparing deep and superficial veins for each genotype studied. P=ns (t test) for 




Figure 90 Normalised leaflet length according to vein type 
This graph shows that there was no difference in normalized valve length, when 
comparing deep and superficial veins for each genotype studied. P=ns (t test) for all 
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Two members of a family affected by the same mutations in GJC2 (encoding 
Cx47) demonstrated markedly different severity in their VV phenotype. 
Participant 2013-19 (age 20) was affected with clinically worse four-limb 
lymphoedema than her grandfather, 2013-20 (age 71). 2013-19 also showed a 
substantial VV structural defect with significantly shorter venous valves. No 
significant difference was seen in the number of valves identified (P=ns). 
Mean values for normalized leaflet length were 2013-19: 0.46, 2013-20: 0.87. 
P=0.005 These data suggest that an unknown interaction between the P316L 
mutation in the intracellular region of Cx47 and the granddaughters 
background has resulted in a clinically significant failure of VV leaflet structure. 
This mutation has also been reported in Ref4 No significant difference was 
seen between two members of the second GJC2 family analysed. 
 
 
Figure 91 Two members of the same family affected by a GJC2 mutation 
Each circle represents a single valve measurement. Participant 2013-19 (Table 4, age 
20) was affected with clinically worse four-limb lymphoedema than her grandfather, 
2013-20 (age 71). 2013-19 also showed a substantial VV structural defect with 
significantly shorter venous valves. No significant difference was seen in the number of 
valves identified (P=ns). Mean values for normalized leaflet length were 2013-19: 0.46, 
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11.5 Discussion 
11.5.1 Ultrasound analysis of VV  
Venous valves were systematically assessed in study participants with known 
genetic mutations, and age and sex matched healthy volunteers. To the best 
of my knowledge the systematic assessment of venous valves has not 
previously been described, and few reports have been made of the use of 
ultrasound (US) to study these structures. Assessment of the number of 
valves in each vein, and in the measured length of valve leaflets, showed a 
degree of reproducibility consistent with utility. Although US measurement of 
popliteal vein valve leaflet thickness has been described182, leaflet thickness 
was not measured in this study as this measure nears the limit of ultrasound 
resolution and therefore felt to be unreliable. 
 
The correlation between length measurements by different observers was 
higher when based on the same images (r=0.95) than when based on 
separate scans (r=0.74). For measurements taken from different scans, error 
may include difficulty in identifying the same valve for measurement. 
Measurement error in valve number or leaflet length would be expected to 
increase the variability seen in the data and reduce the likelihood of 
statistically significant results. Whilst the use of ultrasound to assess the 
structure of a single valve (for example in pre-operative planning) has not 
been specifically validated in this work, these results demonstrate that it is 
reasonable to use ultrasound to compare valves in groups of patients. The 
short saphenous vein contained the highest number of valves identified by 
ultrasound, and therefore tended to produce statistically significant reductions 
of valves in patients. In future work it may be possible to perform a more 
focused assessment on this vein. The LSV is the most commonly treated 
varicose vein, but was not scanned because of its long length and the need to 
reduce the total amount of scanning time.  
 
11.5.2 VV phenotypes in patients with known genetic defects 
Compared to controls, patients with mutations in FOXC2, VEGFR3, GJA1, or 
GJC1 all showed defects in the normalised number of valves identified. This 
was most striking for FOXC2, with affected patients possessing only 23% the 
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normal complement of valves. Patients carrying mutations in VEGFR3, 
FOXC2, GJC2 but not the single patient with a mutation in GJA1 showed a 
reduction in the normalised length of valve leaflets. This is consistent with the 
previous finding that patients carrying mutations in FOXC2 or VEGFR3 show 
increased rates of venous reflux.50  
 
It is particularly notable that patients carrying mutations in GJC2 show clear 
VV structural defects, since the lymphatic phenotype in these patients has 
been attributed to a functional rather than structural defect.4 The present data 
suggests that either the lymphatic and venous phenotypes arise by quite 
different mechanisms, or a lymphatic structural phenotype remains to be 
identified in these patients. Interestingly, two members of the same family, 
both carrying the same mutation in GJC2, show different severity of their 
phenotype, suggesting a possible interaction effect with other genes. This was 
not seen in the second family affected by a GJC2 mutation.  
 
It is unclear why mutations in FOXC2 and VEGFR3 cause lower limb, but not 
upper limb lymphoedema. Patients with VEGFR3 mutations (causing Milroy’s 
disease) typically have lower limb lymphoedema at birth, prior to assuming an 
upright stature. This implies that gravitational effects are not the cause. 
Lymphatic defects have been identified in the upper limb of patients with 
Milroy’s.48 Significant venous valve defects were not identified in the upper 
limbs of patients with Milroy’s, but this may be as a result of the relatively low 
number of patients studied.  
 
Patients with lymphoedema were only examined at a single time point. Further 
work could examine the temporal change in valve structure and function. It is 
possible that a failure to maintain normally developed valves could contribute 
to a later onset of lower limb swelling, for example in lymphoedema 
distichiasis. It would also be interesting to investigate, using these more 
detailed assessments, whether VV failure progresses distally or proximally 
within a limb affected by varicosities. It may also be possible to assess the 
effect of thrombosis on VV, both as a direct effect, and also any effect due to 
altered blood flow. 
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11.5.3 Limitations  
 
• The venous valve scanning protocol required approximately 2hrs of 
ultrasonographer and patient time in order to visualise valves in all four 
limbs. The protocol was therefore limited in the number of veins that 
could be assessed. In addition, it was not practicable to assess reflux 
and vein diameter alongside valve structure. Future work could focus 
on the short saphenous and an upper limb vein whilst utilising a more 
detailed assessment. Measurements of the number of valves or of 
leaflet length were normalised to the corresponding values from the 
same veins in the control groups. The resulting normalised values 
showed a substantial variability (not shown). More accurate data could 
result from normalising to the diameter of the vein at the site of each 
vein. These data were not available for the present analysis. In addition 
a more focused scan could prove efficient for clinical use in assessing 
venous valves, as has previously been suggested.183  
 
• It was not possible within the scope of this work to compare the number 
of valves identified by ultrasound with imaging by another modality, 
such as contrast venography. This invasive procedure represents the 
gold standard for in-vivo imaging of veins, but requires ionising radiation 
and potentially nephrotoxic contrast agents. It is therefore not possible 
to comment on the accuracy of the described ultrasound technique in 
detecting venous valves. This does not detract from the utility of 
ultrasound in comparing groups of patients. The most definitive data on 
valve location derives from post-mortem studies.184, 185 In the popliteal 
vein, 1 valve has been reported to be commonly found just distal to the 
adductor hiatus, with a second valve just above the trifurcation in some 
individuals.184 In the basilic vein, a mean of 9.3 valves was identified.185 
These findings are consistent with the results in this chapter. 
• Ultrasonographers were blinded to the genotype of study participants 
during scanning and offline length measurements. Lymphoedema is 
frequently mild and difficult to identify, but it is not possible to exclude 
that some affected individuals were identifiable.  
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• Participant recruitment was limited by the availability of patients with 
known rare mutations. In particular, only one patient was available with 
lymphoedema caused by a mutation in GJA1, since this disease has 
only very recently been described (in the same family).57 An abnormally 
long popliteal valve in a dilated vein in one limb is likely to represent an 
outlier and skewed the mean measurement for this patient. As 
discussed, normalising to vein diameter could avoid this problem in 
future work.   
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12 GENERAL DISCUSSION & LIMITATIONS 
12.1.1 Methodologies 
This work has provided several methods for the study of venous valve 
development in mice, including confocal microscopy, TEM, SEM of the vein 
endothelium, and SEM of resin casts of the vascular lumen (Chapter 3). 
Widefield and confocal microscopy of immunofluorescence stained VV with 
the vein intact enabled a quantification of VV developmental phenotypes in 
genetic loss of function experiments, or after administration of drug inhibitors. 
In addition, confocal microscopy allowed imaging in fluorescent reporter lines 
alongside immunolocalised proteins. Using these techniques it was also 
possible to visualise valve development at earlier stages than has previously 
been described, leading to the finding that valve development begins earlier 
than previously identified. Building on previously described work in lymphatics, 
methods were developed for the detailed analysis of morphology of VFC’s at 
P0, allowing a detailed examination of phenotypes at this stage (Chapter 8).146 
 
12.1.2 Requirements for specific proteins 
Critical requirements are described for several proteins in venous valve 
development (Table 8, Table 9, Figure 92). These include Foxc2, NFATc1, 
Notch1, Cx37, Cx43, Cx47, integrinα9 and ephrinB2. After the requirement for 
Cx37 was identified in this work, others have described a requirement for 
Cx37 for the presence of VV in adult mice.111 The current data build on these 
findings by describing the expression pattern of Cx37 at earlier stages, and 
identifying the developmental stage at which the VV abnormality arises.111   
 
It is notable that several proteins previously identified as specific and critical 
regulators of arterial and lymphatic identity are found to be expressed in the 
region of the developing venous valve, including ephrinB2, Prox1, Notch1, 
VEGFR3 and Foxc2.88, 186 In particular, Prox1, which has been described as a 
master regulator of lymphatic cell fate, has been found to be widely expressed 
in the femoral vein in the region of the developing VV at E17, and 
subsequently to be strongly expressed in VFC’s.44, 73, 149 This finding is 
confirmed by the activity of the Prox1CreERT2 transgene in venous EC’s, and 
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the finding that Prox1 is required for VV development near the lymphovenous 
junction.176 Nevertheless, these data do not dispute earlier findings for 
example that in arterio-venous specification ephrinB2 is expressed in arteries 
and EphB4 in veins, or that Prox1 is required for venous EC’s to adopt a 
lymphatic identity and sprout from the veins as iLECs.  The finding that at later 
stages of development proteins characterised as regulators of 
arterial/lymphatic development are expressed in veins suggests that after 
vessel specification events are complete, these proteins may perform further 
roles in vessel maturation (including valve formation).  
 
12.1.3 The role of blood flow 
It has previously been demonstrated that fluid flow is oscillatory prior to the 
onset of LV formation, and lymphatic EC’s respond to fluid flows in vitro. I have 
shown for the first time that normal blood flow is required between P0 and P6 
for normal VV developing in-vivo. It was not possible to examine the effects of 
altered flow on protein expression or localisation, or to examine the 
requirement for normal flow in events prior to P0. In vitro, Cx37 and Foxc2 
(amongst other examples) are upregulated in lymphatic EC’s by shear 
stress42, and it is likely that a similar pathway operates in VV development in-
vivo.  
 
12.1.4 Events leading to stage 1 of VV development 
Characterisation of the timing of normal events in VV development enabled 
experimental manipulation of the process at different time points. It was 
possible to identify proteins that are only required for the early stages (leading 
up to stage 1) of VV development, or later stages (leaflet and commissure 
formation). 
 
The earliest events in venous valve development were the heterogeneous 
expression of valve-forming cell (VFC) markers, identifiable in the valve-
forming region of the vein by E17, although it remains impossible to identify 
definite VFC’s at this stage. In VV by P0, wildtype VFC’s had organised into a 
ring of rotated and elongated cells aligned circumferentially around the vein 
lumen.  Three connexins – Cx37, Cx43, Cx47 – were found to have very 
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different expression patterns during early valve development. The importance 
of connexins in LV development, and a requirement of Cx37 for the presence 
of VV in the adult mouse have been described previously.42, 94, 109, 111 Loss of 
Cx37, Cx43 or Cx47 resulted in grossly similar phenotypes of VV 
disorganisation at P0, with defects in the normal elongation and rotation of 
endothelial cells. Similarly, loss of Cx47 resulted in complete absence of 
VFC’s by P2, and by P6 for loss of Cx37. This may be due to defective 
communication between VFC’s, either directly through loss of gap junction 
components, or lack of cell contact secondary to failed organisation events. In 
valves lacking Cx37 there were proportionally fewer VFC’s in the central 
region of the vein than in wildtype littermates. This finding is susceptible to 
bias in the identification of Prox1hi VFC’s, although no differences were 
identified for Cx43 or Cx47. Whilst this is consistent with the suggestion that 
the Cx37 phenotype could also involve defective migration of cells into this 
region, this idea is not supported by the finding that an overall similar 
phenotype is seen following loss of Cx43/47 without any change in the 
proportion of cells in each region.42 These loss-of function approaches to 
connexin function showed that valve development appears to progress 
relatively normally up until P0, by which time these connexins are critically 
required, and so these data suggest that failure of organisation at this stage is 
likely to be the mechanism involved in the human Cx43 and Cx47-related VV 
structural phenotypes identified in this work.   
 
Conditional deletion of Notch1 had no effect after P0, but deletion from E15.5 
resulted in a phenotype at P0 of a widened region of Prox1hi VFC’s, and an 
observed lack of rotated and elongated VFC’s. After this work was completed, 
comparable findings were published following Notch1 deletion in lymphatic 
valve development.90 Expression of a dominant negative Mastermind-like 
transgene resulted in a more severe phenotype than deletion of Notch1, 
suggesting that other Notch proteins may also be signalling in LV formation. In 
cultured cells, activation of Notch1 or Notch4 induced integrin α9, fibronectin 
EIIIA and Cx37 expression.90 It was not possible within the timeframe of this 
work to identify antibodies suitable for localisation of Notch1 by wholemount 
confocal microscopy at P0, and the expression pattern of Notch1 in VV at this 
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stage remains unknown. In LV, it has been noted that conditional deletion of 
Notch1 resulted in a similar phenotype to Cx37 knockout.90 In VV, this is again 
seen, and in addition the phenotype is comparable to that seen following Cx47 
knockout or deletion of Cx43. 
 
It remains to be determined whether the phenotypes observed with loss of 
Cx37, Cx43 or Cx47 result from a loss of gap junctional intercellular 
communication or non-junctional roles. The different expression patterns of the 
connexins, particularly Cx43 in the upstream region and Cx37 in VFC’s, 
suggests that domains of GJIC may be established that allow VFC’s to act in a 
coordinated fashion. Given the recent finding that Notch1 intracellular domain 
activity upregulates Cx37 (and Foxc2), Notch1 could act in VFC’s to select 
VFC’s and establish this signalling.90 
  
EfnB2 promoter activity was imaged using a fluorescent reporter line, and was 
identified much earlier than previously described. It remains unclear how the 
patterns of protein expression seen at P0 are established. Levet et al have 
demonstrated a requirement for BMP9 (likely acting via ALK1) in lymphatic 
valve formation, and shown that BMP9 upregulates Foxc2, Cx37 and 
EphrinB2 in LECs. It is likely that BMP9 is also involved in VV development, 
and it could act upstream of these factors at early stages to upregulate Foxc2 
and EphrinB2 in VFC’s and the downstream region.45  
 
The expression pattern of ephrinB2 identified in Chapter 0 indicates that Cx43 
expression upstream of the VFC’s is in an ephrinB2 non-expressed domain, 
with VFC’s and downstream cells expressing ephrinB2. This again suggests 
that ephrinB2-based cell sorting could be involved in patterning the valve at 
P0. EphrinB2 and ephrinB1 are structurally closely related, and ephrinB1 
physically interacts with Cx43 and regulates GJIC in craniofacial 
development.187 In the frontal bone of chimeric embryos, whilst plaque-like 
Cx43 immunostaining was observed between ephrinB1-null cells, and 
between wildtype cells, almost no Cx43 plaques were observed between 
ephrinB1-null and wildtype cells, suggesting that ephrin based cell sorting may 
assist in the production of GJIC domains of EC’s.187 Given the high degree of 
homology between ephrinB1 and ephrinB2, it is interesting to speculate that 
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ephrinB2 could also interact with Cx43. Treatment of ephrinB1 over-
expressing cells with soluble EphB receptor resulted in loss of membranous 
Cx43 expression.187 In VV development, this hypothesis would be consistent 
with the presence at P0 of Cx43 just upstream of the line of VFC’s (which 
express ephrinB2). 
 
12.1.5 Leaflet and commissure development after stage 1 
Surprisingly neither Foxc2 nor Calcineurin-NFAT signalling were required for 
the earliest events in valve formation. This work does not exclude the 
possibility that redundancy between Foxc2 and NFATc1 allows for 
compensation, or for unidentified expression of other Fox family members 
such as Foxc1. Both NFATc1 and Foxc2 were required for normal maturation 
of the valves beyond P0; loss of NFAT-Calcineurin signalling resulted in 
particularly marked failure of leaflet development. The mechanism underlying 
this failure is not known; it is possible that NFATc1 induces proliferation of 
leaflet cells. 
 
The membrane-bound matrix receptor integrinα9 was previously identified, 
along with ephrinB2, to be critically required for VV development after P0 and 
also maintenance of the adult VV.44 These findings were confirmed using an 
improved method, allowing staging of valve development. Conditional 
homozygous deletion of ephrinB2 or integrinα9 from P0 resulted in complete 
loss of valve leaflets, but in both cases rotated Prox1hi endothelial cells could 
still be identified at P6, although not to the same extent as seen following loss 
of NFAT-calcineurin signalling, suggesting that entegrina9 and ephrinB2 might 
be required for maintenance of the free-edge cell phenotype, to some degree, 
or at least that the mechanisms of valve failure following these deletions 
differs. EphrinB2 was previously described to be expressed in leaflet 
endothelial cells but not free-edge cells, compatible with a requirement for 
reverse signalling into leaflet cells after P0.44 It was not possible to determine 
whether reverse or forward signalling is required for VV development, but 
given the previously identified requirement for ephrinB2 reverse signalling for 
lymphatic valve development, it is possible that reverse signalling is similarly 
required for VV development.73 
 




Table 8 Summary of murine VV phenotypes shown in this thesis 
The table provides a summary of the phenotypes seen with the genetic loss of function 
approaches and model of altered blood flow employed in this thesis.  
 Requirement in early VV 
development: 
 Phenotype at P0 after early 
deletion (≈E15) / inhibition 
Requirement in later VV 
development: 
Phenotype at P6 after later 
deletion (≈P0) / inhibition 
Integrinα9 unknown Failure to develop leaflets. Residual Prox1hi rotated EC’s seen at P6 
EphrinB2 
unknown 
Suggested role in patterning the 
ring of rotated cells at P0 (Stage 1) 
Failure to develop VV leaflets. Some 
residual Prox1hi rotated EC’s seen at 
P6 
Cx37 
Disorganisation of Prox1hi cells, 
possibly reduced proportion of 
Prox1hi cells in centre of vein 
(constitutive knockout) 
Complete absence of any VV cells at 
P6 (constitutive knockout). Loss of 
gap in pericytes 
Cx43 Disorganisation of Prox1
hi cells 
(constitutive deletion) 
No phenotype at P6 following 
conditional deletion from P0. 
Cx47 Disorganisation of Prox1
hi cells 
(constitutive knockout in reporter) 
Complete absence of any VV cells at 
P2 (constitutive knockout). 
Foxc2 No clear phenotype at P0 (conditional deletion) 
Inhibited VV development  
Nfat-
calcineurin 
No clear phenotype at P0 
(conditional CnB1 deletion) 
Marked failure to developed VV 
leaflets, but ring of Prox1hi/Foxc2hi 
rotated cells entirely intact 
Notch1 Disorganised Prox1
hi cells at P0 No phenotype at P6 following 
conditional deletion from P0. 
VEGFR3 
No phenotype with drug inhibition of 
VEGFR3 (but strong phenotype 
with combined inhibition of 
VEGFR1,2,3) 
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Table 9 The factors known to be responsible for VV development and 
maintenance in murine models and in man 
The table summarises existing knowledge of the factors responsible for VV 
development and/or maintenance in mice and in man. * = work in this thesis. U = 
unknown. In man, expression refers to adult VV in patients with clinically normal veins. 
It is unlikely that Cx43 or Notch1 are required for maintenance of the formed VV, since 
deletion of either from P0 did not give a phenotype at P6, but their role in maintenance 
has not been specifically examined in this thesis. Fn-EIIIA = EIIIA splice variant of 









and required 176 
U Expressed 44 
Integrinα9 
Required 44 and 
* 
Ref44 Expressed * 
Fn-EIIIA Required 44 Ref44 U 
EphrinB2 




Required 111 and 
* 
U U 
Cx43 Required * Unlikely  * 
Expressed and 
VV defect * 
Cx47 Required * U 
Expressed and 
VV defect * 
Foxc2 
Expressed 40 
and required * 
U 


















Reflux 53 and VV 
defect * 
(GATA2) U U Expressed * 
Normal blood 
flow 
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12.1.6 Cardiac, Venous and lymphatic valve formation 
Apart from Cx47, all the proteins identified in this work as critical regulators of 
VV development have previously been shown to play roles in cardiac and/or 
lymphatic valve development. It has previously been noted that cardiac and 
lymphatic valves share some regulatory pathways.39 For example, loss of 
Calcineurin-NFAT signalling results in a failure of leaflet elongation in the 
semilunar, venous and lymphatic valves.42, 96. Whilst the interactions between 
several of the proteins studied in this work remain to be examined, it will be 
interesting to determine whether these interactions are consistent in cardiac, 
lymphatic and venous valves. It is likely that work in any one valve type will 
continue to illuminate potential mechanisms of valve formation in others. The 
finding of a structural VV defect following Cx47 knockout is notable as the 
lymphatic phenotypes observed in patients carrying mutations in GJC2 have 
been attributed to a functional and not structural defect.4  
 
12.1.7 Analysis of human VV and phenotypes in patients 
SEM, TEM and immunohistological analysis of murine and human venous 
valves suggest similar cellular structure and protein expression patterns, 
consistent with previous descriptions of human VV.11 Several proteins, 
including integrinα9, NFATc1, Cx43 and Cx47 were localised in adult 
human venous valves. We have previously described expression of Prox1 in 
human VV.44 
The use of ultrasound to quantify structural defects in human VV was 
validated, allowing the identification of VV structural defects in patients with 
known genetic defects. Analysis of valves in patients with mutations in 
FOXC2, VEGFR3, GJC2 (encoding Cx47) and GJA1 (encoding Cx43) showed 
generally reduced numbers of valves and shorter valve leaflets. Although 
patients with Milroy’s disease carry mutations that inactivate the tyrosine 
kinase domain of VEGFR3, inhibition of this domain in the murine model had 
no effect on VV development, either up to P0, or to P6. This unexpected result 
suggests the possibility that mutations carried by patients exert effects that are 
not directly mediated by loss of tyrosine kinase activity. It has previously been 
demonstrated that kinase-dead VEGFR3 proteins reside for a greater period of 
time at the cell membrane, and it is possible that mutant VEGFR3 interferes 
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with normal function of other proteins at the membrane, for example VEGFR2 
or ephrinB2.119, 129 It was not possible to explore these possibilities in the 
current work.  
 
12.1.8 Limitations and future work 
This work has several limitations. Unlike some other vascular model systems 
(for example retinal sprouting angiogenesis), in venous (and lymphatic) valve 
development sequentially occurring processes are not clearly spatially 
separated. In combination with the variability seen in the morphology and 
timing of venous valve development, this complicates interpretation of 
expression data and genetic loss of function phenotypes. 
 
It is not possible to quantify loss of protein in VV following Cre-mediated 
excision of LoxP-flanked sequences. This is likely to vary with different genes, 
due for example to differing rates of protein turnover. Confocal microscopy and 
(in particular) immunohistochemistry are not quantitative techniques and so it 
is not possible to identify small changes in protein expression (although large 
variations may be clearly apparent). There is no technique for isolation of 
valve cells from tissue, and even if this were possible it is highly unlikely that 
sufficient protein would be available for quantitative analysis. mRNA could be 
examined by qPCR (or in situ) but this would not confirm loss of protein.  
 
The analysis of constitutive knockouts (for example of Cx37 or Cx47) may be 
complicated by distant and unidentified effects of protein loss. Where possible 
this has been avoided by the use of conditional deletion in Prox1-expressing 
EC’s, allowing analysis of cell-autonomous roles. In addition, the appropriate 
presence of VFC’s at P0 in Cx37 and Cx47 constitutive knockouts suggests 
that steps up until this time point have proceeded relatively normally. 
 
It is possible for a floxed allele to result in slightly less protein production that a 
wildtype allele, even in the absence of Cre recombinase. Most of the 
phenotypes observed in this thesis required homozygous deletion, with 
relatively normal development occurring following heterozygous deletion. This 
suggests that any relatively small reduction in protein expression in Cre- 
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animals carrying floxed alleles is likely to have a negligible effect. Similarly, the 
lack of a strong phenotype following heterozygous deletion of ephrinB2 or 
Cx47 suggests that the expression patterns observed in the EfnB2GFP 
reporter or Cx47:GFP reporter (both heterozygous knockouts) are relatively 
normal. The lack of a conditional heterozygous ephrinB2 deletion phenotype at 
P6 does not exclude a phenotype from earlier deletion prior to P0. It has been 
shown in the vasculature that knockdown of one connexin can reduce levels of 
others.105 This possibility was reduced where possible with the use of 
conditionally targeted alleles.  
 
The methodology for the analysis of nuclear morphology in Chapter 8 builds 
on previous work in lymphatic valve development.146 Whilst analysis of 
wholemount samples is critical to understanding events in-vivo, it is possible 
that measurements of nuclear morphology could have been affected by areas 
of distortion or damage to the vessel. This was avoided by co-
immunolocalisation of endothelial and smooth muscle markers, avoidance of 
any distorted tissue, and analysis of a large number of nuclei in many 
samples. Windowing of displayed immunosignal can result in an apparent 
change in the dimensions of a structure, but should not affect rotational angle. 
Any variation should be very small within a sample. It was not possible to use 
a signal threshold to identify Prox1hi cells, and this selection was performed 
manually (as previously described in ref 146). Bias in VFC selection could 
therefore have affected the analysis, particular for analysis of the number of 
VFC’s in each region of the valve.  
 
Inhibitors were used to study the effects of inhibition of calcineurin activity, and 
inhibition of VEGFR tyrosine kinase activity. It is not possible the exclude a 
contribution of off-target effects to the observed phenotypes. Axitinib, in 
particular, resulted in general toxicity and the observed phenotype may be due 
to general inhibition of EC growth. It was not possible to analyse the effect of 
conditional deletion of VEGFR2/3. 
 
Calcineurin-NFAT inhibition was analysed using ciclosporin and conditional 
CnB1 deletion by Prox1CreERT2. Whilst conditional CnB1 deletion was 
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confined to EC’s by Prox1CreERT2, ciclosporin would additionally inhibit 
signalling in all other cells.  Both approaches would inhibit nuclear 
translocation of all NFAT’s, including NFATc1. NFATc1 was localised to the 
developing VV, and is critically required for cardiac and lymphatic 
development. It is not possible to exclude potential roles for other NFATs in 
VV development.  
 
A major limitation to the progress of this study has been the paucity of data 
obtained from a single mouse, which possesses only two proximal femoral 
vein valve sites. This contrasts with common methods for study of lymphatic 
valves (in the mesentery and ear) where many valves are analysed in a single 
sample. These techniques lack the advantage of the development of a valve at 
a consistent position. Additionally, the requirement for sample dissection three 
times to process wholemount specimens from ‘mouse to slide’ limits the 
number of samples that can be processed. The model could be improved by 
development of techniques to allow wholemount confocal microscopy of other 
veins, containing more valves for analysis.  This would be facilitated by use of 
endothelial reporter lines.  
 
In further work, it is necessary to perform conditional deletion experiments to 
examine the roles of Cx37, Cx47, VEGFR2/3, during later VV development, 
and also in maintenance (Figure 92, Table 9). The role of Foxc2 and 
Calcineurin-NFAT signalling in maintenance has not been examined, and 
could be explored with the use of conditionally targeted deletion and/or 
ciclosporin. No requirement was shown for Foxc2 or Calcineurin-NFAT in early 
VV development, and it will be important to determine whether redundancy 
between Foxc1/Foxc2/NFATc1 is present in early VV development.  
 
The identity, source(s) and role(s) of interstitial cells have not been examined 
in this thesis. The line used for conditional deletion produces recombination 
only in the VV EC’s. It is likely that interstitial cells play important roles in VV 
development, which may include production or maintenance of the VV matrix 
core, and also roles in signalling with EC’s. It is interesting to speculate that 
neural crest cells, which play critical roles in cardiac valve development, could 
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also have a role in VV (and LV) formation. This could be investigated in a fate 
mapping study with use of a Wnt1Cre line with an appropriate reporter (for 
example mTmG).  
 
Signalling events between VV EC’s and pericytes have not been examined in 
this thesis, but are likely to be required for formation of the ‘gap’ in SMA-
expressing pericytes seen around the formed VV, in a similar way to the 
process that occurs in LV development.  
 
The role of blood flow in early VV development or maintenance has not been 
successfully examined. Analysis of the role of flow in maintenance could have 
particular relevance to human VV disease, potentially including the VV failure 
associated with thrombosis and varicosis. Additional work is required to 
elucidate the mechanotransduction pathways that incorporate signals from 




  223 
13 REFERENCES 
 
1. Meissner M, Moneta G, Burnand K, Gloviczki P, Lohr J, Lurie F, Mattos 
M, McLafferty R, Mozes G, Rutherford R. The hemodynamics and 
diagnosis of venous disease. Journal of Vascular Surgery. 2007;46:S4-
S24 
2. Mozes G, Gloviczki P. New discoveries in anatomy and new 
terminology of leg veins: Clinical implications. Vasc Endovascular Surg. 
2004;38:367-374 
3. Phillips MN, Jones GT, van Rij AM, Zhang M. Micro-venous valves in 
the superficial veins of the human lower limb. Clin Anat. 2004;17:55-60 
4. Ferrell RE, Baty CJ, Kimak MA, Karlsson JM, Lawrence EC, Franke-
Snyder M, Meriney SD, Feingold E, Finegold DN. Gjc2 missense 
mutations cause human lymphedema. Am J Hum Genet. 2010;86:943-
948 
5. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau 
MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488-498 
6. Coleridge-Smith.PD. Leg ulcer treatment. J Vasc Surg. 2009;49:804-
808 
7. Eberhardt RT. Chronic venous insufficiency. Circulation. 
2005;111:2398-2409 
8. Raffeto.J KR. Mechanisms of varicose vein formation: Valve 
dysfunction and wall dilation. Phlebology. 2008;23:85-98 
9. Lim CS, Davies AH. Pathogenesis of primary varicose veins. British 
Journal of Surgery. 2009;96:1231-1242 
 
  224 
10. Meissner MH, Eklof B, Smith PC, Dalsing MC, DePalma RG, Gloviczki 
P, Moneta G, Neglen P, T OD, Partsch H, Raju S. Secondary chronic 
venous disorders. J Vasc Surg. 2007;46 Suppl S:68S-83S 
11. Gottlob R, May R, Geleff S. Venous valves : Morphology, function, 
radiology, surgery. Wien ; New York: Springer-Verlag; 1986. 
12. Gohel MS, Davies AH. Pharmacological agents in the treatment of 
venous disease: An update of the available evidence. Current vascular 
pharmacology. 2009;7:303-308 
13. Moore HM, Gohel MS, Davies AH. The forgotten burden of deep 
venous disease. Phlebology. 2010;25:53 
14. Caggiati AC, L. Surgery of venous valve. Reviews in vascular medicine. 
2013;1:15-23 
15. Perrin M. [surgery for deep venous reflux in the lower limb]. Journal des 
maladies vasculaires. 2004;29:73-87 
16. Neglen P, Raju S. Venous reflux repair with cryopreserved vein valves. 
J Vasc Surg. 2003;37:552-557 
17. Kistner RL. Surgical repair of the incompetent femoral vein valve. Arch 
Surg. 1975;110:1336-1342 
18. Teebken O, Puschmann C, Breitenbach I, Rohde B, Burgwitz K, 
Haverich A. Preclinical development of tissue-engineered vein valves 
and venous substitutes using re-endothelialised human vein matrix. 
European Journal of Vascular and Endovascular Surgery. 2009;37:92-
102 
19. Rosales A, Jørgensen JJ, Slagsvold CE, Stranden E, Risum Ø, Kroese 
AJ. Venous valve reconstruction in patients with secondary chronic 
venous insufficiency. European Journal of Vascular and Endovascular 
Surgery. 2008;36:466-472 
 
  225 
20. Czarniawska-Grzesinska. Development of valves in the great 
saphenous vein of human fetuses. Folia Morphol. 2001;60:118 
21. Kokova.J HM, Horakova.MA. L'evolution des veines pre-et post-natales. 
Phlebologie. 1993;46:241-252 
22. Kampmeier.OF LFBC. The origin and development of the venous 
valves, with particular reference to the saphenous district. American 
Journal of Anatomy. 1927;38:451-499 
23. Czarniawska-Grzesinska. Development of valves in the small 
saphenous vein in human fetuses. Folia Morphol. 2002;61:37-42 
24. Rickenbacher.J. Zur entwicklung der venen der untern extremitat [on 
the development of the veins of the lower extremity]. Zentralbl Phlebol. 
1966 15:6-14 
25. Jager.O. Die entwinklung der venenklappen. Morph. Jahrbuch. 
1926;56:25x 
26. Franklin.KJ. Valves in veins: An historical survey. J.Anat. 1929;64:67 
27. Amoroso EC, Edholm.,O.G, Rewell,R.E. Venous valves in the giraffe, 
okapi, camel and ostrich. Proceedings of the zoological society of 
london. 1947;117:435-440 
28. Franklin KJ. Valves in veins: Further observations. Journal of anatomy. 
1929;64:67-69 
29. Hossler.FE WR. Venous valve anatomy and morphometry: Studies on 




  226 
30. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schonbein GW. 
Venous hypertension, inflammation and valve remodeling. Eur J Vasc 
Endovasc Surg. 2004;28:484-493 
31. Caggiati A, Phillips M, Lametschwandtner A, Allegra C. Valves in small 
veins and venules. European Journal of Vascular and Endovascular 
Surgery. 2006;32:447-452 
32. Van Bemellen SP. Venous valvular incompetence. Amsterdam: Fa. 
Lameris; 1984. 
33. Hossler FE, West RF. Venous valve anatomy and morphometry: 
Studies on the duckling using vascular corrosion casting. Am J Anat. 
1988;181:425-432 
34. Sabin.F. On the origin of the lymphatic system from the veins and the 
development of the lymph hearts and thoracic duct in the pig. American 
Jorunal of Anatomy. 1902;1:367-389 
35. Wigle JT, Oliver G. Prox1 function is required for the development of 
the murine lymphatic system. Cell. 1999;98:769-778 
36. François M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, 
Paavonen K, Karnezis T, Shayan R, Downes M, Davidson T, Tutt D, 
Cheah KSE, Stacker SA, Muscat GEO, Achen MG, Dejana E, 
Koopman P. Sox18 induces development of the lymphatic vasculature 
in mice. Nature. 2008;456:643-647 
37. Hagerling R, Pollmann C, Andreas M, Schmidt C, Nurmi H, Adams RH, 
Alitalo K, Andresen V, Schulte-Merker S, Kiefer F. A novel multistep 
mechanism for initial lymphangiogenesis in mouse embryos based on 
ultramicroscopy. The EMBO journal. 2013;32:629-644 
38. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and 
future promise. Cell. 2010;140:460-476 
 
  227 
39. Norrmen C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, 
Miura N, Puolakkainen P, Horsley V, Hu J, Augustin HG, Yla-Herttuala 
S, Alitalo K, Petrova TV. Foxc2 controls formation and maturation of 
lymphatic collecting vessels through cooperation with nfatc1. The 
Journal of Cell Biology. 2009;185:439-457 
40. Petrova TV, Karpanen T, Norrmén C, Mellor R, Tamakoshi T, Finegold 
D, Ferrell R, Kerjaschki D, Mortimer P, Ylä-Herttuala S, Miura N, Alitalo 
K. Defective valves and abnormal mural cell recruitment underlie 
lymphatic vascular failure in lymphedema distichiasis. Nature Medicine. 
2004;10:974-981 
41. Kampmeier.O.F. The genetic history of the valves in the lymphatic 
system of man. Am J Anat. 1928;40:413-457 
42. Sabine A, Agalarov Y, Maby-El Hajjami H, Jaquet M, Hagerling R, 
Pollmann C, Bebber D, Pfenniger A, Miura N, Dormond O, Calmes JM, 
Adams RH, Makinen T, Kiefer F, Kwak BR, Petrova TV. 
Mechanotransduction, prox1, and foxc2 cooperate to control 
connexin37 and calcineurin during lymphatic-valve formation. Dev Cell. 
2012 
43. Bazigou E, Xie S, Chen C, Weston A, Miura N, Sorokin L, Adams R, 
Muro AF, Sheppard D, Makinen T. Integrin-α9 is required for fibronectin 
matrix assembly during lymphatic valve morphogenesis. Developmental 
Cell. 2009;17:175-186 
44. Bazigou E, Lyons OT, Smith A, Venn GE, Cope C, Brown NA, Makinen 
T. Genes regulating lymphangiogenesis control venous valve formation 
and maintenance in mice. J Clin Invest. 2011;121:2984-2992 
45. Levet S, Ciais D, Merdzhanova G, Mallet C, Zimmers TA, Lee SJ, 
Navarro FP, Texier I, Feige JJ, Bailly S, Vittet D. Bone morphogenetic 
protein 9 (bmp9) controls lymphatic vessel maturation and valve 
formation. Blood. 2013;122:598-607 
 
  228 
46. Connell F, Brice G, Jeffery S, Keeley V, Mortimer P, Mansour S. A new 
classification system for primary lymphatic dysplasias based on 
phenotype. Clinical Genetics. 2010;77:438-452 
47. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, 
Seaver LH, Glover TW. Mutations in foxc2 (mfh-1), a forkhead family 
transcription factor, are responsible for the hereditary lymphedema-
distichiasis syndrome. Am J Hum Genet. 2000;67:1382-1388 
48. Mellor RH, Hubert CE, Stanton AWB, Tate N, Akhras V, Smith A, 
Burnand KG, Jeffery S, Mäkinen T, Levick JR, Mortimer PS. Lymphatic 
dysfunction, not aplasia, underlies milroy disease. Microcirculation. 
2010;17:281-296 
49. Brice G. Analysis of the phenotypic abnormalities in lymphoedema-
distichiasis syndrome in 74 patients with foxc2 mutations or linkage to 
16q24. Journal of Medical Genetics. 2002;39:478-483 
50. Mellor RH, Brice G, Stanton AWB, French J, Smith A, Jeffery S, Levick 
JR, Burnand KG, Mortimer PS. Mutations in foxc2 are strongly 
associated with primary valve failure in veins of the lower limb. 
Circulation. 2007;115:1912-1920 
51. Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, 
Barmada MM, Finegold DN. Hereditary lymphedema: Evidence for 
linkage and genetic heterogeneity. Hum Mol Genet. 1998;7:2073-2078 
52. Evans AL, Brice G, Sotirova V, Mortimer P, Beninson J, Burnand K, 
Rosbotham J, Child A, Sarfarazi M. Mapping of primary congenital 
lymphedema to the 5q35.3 region. Am J Hum Genet. 1999;64:547-555 
53. Brice G. Milroy disease and the vegfr-3 mutation phenotype. Journal of 
Medical Genetics. 2005;42:98-102 
 
  229 
54. Gordon K, Schulte D, Brice G, Simpson MA, Roukens MG, van Impel A, 
Connell F, Kalidas K, Jeffery S, Mortimer PS, Mansour S, Schulte-
Merker S, Ostergaard P. Mutation in vascular endothelial growth factor-
c, a ligand for vascular endothelial growth factor receptor-3, is 
associated with autosomal dominant milroy-like primary lymphedema. 
Circ Res. 2013;112:956-960 
55. Balboa-Beltran E F-SM, Pérez-Muñuzuri A, Lago R, García-Magán C, 
Couce ML, Sobrino B, Amigo J, Carracedo A, Barros F. A novel stop 
mutation in the vascular endothelial growth factor-c gene (vegfc) results 
in milroy-like disease. J Med Genet. 2014 
56. Laird DW. Syndromic and non-syndromic disease-linked cx43 
mutations. FEBS Lett. 2014;588:1339-1348 
57. Brice G, Ostergaard P, Jeffery S, Gordon K, Mortimer P, Mansour S. A 
novel mutation in gja1 causing oculodentodigital syndrome and primary 
lymphoedema in a three generation family. Clin Genet. 2013 
58. Ostergaard P, Simpson MA, Brice G, Mansour S, Connell FC, 
Onoufriadis A, Child AH, Hwang J, Kalidas K, Mortimer PS, Trembath 
R, Jeffery S. Rapid identification of mutations in gjc2 in primary 
lymphoedema using whole exome sequencing combined with linkage 
analysis with delineation of the phenotype. J Med Genet. 2011;48:251-
255 
59. Orthmann-Murphy JL, Enriquez AD, Abrams CK, Scherer SS. Loss-of-
function gja12/connexin47 mutations cause pelizaeus-merzbacher-like 
disease. Molecular and cellular neurosciences. 2007;34:629-641 
60. Diekmann S, Henneke M, Burckhardt BC, Gartner J. Pelizaeus-
merzbacher-like disease is caused not only by a loss of connexin47 
function but also by a hemichannel dysfunction. Eur J Hum Genet. 
2010;18:985-992 
 
  230 
61. Odermatt B, Wellershaus K, Wallraff A, Seifert G, Degen J, Euwens C, 
Fuss B, Bussow H, Schilling K, Steinhauser C, Willecke K. Connexin 47 
(cx47)-deficient mice with enhanced green fluorescent protein reporter 
gene reveal predominant oligodendrocytic expression of cx47 and 
display vacuolized myelin in the cns. The Journal of neuroscience : the 
official journal of the Society for Neuroscience. 2003;23:4549-4559 
62. Gupta SK, Vlahakis NE. Integrin alpha9beta1: Unique signaling 
pathways reveal diverse biological roles. Cell adhesion & migration. 
2010;4:194-198 
63. Hoye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A. The 
newcomer in the integrin family: Integrin alpha9 in biology and cancer. 
Advances in biological regulation. 2012;52:326-339 
64. Palmer EL, Ruegg C, Ferrando R, Pytela R, Sheppard D. Sequence 
and tissue distribution of the integrin alpha 9 subunit, a novel partner of 
beta 1 that is widely distributed in epithelia and muscle. J Cell Biol. 
1993;123:1289-1297 
65. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, Farese RV, Jr., 
Sheppard D. Fatal bilateral chylothorax in mice lacking the integrin 
alpha9beta1. Molecular and cellular biology. 2000;20:5208-5215 
66. Ma GC, Liu CS, Chang SP, Yeh KT, Ke YY, Chen TH, Wang BB, Kuo 
SJ, Shih JC, Chen M. A recurrent itga9 missense mutation in human 
fetuses with severe chylothorax: Possible correlation with poor 
response to fetal therapy. Prenat Diagn. 2008;28:1057-1063 
67. Yang YS, Ma GC, Shih JC, Chen CP, Chou CH, Yeh KT, Kuo SJ, Chen 
TH, Hwu WL, Lee TH, Chen M. Experimental treatment of bilateral fetal 
chylothorax using in-utero pleurodesis. Ultrasound Obstet Gynecol. 
2012;39:56-62 
 
  231 
68. Danussi C, Spessotto P, Petrucco A, Wassermann B, Sabatelli P, 
Montesi M, Doliana R, Bressan GM, Colombatti A. Emilin1 deficiency 
causes structural and functional defects of lymphatic vasculature. 
Molecular and cellular biology. 2008;28:4026-4039 
69. Wiester.LM GC. Expression and function of the integrin alpha9beta1 in 
bovine aortic valve interstitial cells. Journal of Heart Valve Disease. 
2003;12:605-616 
70. Kullander K, Klein R. Mechanisms and functions of eph and ephrin 
signalling. Nature reviews. Molecular cell biology. 2002;3:475-486 
71. Cowan CA, Yokoyama N, Saxena A, Chumley MJ, Silvany RE, Baker 
LA, Srivastava D, Henkemeyer M. Ephrin-b2 reverse signaling is 
required for axon pathfinding and cardiac valve formation but not early 
vascular development. Developmental Biology. 2004;271:263-271 
72. Pitulescu ME, Adams RH. Eph/ephrin molecules--a hub for signaling 
and endocytosis. Genes Dev. 2010;24:2480-2492 
73. Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, 
Wilkinson GA. Pdz interaction site in ephrinb2 is required for the 
remodeling of lymphatic vasculature. Genes Dev. 2005;19:397-410 
74. Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of human 
and mouse forkhead box (fox) gene families. Human genomics. 
2010;4:345-352 
75. Kaestner KH, Lee KH, Schlondorff J, Hiemisch H, Monaghan AP, 
Schutz G. Six members of the mouse forkhead gene family are 
developmentally regulated. Proc Natl Acad Sci U S A. 1993;90:7628-
7631 
76. Seo S, Fujita H, Nakano A, Kang M, Duarte A, Kume T. The forkhead 
transcription factors, foxc1 and foxc2, are required for arterial 
 
  232 
specification and lymphatic sprouting during vascular development. 
Developmental Biology. 2006;294:458-470 
77. <fang j am j hum genet 2000 mutations in foxc2 (mfh-1), a forkhead 
family transcription factor, are responsible for the hereditary 
lymphedema-distichiasis syndrome..Pdf>.  
78. Finegold DN, Kimak MA, Lawrence EC, Levinson KL, Cherniske EM, 
Pober BR, Dunlap JW, Ferrell RE. Truncating mutations in foxc2 cause 
multiple lymphedema syndromes. Hum Mol Genet. 2001;10:1185-1189 
79. Tumer Z, Bach-Holm D. Axenfeld-rieger syndrome and spectrum of 
pitx2 and foxc1 mutations. Eur J Hum Genet. 2009;17:1527-1539 
80. Winnier GE, Kume T, Deng K, Rogers R, Bundy J, Raines C, Walter 
MA, Hogan BL, Conway SJ. Roles for the winged helix transcription 
factors mf1 and mfh1 in cardiovascular development revealed by 
nonallelic noncomplementation of null alleles. Dev Biol. 1999;213:418-
431 
81. Topczewska JM, Topczewski J, Shostak A, Kume T, Solnica-Krezel L, 
Hogan BL. The winged helix transcription factor foxc1a is essential for 
somitogenesis in zebrafish. Genes Dev. 2001;15:2483-2493 
82. Kume T. The murine winged helix transcription factors, foxc1 and foxc2, 
are both required for cardiovascular development and somitogenesis. 
Genes & Development. 2001;15:2470-2482 
83. Kidson SH, Kume T, Deng K, Winfrey V, Hogan BL. The 
forkhead/winged-helix gene, mf1, is necessary for the normal 
development of the cornea and formation of the anterior chamber in the 
mouse eye. Dev Biol. 1999;211:306-322 
 
  233 
84. Kume T, Deng KY, Winfrey V, Gould DB, Walter MA, Hogan BL. The 
forkhead/winged helix gene mf1 is disrupted in the pleiotropic mouse 
mutation congenital hydrocephalus. Cell. 1998;93:985-996 
85. Alitalo K. The lymphatic vasculature in disease. Nat Med. 
2011;17:1371-1380 
86. Bouvree K, Brunet I, Del Toro R, Gordon E, Prahst C, Cristofaro B, 
Mathivet T, Xu Y, Soueid J, Fortuna V, Miura N, Aigrot MS, Maden CH, 
Ruhrberg C, Thomas JL, Eichmann A. Semaphorin3a, neuropilin-1, and 
plexina1 are required for lymphatic valve formation. Circ Res. 
2012;111:437-445 
87. Hayashi H, Sano H, Seo S, Kume T. The foxc2 transcription factor 
regulates angiogenesis via induction of integrin  3 expression. Journal 
of Biological Chemistry. 2008;283:23791-23800 
88. Kume T. Foxc2 transcription factor: A newly described regulator of 
angiogenesis. Trends in Cardiovascular Medicine. 2008;18:224-228 
89. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, 
Grossfeld PD, Srivastava D. Mutations in notch1 cause aortic valve 
disease. Nature. 2005;437:270-274 
90. Murtomaki A, Uh MK, Kitajewski C, Zhao J, Nagasaki T, Shawber CJ, 
Kitajewski J. Notch signaling functions in lymphatic valve formation. 
Development. 2014;141:2446-2451 
91. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by 
calcium, calcineurin, and nfat. Genes Dev. 2003;17:2205-2232 
92. Crabtree GR, Olson EN. Nfat signaling: Choreographing the social lives 
of cells. Cell. 2002;109 Suppl:S67-79 
 
  234 
93. Kumai M, Nishii K, Nakamura K, Takeda N, Suzuki M, Shibata Y. Loss 
of connexin45 causes a cushion defect in early cardiogenesis. 
Development. 2000;127:3501-3512 
94. Sabine A, Petrova TV. Interplay of mechanotransduction, foxc2, 
connexins, and calcineurin signaling in lymphatic valve formation. 
Advances in anatomy, embryology, and cell biology. 2014;214:67-80 
95. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by 
ca(2+)/calcineurin and nfatc3/c4 pattern the developing vasculature. 
Cell. 2001;105:863-875 
96. Chang C-P, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, 
Graef IA, Crabtree GR. A field of myocardial-endocardial nfat signaling 
underlies heart valve morphogenesis. Cell. 2004;118:649-663 
97. Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, 
Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef 
IA, Crabtree GR. Nfat dysregulation by increased dosage of dscr1 and 
dyrk1a on chromosome 21. Nature. 2006;441:595-600 
98. Abdul-Sater Z, Yehya A, Beresian J, Salem E, Kamar A, Baydoun S, 
Shibbani K, Soubra A, Bitar F, Nemer G. Two heterozygous mutations 
in nfatc1 in a patient with tricuspid atresia. PLoS One. 2012;7:e49532 
99. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual 
regulation of snail by gsk-3beta-mediated phosphorylation in control of 
epithelial-mesenchymal transition. Nat Cell Biol. 2004;6:931-940 
100. Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, 
Hoey T, Mickanin C, Baldwin HS, Glimcher LH. The transcription factor 
nf-atc is essential for cardiac valve formation. Nature. 1998;392:186-
190 
 
  235 
101. de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, 
Samper E, Potter J, Wakeham A, Marengere L, Langille BL, Crabtree 
GR, Mak TW. Role of the nf-atc transcription factor in morphogenesis of 
cardiac valves and septum. Nature. 1998;392:182-186 
102. Schulz RA, Yutzey KE. Calcineurin signaling and nfat activation in 
cardiovascular and skeletal muscle development. Dev Biol. 2004;266:1-
16 
103. Kulkarni RM, Greenberg JM, Akeson AL. Nfatc1 regulates lymphatic 
endothelial development. Mechanisms of Development. 2009;126:350-
365 
104. Sohl G, Willecke K. Gap junctions and the connexin protein family. 
Cardiovasc Res. 2004;62:228-232 
105. Goodenough DA, Paul DL. Gap junctions. Cold Spring Harbor 
perspectives in biology. 2009;1:a002576 
106. Meens MJ, Sabine A, Petrova TV, Kwak BR. Connexins in lymphatic 
vessel physiology and disease. FEBS Lett. 2014;588:1271-1277 
107. Solan JL, Lampe PD. Connexin43 phosphorylation: Structural changes 
and biological effects. Biochem J. 2009;419:261-272 
108. Laird DW. Life cycle of connexins in health and disease. Biochem J. 
2006;394:527-543 
109. Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM. 
Connexin37 and connexin43 deficiencies in mice disrupt lymphatic 
valve development and result in lymphatic disorders including 
lymphedema and chylothorax. Dev Biol. 2011;354:253-266 
110. Kanady JD, Simon AM. Lymphatic communication: Connexin junction, 
what's your function? Lymphology. 2011;44:95-102 
 
  236 
111. Munger SJ, Kanady JD, Simon AM. Absence of venous valves in mice 
lacking connexin37. Dev Biol. 2013;373:338-348 
112. Fang JS, Angelov SN, Simon AM, Burt JM. Cx40 is required for, and 
cx37 limits, postischemic hindlimb perfusion, survival and recovery. J 
Vasc Res. 2012;49:2-12 
113. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, 
Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial 
infarction from polymorphisms in candidate genes. N Engl J Med. 
2002;347:1916-1923 
114. Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of 
vascular connexin expression in atherosclerotic plaques. Arterioscler 
Thromb Vasc Biol. 2002;22:225-230 
115. Francis R, Xu X, Park H, Wei CJ, Chang S, Chatterjee B, Lo C. 
Connexin43 modulates cell polarity and directional cell migration by 
regulating microtubule dynamics. PLoS One. 2011;6:e26379 
116. Rhee DY, Zhao XQ, Francis RJ, Huang GY, Mably JD, Lo CW. 
Connexin 43 regulates epicardial cell polarity and migration in coronary 
vascular development. Development. 2009;136:3185-3193 
117. Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, 
Juneja SC, Kidder GM, Rossant J. Cardiac malformation in neonatal 
mice lacking connexin43. Science. 1995;267:1831-1834 
118. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. Vegf receptor 
signalling - in control of vascular function. Nature reviews. Molecular 
cell biology. 2006;7:359-371 
119. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, 
Acker T, Acker-Palmer A. Ephrin-b2 regulates vegfr2 function in 
developmental and tumour angiogenesis. Nature. 2010;465:487-491 
 
  237 
120. Blanco R, Gerhardt H. Vegf and notch in tip and stalk cell selection. 
Cold Spring Harbor perspectives in medicine. 2013;3:a006569 
121. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, 
Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, 
Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival 
and migratory signals via the vegf-c/d receptor vegfr-3. The EMBO 
journal. 2001;20:4762-4773 
122. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola 
K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos 
deficient in vegf receptor-3. Science. 1998;282:946-949 
123. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, 
Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, 
Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, 
Gerhardt H, Alitalo K. Vegfr-3 controls tip to stalk conversion at vessel 
fusion sites by reinforcing notch signalling. Nat Cell Biol. 2011;13:1202-
1213 
124. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas 
O, Duarte A, Pytowski B, Adams RH. Notch-dependent vegfr3 
upregulation allows angiogenesis without vegf-vegfr2 signalling. Nature. 
2012;484:110-114 
125. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen 
KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Yla-Herttuala S, 
Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in 
transgenic mice expressing soluble vegf receptor-3. Nat Med. 
2001;7:199-205 
126. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin 
ME, Stacker SA, Achen MG, Alitalo K. Deletion of vascular endothelial 
growth factor c (vegf-c) and vegf-d is not equivalent to vegf receptor 3 
 
  238 
deletion in mouse embryos. Molecular and cellular biology. 
2008;28:4843-4850 
127. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, 
Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas 
C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, 
Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Blocking 
vegfr-3 suppresses angiogenic sprouting and vascular network 
formation. Nature. 2008;454:656-660 
128. Gordon K, Spiden SL, Connell FC, Brice G, Cottrell S, Short J, Taylor 
R, Jeffery S, Mortimer PS, Mansour S, Ostergaard P. Flt4/vegfr3 and 
milroy disease: Novel mutations, a review of published variants and 
database update. Hum Mutat. 2013;34:23-31 
129. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, 
McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with 
vegfr-3 signalling in primary lymphoedema. Nat Genet. 2000;25:153-
159 
130. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, 
Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-
Herttuala S, Finegold DN, Ferrell RE, Alitalo K. A model for gene 
therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 
2001;98:12677-12682 
131. Hove JR, Koster RW, Forouhar AS, Acevedo-Bolton G, Fraser SE, 
Gharib M. Intracardiac fluid forces are an essential epigenetic factor for 
embryonic cardiogenesis. Nature. 2003;421:172-177 
132. Hogers B, DeRuiter MC, Gittenberger-de Groot AC, Poelmann RE. 
Extraembryonic venous obstructions lead to cardiovascular 
malformations and can be embryolethal. Cardiovasc Res. 1999;41:87-
99 
 
  239 
133. Vermot J, Forouhar AS, Liebling M, Wu D, Plummer D, Gharib M, 
Fraser SE. Reversing blood flows act through klf2a to ensure normal 
valvulogenesis in the developing heart. PLoS Biol. 2009;7:e1000246 
134. Yashiro K, Shiratori H, Hamada H. Haemodynamics determined by a 
genetic programme govern asymmetric development of the aortic arch. 
Nature. 2007;450:285-288 
135. Kwak BR, Silacci P, Stergiopulos N, Hayoz D, Meda P. Shear stress 
and cyclic circumferential stretch, but not pressure, alter connexin43 
expression in endothelial cells. Cell communication & adhesion. 
2005;12:261-270 
136. Jong Lee H. Shear stress activates tie2 receptor tyrosine kinase in 
human endothelial cells. Biochemical and Biophysical Research 
Communications. 2003;304:399-404 
137. Kume T, Deng K, Hogan BL. Murine forkhead/winged helix genes foxc1 
(mf1) and foxc2 (mfh1) are required for the early organogenesis of the 
kidney and urinary tract. Development. 2000;127:1387-1395 
138. Makinen T. Pdz interaction site in ephrinb2 is required for the 
remodeling of lymphatic vasculature. Genes & Development. 
2005;19:397-410 
139. Feil R, Wagner J, Metzger D, Chambon P. Regulation of cre 
recombinase activity by mutated estrogen receptor ligand-binding 
domains. Biochem Biophys Res Commun. 1997;237:752-757 
140. Leone DP, Genoud S, Atanasoski S, Grausenburger R, Berger P, 
Metzger D, Macklin WB, Chambon P, Suter U. Tamoxifen-inducible 
glia-specific cre mice for somatic mutagenesis in oligodendrocytes and 
schwann cells. Molecular and cellular neurosciences. 2003;22:430-440 
 
  240 
141. Nagy A. Cre recombinase: The universal reagent for genome tailoring. 
Genesis. 2000;26:99-109 
142. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. 
Preparation of pcr-quality mouse genomic DNA with hot sodium 
hydroxide and tris (hotshot). Biotechniques. 2000;29:52, 54 
143. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. 
Development of the heart: (3) formation of the ventricular outflow tracts, 
arterial valves, and intrapericardial arterial trunks. Heart. 2003;89:1110-
1118 
144. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, 
Deutsch U, Sato TN. Uniform vascular-endothelial-cell-specific gene 
expression in both embryonic and adult transgenic mice. Proc Natl 
Acad Sci U S A. 1997;94:3058-3063 
145. Coxam B, Sabine A, Bower NI, Smith KA, Pichol-Thievend C, 
Skoczylas R, Astin JW, Frampton E, Jaquet M, Crosier PS, Parton RG, 
Harvey NL, Petrova TV, Schulte-Merker S, Francois M, Hogan BM. 
Pkd1 regulates lymphatic vascular morphogenesis during development. 
Cell reports. 2014;7:623-633 
146. Tatin F, Taddei A, Weston A, Fuchs E, Devenport D, Tissir F, Makinen 
T. Planar cell polarity protein celsr1 regulates endothelial adherens 
junctions and directed cell rearrangements during valve 
morphogenesis. Dev Cell. 2013;26:31-44 
147. Hemmeryckx B, Emmerechts J, Bovill EG, Hoylaerts MF, Lijnen HR. 
Effect of ageing on the murine venous circulation. Histochem Cell Biol. 
2012;137:537-546 
148. Bazigou E, Makinen T. Flow control in our vessels: Vascular valves 
make sure there is no way back. Cellular and molecular life sciences : 
CMLS. 2013;70:1055-1066 
 
  241 
149. Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, 
Finegold DN, Kerjaschki D, Yla-Herttuala S, Alitalo K. Lymphatic 
endothelial reprogramming of vascular endothelial cells by the prox-1 
homeobox transcription factor. EMBO J. 2002;21:4593-4599 
150. Ostrowski MA, Huang NF, Walker TW, Verwijlen T, Poplawski C, Khoo 
AS, Cooke JP, Fuller GG, Dunn AR. Microvascular endothelial cells 
migrate upstream and align against the shear stress field created by 
impinging flow. Biophysical journal. 2014;106:366-374 
151. Shen B, Shang Z, Wang B, Zhang L, Zhou F, Li T, Chu M, Jiang H, 
Wang Y, Qiao T, Zhang J, Sun W, Kong X, He Y. Genetic dissection of 
tie pathway in mouse lymphatic maturation and valve development. 
Arterioscler Thromb Vasc Biol. 2014;34:1221-1230 
152. Singh P, Chen C, Pal-Ghosh S, Stepp MA, Sheppard D, Van De Water 
L. Loss of integrin alpha9beta1 results in defects in proliferation, 
causing poor re-epithelialization during cutaneous wound healing. J 
Invest Dermatol. 2009;129:217-228 
153. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-
fluorescent cre reporter mouse. genesis. 2007;45:593-605 
154. Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: Valve 
dysfunction and wall dilation. Phlebology. 2008;23:85-98 
155. Davy A, Soriano P. Ephrin-b2 forward signaling regulates somite 
patterning and neural crest cell development. Dev Biol. 2007;304:182-
193 
156. Grunwald IC, Korte M, Adelmann G, Plueck A, Kullander K, Adams RH, 
Frotscher M, Bonhoeffer T, Klein R. Hippocampal plasticity requires 
postsynaptic ephrinbs. Nature neuroscience. 2004;7:33-40 
 
  242 
157. Mellitzer G, Xu Q, Wilkinson DG. Eph receptors and ephrins restrict cell 
intermingling and communication. Nature. 1999;400:77-81 
158. Oike Y, Ito Y, Hamada K, Zhang XQ, Miyata K, Arai F, Inada T, Araki K, 
Nakagata N, Takeya M, Kisanuki YY, Yanagisawa M, Gale NW, Suda 
T. Regulation of vasculogenesis and angiogenesis by ephb/ephrin-b2 
signaling between endothelial cells and surrounding mesenchymal 
cells. Blood. 2002;100:1326-1333 
159. Kawasaki J, Aegerter S, Fevurly RD, Mammoto A, Mammoto T, Sahin 
M, Mably JD, Fishman SJ, Chan J. Rasa1 functions in ephb4 signaling 
pathway to suppress endothelial mtorc1 activity. J Clin Invest. 
2014;124:2774-2784 
160. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, 
Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of 
complicated vascular anomalies in children. Pediatric blood & cancer. 
2011;57:1018-1024 
161. Kriederman BM. Foxc2 haploinsufficient mice are a model for human 
autosomal dominant lymphedema-distichiasis syndrome. Human 
Molecular Genetics. 2003;12:1179-1185 
162. Iida K, Koseki H, Kakinuma H, Kato N, Mizutani-Koseki Y, Ohuchi H, 
Yoshioka H, Noji S, Kawamura K, Kataoka Y, Ueno F, Taniguchi M, 
Yoshida N, Sugiyama T, Miura N. Essential roles of the winged helix 
transcription factor mfh-1 in aortic arch patterning and skeletogenesis. 
Development. 1997;124:4627-4638 
163. Sasman A, Nassano-Miller C, Shim KS, Koo HY, Liu T, Schultz KM, 
Millay M, Nanano A, Kang M, Suzuki T, Kume T. Generation of 
conditional alleles for foxc1 and foxc2 in mice. genesis. 2012;50:766-
774 
 
  243 
164. Schweisguth F, Hayashi H, Kume T. Foxc transcription factors directly 
regulate dll4 and hey2 expression by interacting with the vegf-notch 
signaling pathways in endothelial cells. PLoS ONE. 2008;3:e2401 
165. Saiki S, Sakai K, Saiki M, Kitagawa Y, Umemori T, Murata K, Matsui M, 
Hirose G. Varicose veins associated with cadasil result from a novel 
mutation in the notch3 gene. Neurology. 2006;67:337-339 
166. Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa 
T, Bear MF, Tonegawa S. Forebrain-specific calcineurin knockout 
selectively impairs bidirectional synaptic plasticity and working/episodic-
like memory. Cell. 2001;107:617-629 
167. Johnson EN. Nfatc1 mediates vascular endothelial growth factor-
induced proliferation of human pulmonary valve endothelial cells. 
Journal of Biological Chemistry. 2002;278:1686-1692 
168. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. Igf-1 
induces skeletal myocyte hypertrophy through calcineurin in association 
with gata-2 and nf-atc1. Nature. 1999;400:581-585 
169. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, 
Woollard WJ, Dafou D, Kilo T, Smithson S, Lunt P, Murday VA, 
Hodgson S, Keenan R, Pilz DT, Martinez-Corral I, Makinen T, Mortimer 
PS, Jeffery S, Trembath RC, Mansour S. Mutations in gata2 cause 
primary lymphedema associated with a predisposition to acute myeloid 
leukemia (emberger syndrome). Nat Genet. 2011;43:929-931 
170. Zhou B, Wu B, Tompkins KL, Boyer KL, Grindley JC, Baldwin HS. 
Characterization of nfatc1 regulation identifies an enhancer required for 
gene expression that is specific to pro-valve endocardial cells in the 
developing heart. Development. 2005;132:1137-1146 
171. Simon AM, Goodenough DA, Li E, Paul DL. Female infertility in mice 
lacking connexin 37. Nature. 1997;385:525-529 
 
  244 
172. Lohmann CH, Schwartz Z, Liu Y, Li Z, Simon BJ, Sylvia VL, Dean DD, 
Bonewald LF, Donahue HJ, Boyan BD. Pulsed electromagnetic fields 
affect phenotype and connexin 43 protein expression in mlo-y4 
osteocyte-like cells and ros 17/2.8 osteoblast-like cells. J Orthop Res. 
2003;21:326-334 
173. Kirkin V, Thiele W, Baumann P, Mazitschek R, Rohde K, Fellbrich G, 
Weich H, Waltenberger J, Giannis A, Sleeman JP. Maz51, an 
indolinone that inhibits endothelial cell and tumor cell growth in vitro, 
suppresses tumor growth in vivo. Int J Cancer. 2004;112:986-993 
174. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, 
Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue 
MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. 
Nonclinical antiangiogenesis and antitumor activities of axitinib (ag-
013736), an oral, potent, and selective inhibitor of vascular endothelial 
growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 
2008;14:7272-7283 
175. Evans CE, Grover SP, Humphries J, Saha P, Patel AP, Patel AS, Lyons 
OT, Waltham M, Modarai B, Smith A. Antiangiogenic therapy inhibits 
venous thrombus resolution. Arterioscler Thromb Vasc Biol. 
2014;34:565-570 
176. Srinivasan.RS OG. Prox1 dosage controls the number of lymphatic 
endothelial cell progenitors and the formation of the lymphovenous 
valves. Genes Dev. 2011;25:2187-2197 
177. Persaud K, Tille JC, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao HQ, 
Brennan LA, Witte L, Pepper MS, Pytowski B. Involvement of the vegf 
receptor 3 in tubular morphogenesis demonstrated with a human anti-
human vegfr-3 monoclonal antibody that antagonizes receptor 
activation by vegf-c. J Cell Sci. 2004;117:2745-2756 
 
  245 
178. Groenendijk BCW. Changes in shear stress-related gene expression 
after experimentally altered venous return in the chicken embryo. 
Circulation Research. 2005;96:1291-1298 
179. Gotoh.H MY, Imamura.K. General anaesthesia of infant mice by 
isoflurane inhalation for medium-duration surgery. Exp Anim. 
2004;53:63-65 
180. Park.CM CK, Harvey-Clark.CJ, et al. . Improved techniques for 
successful neonatal rat surgery. Lab Anim Sci. 1992;5:508-514 
181. Lurie F, Kistner RL. The relative position of paired valves at venous 
junctions suggests their role in modulating three-dimensional flow 
pattern in veins. Eur J Vasc Endovasc Surg. 2012;44:337-340 
182. van Langevelde K, Sramek A, Rosendaal FR. The effect of aging on 
venous valves. Arterioscler Thromb Vasc Biol. 2010;30:2075-2080 
183. Lane R, Graiche, JA, Cuzzilla, ML, Coroneos, JC. Incompetent venous 
valves: Ultrasound imaging and exo-stent repair. Phlebolymphology. 
2007;14:105-115 
184. Moore HM, Gohel M, Davies AH. Number and location of venous valves 
within the popliteal and femoral veins: A review of the literature. Journal 
of anatomy. 2011;219:439-443 
185. Iimura A, Nakamura Y, Itoh M. Anatomical study of distribution of valves 
of the cutaneous veins of adult's limbs. Annals of anatomy = 
Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft. 
2003;185:91-95 
186. Sano H, LeBoeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM, 
Kume T. The foxc2 transcription factor regulates tumor angiogenesis. 
Biochemical and Biophysical Research Communications. 
2010;392:201-206 
 
  246 
187. Davy A, Bush JO, Soriano P. Inhibition of gap junction communication 
at ectopic eph/ephrin boundaries underlies craniofrontonasal syndrome. 
PLoS Biol. 2006;4:e315 
188. Laemmli UK. Cleavage of structural proteins during the assembly of the 




  247 
Appendix 1 
Solutions and buffers 
 
General solutions 
PBS: Dulbecco’s PBS (Sigma D5652) 



















Localisation of βgal in Tie2LacZ reporter  
Fixative 
5ml formaldehyde, 0.8ml glutaraldehyde, 200µl MgCl2, 190mg EDTA made up 
to 100ml with Phosphate Buffered Saline (PBS) 
 
Washing solution 
200µl MgCl2, 200µl NP40, 0.1g Na deoxycholate, made up to 100ml PBS 
 




165mg K3Fe(CN)6, 211mg K4Fe(CN)6.H20, 200µl MgCl2, 10mg Na 
Deoxycholate, 20µl NP40 made up to 400ml PBS 
 
Stock substrate 
40mg/ml Xgal dissolved in dimethylformamide.  
Final staining solution = stock substrate + staining solution 1:40.  
 
 
Solutions for SEM at SGUL 
Stock (2x) cacodylate buffer 
Sodium cacodylate 10.7g, sodium chloride 7.1g, dissolved in 450ml dH20 and 
adjusted to pH 7.4 and made up to 500ml. Store at +4oc 
 
SEM fix 
50ml Stock cacodylate buffer, 8ml 25% electron microscopy grade 
glutaraldehyde, 2.5ml 38-40% formaldehyde, 39.5ml dH20, made fresh on the 
day of use. 
 
 
Solutions for SEM/TEM at KCL 
Stock Solutions: 
Part 1 0.2M di-sodium hydrogen orthophosphate dihydrate (Alkali 
solution) 
Dissolve 35.6g of solid into 1 Litre of distilled water and store at 
RT. 
Part 2  0.2M Sodium dihydrogen orthophosphate  (Acid solution) 
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2.5% Glutaraldehyde fixative in phosphate buffer 
77ml Part 1, 23ml of Part 2, 100ml dH20, adjusted to pH 7.35. Withdraw 190ml 
and add to 10ml 50% Vacuum distilled glutaraldehyde. Store at +4oc. Make 
fresh on day of use. 
 
Glutaraldehyde Wash Solution 
34.22g Sucrose, 50ml dH20.  
128ml Part 1, 38ml Part 2 adjusted to pH 7.3 
Withdraw 62.5ml and make up to 250ml with dH20, add 165ml phosphate 
solution and make up to 500ml. Store at +4oc 
 
General transmission electron microscopy 




In a fume hood add 40g paraformaldehyde and 500ul 3M NaOH to 1L 
Dulbecco’s PBS, heat to approximately 65oc whilst stirring, until dissolved.  
Once cooled adjust pH to 7.35 with HCl. Pass through a 0.22µm filter and 
freeze 30ml aliquots in 50ml falcon tubes at -20oc. Thawed immediately before 
use. (Only freshly thawed solutions were used). 
 
Wash Solution 
Permeabilise and wash in PBST 
 
Blocking solution 
3% Foetal calf serum (Source Biosciences SBS10022) in PBST (above). Pass 
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Mowiol-based mounting solution (Courtesy of Dr Taija Makinen) 
Mix: 36g glycerol, 14.4g Mowiol (Calbiochem 475904), 93ml dH20.                   
Stir overnight at RT. 
Add 14.4ml 1M Tris pH 8,5 
Heat to 50oc for 10mins whilst stirring 
Once Mowiol has dissolved, centrifuge at 5000xg for 15mins. 
Aliquot (approx 200µl) and store at -20oc until required 
 
(Prolong Gold (Invitrogen) was subsequently used as an alternative mounting 
medium). 
 
HotSHOT DNA extraction for genotyping 
 
These solutions were taken from Ref 142 
 
HotSHOT alkaline lysis reagent 
25 mM NaOH, 0.2 mM disodium EDTA (pH12) 
 
Neutralising reagent 
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Appendix 2 
Immunolocalisation of non-immune IgG in 
murine VV 
 
Figure 93 Non-immune IgG control imunostaining of Balb/c venous valves.  
A) Goat IgG 10µg/ml with Donkey anti Goat-647  
B) Rabbit IgG 10 µg/ml with Donkey anti Rabbit-647  
C) Sheep IgG 10µg/ml with Donkey anti Sheep-647.  
Red- IgG; Blue: PECAM1-550 (primary conjugate).  
Adipose tissue caused significant autofluorescence and loss of signal at all ages, and 
prevented imaging beyond P8.  * = venous valve. Scale bars 50µm. 
 49 
 
(Figure 11) The secondaries chosen were donkey anti-Rb/Shp/Goat conjugated to Dylight-
647 fluorophore, because in all experiments at KCL this secondary Ab-fluorophore 
combination produced the strongest signal. Other secondaries used (Donkey anti Rabbit, 
Goat, Sheep conjugated to Dy-405, 488, 550) were also tested alone and did not give any 
signal. The same Smart Offset (-2.4) and comparative Smar Gain (1000V) were used as in 
test experi ents. 
 
Figure 11: Control valves stained with non-immune IgG 
A) Goat IgG 10 g/ml with Donkey anti Goat-647 B) Rabbit 10 g/ml Donkey anti Rabbit-647 
C) Sheep10 g/ml Donkey anti Sheep-647. P6 Balb/c. * = venous valve. Scale bars 50 m. 
Red: IgG Blue: PECAM1-550 (primary conjugate). 
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Appendix 3 
Antibodies and detection reagents 
 
Table 10 Primary Antibodies 
Target Protein Target 
Species 
Supplier Catalogue Concentration 






Cx43 Mouse Cell signalling 3512 5µg/ml 
Cx43 Human Invitrogen 71-0700 10µg/ml 
Cx47 Human Sigma-Aldrich SAB2100924 10µg/ml 
GFP Aequorea 
victoria 
Abcam ab69313 2µg/ml 
Integrin-α9 Human Sigma HPA030609 0.27µg/ml 
Integrin-α9 Mouse R&D AF3827 2 µg/ml 
α smooth muscle 
actin 
Human, mouse Sigma C6198 7 µg/ml 
FOXC2 Mouse R&D AF6989 7.5 µg/ml 
GATA-2 Human Sigma HPA005633 2.3 µg/ml 
NFATc1 Human Santa Cruz Sc-17834 2 µg/ml 
NFATc1 Mouse R&D AF5640 10µg/ml 
CD31/PECAM1 Mouse  Novus NB600-1475G 
(Mec13.1) 
2.5-5 µg/ml 
Prox1 Mouse Angiobio 11-002 10 µg/ml 
Prox1 Human R&D Baf2727 2µg/ml 
VEGFR2 Mouse R&D BAF644 5µg/ml 
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Conjugate Supplier Catalogue Concentration 
Goat Donkey Dylight-405 JIR 705-475-147 7.5 µg/ml 
Goat Donkey Dylight-488 JIR 705-485-147 7.5 µg/ml 
Goat Donkey Dylight-549 JIR 705-505-147 7.5 µg/ml 
Goat Donkey Dylight-647 JIR 705-605-147 7.5 µg/ml 
Rabbit Donkey Dylight-405 JIR 711-475-152 7.5 µg/ml 
Rabbit Donkey Dylight-488 JIR 711-485-152 7.5 µg/ml 
Rabbit Donkey Cy3 JIR 711-165-152 7.5 µg/ml 
Rabbit Donkey Dylight-649 JIR 711-495-152 7.5 µg/ml 
Rat Donkey Dylight-405 JIR 712-475-153 7.5 µg/ml 
Sheep Donkey Dylight-649 JIR 713-495-147 7.5 µg/ml 
 
Fluorophores were stored at -20oc, aliquoted in 50% glycerol.  
JIR = Jackson Immunoresearch 
 
Labelled detecting agents 
- Streptavidin-alexafluor-488 JIR 016-540-084 (1/200), Streptavidin-alexafluor-
647 JIR 016-600-084 (1/500, 1.8µg/ml) 
- Extravidin-ALP Sigma E2636 (1/200) 2.9µg/ml 
- Polymer-HRP (Unknown host, anti-Rabbit/Mouse) Menarini Diagnostics, MP-
XCP-PO25 (used neat as per manufacturer’s instructions) 
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Appendix 4 
PCR primer sequences and conditions 
Itga9lx 
a9lxF (a9F1): 5’CCCTTACAGGGCTCTAGGAAAGGGG3’ 
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Appendix 5 
EfnB2GFP reporter analysis  
 
Figure 94 Analysis of EfnB2GFP reporter at P0 
Images are 2D maximum projections of filtered confocal z stacks. EfnB2GFP, with 
immunolocalisation of PECAM1, Prox1, NFATc1. Reporter is heterozygous for 
ephrinB2. N = 6 at P0. Some images reflected so flow left to right in all images. Artifact 
from injection syringe material shows in top two rows in the Prox1 channel. Scale bar 
50µm. 
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Appendix 6  
Detection of Foxc1 by western blot 
 
Aim 
This experiment aimed to identify expression of Foxc1 (a nuclear transcription 
factor closely related to Foxc2) by western blotting of lysed human venous 
valve leaflets.  
 
Methods 
1. Human long saphenous veins were obtained from patients undergoing 
CABG as described in the General Methods Chapter. Veins were 
dissected under a microscope (Leica, UK) in PBS and valve leaflets 
removed and snap frozen in isopentane and stored at -80oc. Sections of 
vein that did not contain a valve were similarly snap frozen and stored 
at -80oc. HEK293 cell lysate (following Cx37 overexpression) was 
obtained from Novus Biologicals (NBL1-11088). 
 
2. Tissue samples (pooled valve leaflets, or non-valved vein) were thawed 
on ice and homogenized in ice-cold radioimmunoprecipitation (RIPA) 
buffer (Thermo Fisher scientific, USA), supplemented with Halt protease 
inhibitors  (Thermo Fisher Scientific, USA) using an pestle (Eppendorf) 
and then incubated on ice for 10mins. 
3. Lysates were then cleared by centrifugation at 16,000xg for 15mins at 
4°c and the resulting supernatant was transferred to a new 
microcentrifuge tube.  
4. Total soluble protein concentration of tissue lysates were determined 
using the bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, 
USA) as per the manufacturer’s instructions. 
5. Proteins were separated by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE).188 Lysates were prepared by addition 
of LDS sample buffer (Invitrogen, UK) and heating for 5mins at 95°C.  
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6. Samples were loaded onto a 4-20% gradient gel (Biorad, UK) and 
electrophoresed in running buffer (25mM Tris, 192mM glycine, 0.1% 
(w/v) SDS) at 100V for 100mins.  
7. Gels were equilibrated in transfer buffer (25mM Tris, 192mM glycine, 
10% (v/v) methanol) for 5mins before being transferred to methanol 
activated polyvinylidene difluoride (PVDF) membranes (Amersham, UK) 
using a TransBlot Turbo (Biorad, UK).  
8. Membranes were blocked in PBS supplemented with 5% low fat milk 
powder (Marvel, UK) for 1hr at room temperature, then washed for 6 x 
5mins in PBS+0.05% Tween20 (PBST). 
9. The primary antibody (monoclonal mouse anti-human Foxc1, R&D 
Systems MAB6329) was diluted to 1µg/ml in PBST+ 5% low fat milk 
powder. Membranes were incubated overnight at 4°C with agitation on 
the belly dancer.  
10. Membranes were rinsed 3 times and washed 6 times for 5mins in PBST 
prior to incubation with secondary antibody (Goat anti-mouse HRP, 
Sigma AO168), diluted 1/80,000 in PBST + 5% low fat milk powder and 
incubated with the membranes for 1hr at room temperature.  
11. Membranes were rinsed 3 times then washed 6 times for 5 minutes in 
PBST and incubated with a chemiluminescent substrate (KPL signalock 
HRP chemiwestern kit, 54-54-00). Luminescence was detected over 3 
minutes using a ChemiDoc MP (Biorad, UK).  
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Results 
 
Figure 95 Western blot for Foxc1 
This figure shows detection of a band of soluble protein at approximately 53.8 kDa in 
lysed human venous valve leaflet (Lane 4), using a monoclonal antibody against human 
Foxc1. No similar band was detected in whole lysed vein (lane 2) or HEK293 cell lysate 
(lane 3). The predicted molecular weight of Foxc1 is 57kDa (Uniprot), which is within 
10% of the observed band. This result suggests expression of Foxc1 in human venous 
valve leaflets, but not the rest of the vein. 
MW refers to weight in kDa, determined from markers in lanes 1 and 5.  
Lane 1: MW marker (SeeBlue 2 plus, 10µl), as indicated in kDa 
Lane 2: Whole lysed vein (30µg) 
Lane 3: HEK293 cell lysate (15µg) 
Lane 4: Lysed human VV leaflets (15µg). Major band calculated MW=53.8 
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Appendix 7 Calcineurin-NFAT signalling 
Effect of Ciclosporin on pup growth 
Pups in two litters of 6 and 8 were randomly allocated to receive ciclosporin 
(N=7) or solvent control (N=7) bid as described in Chapter 7. Ciclosporin 
treatment was associated with a failure to survive and sub-normal weight gain. 
 
Figure 96 Growth (weight) of pups treated with ciclosporin 
This graph shows that surviving ciclosporin-treated pups showed a failure to gain weight 
normally (P=0.015, ANOVA). Heavy line indicates median, box indicates inter-quartile 
range, and whiskers the range. 
Template for measuring VV leaflet length 
 
Figure 97 Template used for reference when measuring VV leaflets  
The template shown on A was centered on the 2D projection of the confocal z-stack of 
the VV, and measurements of leaflet length (perpendicular to the free edge) were taken 
at each point where template lines bisected the free edges of the valve leaflets. An 
example valve is shown in B, with positions of measurements highlighted in B’. A mean 
of all 8 measurements was analysed for each valve. Scale bar 20µm. 
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Localisation of GATA2 in human VV 
Immunolocalisation of the nuclear transcription factor GATA2 was performed 
as described in the General Methods chapter, using Polymer Amplification 
(Menarini) followed by Vector SG substrate to localise HRP activity. Human 
valves were obtained from clinically normal long saphenous veins as 
described in the General Methods chapter. Nuclear GATA2 expression was 




Figure 98 Localisation of GATA2 to adult human VV 
A) GATA2 is expressed by endothelial cells on both surfaces of the human VV leaflet 
(dark blue nuclei marked by * in A). Some expression may be present in the interstitial 
cells of the leaflet. The non-immune IgG control is shown in B.  Scale 50µm. 
Counterstain = nuclear fast red. 
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Appendix 8 
Effect of axitinib treatment on survival and 
growth 
 
Administration of the VEGFR tyrosine kinase inhibition with Axitinib was 
associated with failure to survive (Figure 99) but not failure to gain weight 
(P=ns, ANOVA) in survivors (Figure 100).  
 
Figure 99 Kaplan-Meier plot of survival with postnatal axitinib 
Survival in axitinib treated pups (n=8) compared with littermates treated with solvent 
only (n=7). Axitinib was associated with lethality from P1.5 onwards, whilst no deaths 
occurred in the control group.  
 
Figure 100 Effect of axitinib on postnatal weight gain 
No difference was seen in weight gain in surviving axitinib treated pups (n=8) compared 
with littermates treated with vehicle only (n=7). P=ns (ANOVA) Heavy line indicates 
median, box the inter-quartile range, and whiskers the range. 
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Appendix 9 
Analysis of P0 wildtype Prox1hi nuclear 
morphology 
Because polarity could not be assigned to nuclei it was only possible to 
analyse the deviation of the axis of each nucleus away from the midline of the 
vessel. To appropriately convert angles from 0-360o to the range 0-90o, the 
angle derived from each length measurement was converted to radians, and 
the following function applied. 
 
Converted angle = asin(sqrt(sin^2) of original angle  
 
The results of this expression (using a dummy variables at 5o intervals) are 
shown in Figure 101 in which it can be seen that nuclear angles are 
appropriately converted into angles between 0-90o, reflecting the deviation of 
the axis of nuclear elongation away from the centreline of the vessel. These 
values were analysed as ‘nuclear rotation’ in all subsequent analyses of 
phenotypes associated with connexin deletion.  
 
Figure 101 Conversion of rotation into deviation away from vessel midline 
Nuclei below the graph demonstrate raw measurements taken from images, whilst 
those to the right reflect deviation away from the vessel midline.  This figure relates to  
Figure 46 in the main text.  
These data relate to the pooled analysis of Prox1hi valve forming cell nuclei at 
P0 in the wildtype littermates analysed as part of the investigation of connexin 
37/43/47 phenotypes.  
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Figure 102 No correlation between Prox1hi nuclear rotation and elongation 
This graph shows the extremely weak correlation between nuclear rotation and 
elongation (Pearson’s r=-0.153, P<0.0005) and so these parameters were subsequently 
analysed separately.  A hex-binned scatter plot is shown in which colour represents the 
number (count) of measured Prox1hi nuclei in each area. N=1388 nuclei. 
 
Figure 103 Mean nuclear rotation by tertile position across vein 
This graph shows that in a pooled analysis of WT nuclei, each tertile showed a different 
mean nuclear rotation relative to the long axis of the vein. These three regions were 
subsequently analysed separately. Error bars represent 95% confidence intervals. 
N=1388 nuclei. A similar pattern was not seen for nuclear elongation, which was 
distributed relatively evenly across the vein (Figure 105). P<0.0005 (ANOVA) Bonferroni 
post-hoc tests showed no difference (P=ns) between tertiles 1 and 3, but both were 
significantly (P<0.005) less rotated that tertile 2.   
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Figure 104 Normal variation in Prox1hi nuclear rotation by position across the 
vein 
This hex-binned scatter plot shows the variation in Prox1hi nuclear rotation with the 
position across the vein from superior to inferior. Colour indicates the number (count) f 
measured nuclei in each area. The graph shows two regions with a high number of 
nuclei with low rotation at the superior and inferior limits of the vessel, whilst the most 
rotated nuclei are found in the central region of the vessel (corresponding to the 2nd 
tertile). Statistical analysis of rotation in each tertile is given in Figure 103. Only nuclei 
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Figure 105 Normal variation in Prox1hi nuclear elongation by position across 
the vein 
This hex-binned scatter plot show the lack of significant variation in Prox1hi nuclear 
elongation with the position across the vein from superior (0) to inferior (100). All 
measured wildtype nuclei are shown. N=1388 nuclei. Statistical analysis showed no 
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Figure 106 Proportion of analysed VFC’s in each region at P0 following Cx43 
deletion 
This graph shows that there was no significant difference in the proportion of measured 
nuclei in each tertile, when comparing wildtype littermates and Cx43-deleted VV. Error 
bars represent 1 SEM. P=ns for all comparisons (t test). 
 
 
Figure 107 Proportion of analysed VFC’s in each region at P0 following Cx47 
knockout 
This graph shows that there was no significant difference in the proportion of measured 
nuclei in each tertile, when comparing wildtype littermates and Cx47-deleted VV. Error 
bars represent 1 SEM. P=ns for all comparisons (t test). 
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Appendix 10 




Figure 108 Reproducibility of detection of the number of valves in a vein 
This graph shows a strong correlation between repeated measures of the number of 
valves in a vein by two different ultrasonographers. Intraclass correlation coefficient 
0.896, P<0.0005. Overlapping integer values are concealed in the above graph but 
shown side by side in Figure 82 in the main text, which demonstrates all data points. A 
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Appendix 11 
Lack of evidence for the endothelial origin 





Figure 109 Lack of evidence for endothelial origin (after P1) of interstitial 
cells 
 
A) A routine 2D projection of a confocal z-stack through VV in a mTmG;Prox1CreERT2 
mouse, injected with 4OHT at P1+P2 and analysed at P6 is shown. Green=GFP, Blue=Foxc2, 
Red=Prox1 (tdTomato not scanned) Scale bar 20µm. 
 
B) An XZ (side) projection of a deconvolved z-stack through the boxed region in A. 
Arrowheads indicate GFP expressing endothelial cells lining the vein. Arrowheads indicate 
immunolocalisation of Prox1 and Foxc2 within the nucleus of a free-edge cell. * = known 
positions of interstitial cells, which are GFP-ve indicating that endothelial to mesenchymal 
(interstitial cell) transition has not occurred after P1. Green=GFP signal (membrane targeted), 
magenta=Foxc2, cyan=Prox1 immunolocalisation. tdTomato signal (red) is not clearly visible. 
An mTmG;Prox1CreERT2 mouse was injected with 4OHT at P1+P2 and analysed at P6, with 
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immunolocalisation of Prox1, Foxc2 as well as tdtomato and GFP. Imaging was performed on 
a Leica SP5 confocal microscope using 63x lens, 2048x2048 resolution, 200Hz, frame 
averaging of 2, 125nm z-step (413 slices), 4 channels. Data were deconvolved in Huygens 
(SVI) using classic maximum likelihood estimation, with medium RI, SNR and quality threshold 
parameters optimized for sharp cell membranes in the GFP channel. Data were exported into 
NIH ImageJ and re-sliced to give XZ projections; an example slice is shown. Images are 
representative of N = 5 deconvolved stacks in 5 valve leaflets of 3 mice. Flow from left to right 
in A and B.  
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Appendix 12 
Model of altered flow in VV development 
 
 
Figure 110 No correlation between weight at P6 and observed valve area. 





Figure 111 Operated pups gain weight normally. 
Taking operated and unoperated pups from the same litters, the effects of surgery and 
anaesthesia did not alter weight gain at P6. N=10 littermate controls, 16 operated pups. 
P=0.355 (independent samples t test, unequal variance).  
  
